"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,EP,B1,EP 1418666 B1,190-304-265-132-088,2006-08-02,2006,EP 02102549 A,2002-11-07,EP 02102549 A,2002-11-07,Adaptive delay driver for class-D amplifier,,TEXAS INSTRUMENTS INC,RISBO LARS;;JOSEFSEN ANKER,TEXAS INSTRUMENTS DENMARK A/S (2005-01-05);;TEXAS INSTRUMENTS INCORPORATED (2006-08-02),https://lens.org/190-304-265-132-088,Granted Patent,yes,3,0,4,4,0,H03F3/2173;;H03F2200/351,H03F3/217,,2,0,,,"NIELSEN K: ""PEDEC-a novel pulse referenced control method for high quality digital PWM switching power amplification"" , POWER ELECTRONICS SPECIALISTS CONFERENCE, 1998. PESC 98 RECORD. 29TH ANNUAL IEEE FUKUOKA, JAPAN 17-22 MAY 1998, NEW YORK, NY, USA,IEEE, US, PAGE(S) 200-207 XP010294870 ISBN: 0-7803-4489-8 * the whole document *;;ATTWOOD B E: ""DESIGN PARAMETERS IMPORTANT FOR THE OPTIMIZATION OF VERY-HIGH-FIDELITY PWM (CLASS D) AUDIO AMPLIFIERS"" , JOURNAL OF THE AUDIO ENGINEERING SOCIETY, AUDIO ENGINEERING SOCIETY. NEW YORK, US, VOL. 31, NR. 11, PAGE(S) 842-853 XP000942479 ISSN: 0004-7554 * Section 2.1 *",EXPIRED
2,US,B2,US 7034609 B2,009-573-048-638-405,2006-04-25,2006,US 71274603 A,2003-11-12,US 71274603 A,2003-11-12,Switching circuits,"A technique to implement removal of dead time control circuitry from the back-end of a digital switching amplifier system 100 and add dead time control circuitry on the front-end digital modulator chip. The front-end dead time control circuitry adaptively adjusts timing of the output PWM control signals 124 to optimize performance and power consumption, i.e. operate with minimum dead time for all transitions. The front-end dead time control circuitry controls all propagation delays associated with the digital switching amplifier system 100.",TEXAS INSTRUMENTS INC,RISBO LARS;;JOSEFSEN ANKER,TEXAS INSTRUMENTS INCORPORATED (2004-05-13),https://lens.org/009-573-048-638-405,Granted Patent,yes,6,20,2,2,0,H03F3/217;;H03F3/217;;H03F3/45085;;H03F3/45085;;H03F2203/45636;;H03F2203/45636,H03F3/38;;H03F3/217;;H03F3/45,330/10;;X330270 A;;330/251,0,0,,,,EXPIRED
3,EP,A1,EP 1418666 A1,141-081-410-692-047,2004-05-12,2004,EP 02102549 A,2002-11-07,EP 02102549 A,2002-11-07,Adaptive delay driver for class-D amplifier,"A technique to implement removal of dead time control circuitry from the back-end of a digital switching amplifier system 100 and add dead time control circuitry on the front-end digital modulator chip. The front-end dead time control circuitry adaptively adjusts timing of the output PWM control signals 124 to optimize performance and power consumption, i.e. operate with minimum dead time for all transitions. The front-end dead time control circuitry controls all propagation delays associated with the digital switching amplifier system 100.",TEXAS INSTRUMENTS INC;;TEXAS INSTR DENMARK AS,RISBO LARS;;JOSEFSEN ANKER,TEXAS INSTRUMENTS DENMARK A/S (2005-01-05);;TEXAS INSTRUMENTS INCORPORATED (2006-08-02),https://lens.org/141-081-410-692-047,Patent Application,yes,3,4,4,4,0,H03F3/2173;;H03F2200/351,H03F3/217,,2,1,048-822-691-248-018,10.1109/pesc.1998.701900,"NIELSEN K: ""PEDEC-a novel pulse referenced control method for high quality digital PWM switching power amplification"", POWER ELECTRONICS SPECIALISTS CONFERENCE, 1998. PESC 98 RECORD. 29TH ANNUAL IEEE FUKUOKA, JAPAN 17-22 MAY 1998, NEW YORK, NY, USA,IEEE, US, PAGE(S) 200-207, ISBN: 0-7803-4489-8, XP010294870;;ATTWOOD B E: ""DESIGN PARAMETERS IMPORTANT FOR THE OPTIMIZATION OF VERY-HIGH-FIDELITY PWM (CLASS D) AUDIO AMPLIFIERS"", JOURNAL OF THE AUDIO ENGINEERING SOCIETY, AUDIO ENGINEERING SOCIETY. NEW YORK, US, VOL. 31, NR. 11, PAGE(S) 842-853, ISSN: 0004-7554, XP000942479",EXPIRED
4,DE,D1,DE 60213614 D1,066-389-599-821-692,2006-09-14,2006,DE 60213614 T,2002-11-07,EP 02102549 A,2002-11-07,"Treiber mit geregelter Zeitverzögerung, für Klasse-D Verstärker",,TEXAS INSTRUMENTS INC,RISBO LARS;;JOSEFSEN ANKER,,https://lens.org/066-389-599-821-692,Granted Patent,no,0,0,4,4,0,H03F3/2173;;H03F2200/351,H03F3/217,,0,0,,,,EXPIRED
5,DE,T2,DE 60213614 T2,013-068-883-763-979,2007-08-09,2007,DE 60213614 T,2002-11-07,EP 02102549 A,2002-11-07,"Treiber mit geregelter Zeitverzögerung, für Klasse-D Verstärker",,TEXAS INSTRUMENTS INC,RISBO LARS;;JOSEFSEN ANKER,,https://lens.org/013-068-883-763-979,Granted Patent,no,0,0,4,4,0,H03F3/2173;;H03F2200/351,H03F3/217,,0,0,,,,EXPIRED
6,US,A1,US 2005/0099226 A1,063-587-713-865-305,2005-05-12,2005,US 71274603 A,2003-11-12,US 71274603 A,2003-11-12,Switching circuits,"A technique to implement removal of dead time control circuitry from the back-end of a digital switching amplifier system 100 and add dead time control circuitry on the front-end digital modulator chip. The front-end dead time control circuitry adaptively adjusts timing of the output PWM control signals 124 to optimize performance and power consumption, i.e. operate with minimum dead time for all transitions. The front-end dead time control circuitry controls all propagation delays associated with the digital switching amplifier system 100.",RISBO LARS;;JOSEFSEN ANKER,RISBO LARS;;JOSEFSEN ANKER,TEXAS INSTRUMENTS INCORPORATED (2004-05-13),https://lens.org/063-587-713-865-305,Patent Application,yes,6,9,2,2,0,H03F3/217;;H03F3/217;;H03F3/45085;;H03F3/45085;;H03F2203/45636;;H03F2203/45636,H03F3/217;;H03F3/38;;H03F3/45,330/10,0,0,,,,EXPIRED
7,DE,A1,DE 2250158 A1,154-535-157-099-121,1973-04-19,1973,DE 2250158 A,1972-10-13,SE 1309471 A,1971-10-15,GRILLGERAET MIT GASBRENNER,,PRIMUS SIEVERT AB,MEJYR CARL-ANKER;;LEDIN LARS,,https://lens.org/154-535-157-099-121,Patent Application,no,0,2,6,6,0,A47J37/0713;;A47J37/0713,A47J37/07,,0,0,,,,DISCONTINUED
8,US,B2,US 10584683 B2,104-004-740-830-771,2020-03-10,2020,US 201716084206 A,2017-03-09,DK PA201670147 A;;IB 2017051387 W,2016-03-14,Method of condition monitoring one or more wind turbines and parts thereof and performing instant alarm when needed,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator) comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements. Collection of nacelle direction measurements. Collection of meteorological conditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG. The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,VENTUS ENGINEERING GMBH (2018-11-01),https://lens.org/104-004-740-830-771,Granted Patent,yes,24,5,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;F03D7/04;;G06T7/00,,0,0,,,,ACTIVE
9,CN,A,CN 109154274 A,012-208-593-489-049,2019-01-04,2019,CN 201780029610 A,2017-03-09,DK PA201670147 A;;IB 2017051387 W,2016-03-14,METHOD OF CONDITION MONITORING ONE OR MORE WIND TURBINES AND PARTS THEREOF AND PERFORMING INSTANT ALARM WHEN NEEDED,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator) comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements. Collection of nacelle direction measurements. Collection of meteorological conditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG. The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LYSGAARD LARS;;LUBKER POUL ANKER SKAARUP,,https://lens.org/012-208-593-489-049,Patent Application,no,8,7,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;G01P5/26,,0,0,,,,ACTIVE
10,US,A1,US 2018/0031260 A1,006-572-836-548-271,2018-02-01,2018,US 201515549907 A,2015-02-09,EP 2015052636 W,2015-02-09,CONTROL UNIT FOR A HVAC SYSTEM COMPRISING A DISPLAY,"Disclosed herein is a method of communicating control unit data from a control unit of a HVAC system to a portable reading device, the control unit comprising a display, the method comprising; generating a code based on said control unit data, converting said code into a graphical layout, and providing said graphical layout via the display. Disclosed herein is also a control unit of a HVAC system comprising a display and a processing unit, said control unit is configured to communicate control unit data, wherein the processing unit is configured to perform said method and the display is configured to provide the graphical layout. The invention further relates to a method of obtaining control unit data with a portable reading device from a control unit of a HVAC system, the method comprising; scanning a graphical layout, generating a code based on the graphical layout, decoding the code by accessing a website, and obtaining the control unit data based on the decoded code.",OJ ELECTRONICS AS,BERNBOM LARS KRUSE;;CHRISTENSEN ANKER BO,OJ ELECTRONICS A/S (2017-11-16),https://lens.org/006-572-836-548-271,Patent Application,yes,1,7,2,2,0,G05D23/1905;;F24F11/62;;F24F11/64;;F24F11/30;;F24F11/56;;F24F11/52;;G05D23/1905;;F24F11/62;;F24F11/64;;F24F11/30;;F24F11/56;;F24F11/52;;G05B15/02;;G05B2219/2614,F24F11/00;;G05B15/02,,0,0,,,,DISCONTINUED
11,US,A1,US 2019/0072082 A1,194-367-243-508-439,2019-03-07,2019,US 201716084206 A,2017-03-09,DK PA201670147 A;;IB 2017051387 W,2016-03-14,METHOD OF CONDITION MONITORING ONE OR MORE WIND TURBINES AND PARTS THEREOF AND PERFORMING INSTANT ALARM WHEN NEEDED,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator) comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements. Collection of nacelle direction measurements. Collection of meteorological conditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG. The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,VENTUS ENGINEERING GMBH (2018-11-01),https://lens.org/194-367-243-508-439,Patent Application,yes,0,26,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D17/00;;F03D7/02;;F03D7/04;;G05B17/02;;G06T7/00,,0,0,,,,ACTIVE
12,DK,T3,DK 3430255 T3,137-386-350-075-364,2020-08-03,2020,DK 17711351 T,2017-03-09,DK PA201670147 A;;IB 2017051387 W,2016-03-14,FREMGANGSMÅDE TIL TILSTANDSOVERVÅGNING EN ELLER FLERE VINDTURBINER OG DELE DERAF OG UDFØRE OMGÅENDE ALARM NÅR DET KRÆVES,,VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,,https://lens.org/137-386-350-075-364,Granted Patent,no,0,0,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;G01P5/26,,0,0,,,,ACTIVE
13,DK,B1,DK 179018 B1,062-276-709-004-874,2017-08-21,2017,DK PA201670147 A,2016-03-14,DK PA201670147 A,2016-03-14,Method of condition monitoring one or more wind turbines and parts thereof and performing instant alarm when needed,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator)comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements.Collection of nacelle direction measurements. Collection of meteorologicalconditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG.The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LÜBKER POUL ANKER SKAARUP;;LYSGAARD LARS,,https://lens.org/062-276-709-004-874,Granted Patent,no,5,3,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D17/00,,0,0,,,,ACTIVE
14,WO,A1,WO 2016/128019 A1,144-675-177-511-808,2016-08-18,2016,EP 2015052636 W,2015-02-09,EP 2015052636 W,2015-02-09,CONTROL UNIT FOR A HVAC SYSTEM COMPRISING A DISPLAY,"Disclosed herein is a method of communicating control unit data from a control unit of a HVAC system to a portable reading device, the control unit comprising a display, the method comprising; generating a code based on said control unit data, converting said code into a graphical layout, and providing said graphical layout via the display. Disclosed herein is also a control unit of a HVAC system comprising a display and a processing unit, said control unit is configured to communicate control unit data, wherein the processing unit is configured to perform said method and the display is configured to provide the graphical layout. The invention further relates to a method of obtaining control unit data with a portable reading device from a control unit of a HVAC system, the method comprising; scanning a graphical layout, generating a code based on the graphical layout, decoding the code by accessing a website, and obtaining the control unit data based on the decoded code.",OJ ELECTRONICS AS,BERNBOM LARS KRUSE;;CHRISTENSEN ANKER BO,,https://lens.org/144-675-177-511-808,Patent Application,yes,4,3,2,2,0,G05D23/1905;;F24F11/62;;F24F11/64;;F24F11/30;;F24F11/56;;F24F11/52;;G05D23/1905;;F24F11/62;;F24F11/64;;F24F11/30;;F24F11/56;;F24F11/52;;G05B15/02;;G05B2219/2614,G05D23/19,,0,0,,,,PENDING
15,US,A1,US 2023/0213021 A1,110-290-707-004-74X,2023-07-06,2023,US 202318092785 A,2023-01-03,US 202318092785 A;;DK PA201670147 A;;US 202016744119 A;;US 201816084206 A;;IB 2017051387 W,2016-03-14,METHOD OF CONDITION MONITORING ONE OR MORE WIND TURBINES AND PARTS THEREOF AND PERFORMING INSTANT ALARM WHEN NEEDED,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator) comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements. Collection of nacelle direction measurements. Collection of meteorological conditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG. The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LYSGAARD LARS;;LUBKER POUL ANKER SKAARUP,VENTUS ENGINEERING GMBH (2018-11-01),https://lens.org/110-290-707-004-74X,Patent Application,yes,0,0,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;F03D7/04;;G01M11/08;;G01N21/88;;G06T7/00,,0,0,,,,PENDING
16,DK,A1,DK 201670147 A1,031-452-358-232-669,2017-08-21,2017,DK PA201670147 A,2016-03-14,DK PA201670147 A,2016-03-14,Method of condition monitoring one or more wind turbines and parts thereof and performing instant alarm when needed,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator)comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements.Collection of nacelle direction measurements. Collection of meteorologicalconditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG.The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LÜBKER POUL ANKER SKAARUP;;LYSGAARD LARS,,https://lens.org/031-452-358-232-669,Unknown,no,5,1,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D17/00,,0,0,,,,ACTIVE
17,US,B2,US 11549492 B2,018-987-072-190-985,2023-01-10,2023,US 202016744119 A,2020-01-15,US 202016744119 A;;DK PA201670147 A;;US 201816084206 A;;IB 2017051387 W,2016-03-14,Method of condition monitoring one or more wind turbines and parts thereof and performing instant alarm when needed,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator) comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements. Collection of nacelle direction measurements. Collection of meteorological conditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG. The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,VENTUS ENGINEERING GMBH (2018-11-01),https://lens.org/018-987-072-190-985,Granted Patent,yes,76,0,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D17/00;;F03D7/02;;F03D7/04;;G01M11/08;;G01N21/88;;G06T7/00,,0,0,,,,ACTIVE
18,WO,A1,WO 2017/158479 A1,050-234-657-852-263,2017-09-21,2017,IB 2017051387 W,2017-03-09,DK PA201670147 A,2016-03-14,METHOD OF CONDITION MONITORING ONE OR MORE WIND TURBINES AND PARTS THEREOF AND PERFORMING INSTANT ALARM WHEN NEEDED,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator) comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements. Collection of nacelle direction measurements. Collection of meteorological conditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG. The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,,https://lens.org/050-234-657-852-263,Patent Application,yes,5,7,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;G01P5/26,,0,0,,,,PENDING
19,US,A1,US 2020/0158092 A1,066-065-251-531-255,2020-05-21,2020,US 202016744119 A,2020-01-15,US 202016744119 A;;DK PA201670147 A;;US 201816084206 A;;IB 2017051387 W,2016-03-14,METHOD OF CONDITION MONITORING ONE OR MORE WIND TURBINES AND PARTS THEREOF AND PERFORMING INSTANT ALARM WHEN NEEDED,Disclosed is a method of condition monitoring a WTG (Wind Turbine Generator) comprising acts of collecting and storage of at least the following data sets together with their time stamps. Collection of generator power production measurements. Collection of mechanical status measurements. Collection of generator torque measurements. Collection of nacelle direction measurements. Collection of meteorological conditions measurements. The method compromises a further act of synchronizing the data sets. The invention also relates to a system for condition monitoring a WTG. The invention further relates to a system for visually inspecting a WTG.,VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,VENTUS ENGINEERING GMBH (2018-11-01),https://lens.org/066-065-251-531-255,Patent Application,yes,51,2,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D17/00;;F03D7/02;;F03D7/04;;G01P5/26;;G06T7/00,,0,0,,,,ACTIVE
20,DK,A1,DK 202370533 A1,036-128-215-537-366,2023-10-19,2023,DK PA202370533 A,2023-10-13,DK PA201670147 A;;DK PA201870465 A,2016-03-14,Method of visually inspecting a wind turbine generator (WTG) and parts thereof,"Disclosed is a method of visually inspecting a wind turbine generator (WTG) and parts thereof comprising acts of pointing a visual inspection system with a field of view about a line of sight of a plane wherein a rotor blade will be present and capturing multiple images of the field of view, which images comprises at least multiple images with at least part of the rotor blade in the image. The method further comprises acts of selecting at least one reference image amongst one or more captured images and of comparing at least one other captured image with the reference image. Hereby is obtained the measures of inspecting and diagnosing individual rotor blade pitch angles, imbalanced rotors, structural- or visible blade surface damages, dynamic behaviour of the wind turbine tower and measures for inspecting and allowing for seasonal adjustments of rotor blade configuration and pitch angels.",VENTUS ENG GMBH,LARS LYSGAARD;;POUL ANKER SKAARUP LÜBKER,,https://lens.org/036-128-215-537-366,Unknown,no,0,0,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D17/00;;G01M5/00;;G01N21/95;;G06T7/246,,0,0,,,,PENDING
21,DK,A1,DK 201870465 A1,056-921-120-342-274,2018-11-06,2018,DK PA201870465 A,2018-07-06,DK PA201670147 A;;IB 2017051387 W,2016-03-14,Method of visually inspecting a wind turbine generator (WTG) and parts thereof,"Disclosed is a method of visually inspecting a wind turbine generator (WTG) and parts thereof comprising acts of pointing a visual inspection system with a field of view about a line of sight of a plane wherein a rotor blade will be present and capturing multiple images of the field of view, which images comprises at least multiple images with at least part of the rotor blade in the image. The method further comprises acts of selecting at least one reference image amongst one or more captured images and of comparing at least one other captured image with the reference image. Hereby is obtained the measures of inspecting and diagnosing individual rotor blade pitch angles, imbalanced rotors, structural- or visible blade surface damages, dynamic behaviour of the wind turbine tower and measures for inspecting and allowing for seasonal adjustments of rotor blade configuration and pitch angels.",VENTUS ENG GMBH,LARS LYSGAARD;;POUL ANKER SKAARUP LÜBKER,,https://lens.org/056-921-120-342-274,Unknown,no,0,0,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;G01P5/26,,0,0,,,,PENDING
22,EP,A1,EP 3430255 A1,030-336-362-548-565,2019-01-23,2019,EP 17711351 A,2017-03-09,DK PA201670147 A;;IB 2017051387 W,2016-03-14,METHOD OF CONDITION MONITORING ONE OR MORE WIND TURBINES AND PARTS THEREOF AND PERFORMING INSTANT ALARM WHEN NEEDED,,VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,"VENTUS ENGINEERING GMBH (2019-06-12);;VENTUS WIND SERVICES GMBH, AT (2021-03-02)",https://lens.org/030-336-362-548-565,Patent Application,yes,0,5,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;G01P5/26,,0,0,,,,ACTIVE
23,EP,B1,EP 3430255 B1,110-240-007-392-061,2020-05-06,2020,EP 17711351 A,2017-03-09,DK PA201670147 A;;IB 2017051387 W,2016-03-14,METHOD OF CONDITION MONITORING ONE OR MORE WIND TURBINES AND PARTS THEREOF AND PERFORMING INSTANT ALARM WHEN NEEDED,,VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,"VENTUS ENGINEERING GMBH (2019-06-12);;VENTUS WIND SERVICES GMBH, AT (2021-03-02)",https://lens.org/110-240-007-392-061,Granted Patent,yes,5,0,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;G01P5/26,,0,0,,,,ACTIVE
24,CN,A,CN 112539137 A,073-979-442-122-643,2021-03-23,2021,CN 202011303428 A,2017-03-09,DK PA201670147 A;;CN 201780029610 A,2016-03-14,A method of monitoring wind turbine and performing alert if necessary,"A method of condition monitoring WTG (Wind Turbine Generator) is disclosed that includes actions of collecting and storing at least the following data sets and timestamps thereof: a generator power production measurement set, a mechanical state measurement set, a generator torque measurement set, a nacelle direction measurement set, and a meteorological condition measurement set. The method includes further actions of synchronizing the dataset. The invention also relates to a system for condition monitoring WTG. The invention also relates to a system for visual inspection of WTG.",VENTUS ENG GMBH,LYSGAARD LARS;;LUBKER POUL ANKER SKAARUP,,https://lens.org/073-979-442-122-643,Patent Application,no,6,0,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;G01P5/26,,0,0,,,,PENDING
25,ES,T3,ES 2806806 T3,180-396-563-747-767,2021-02-18,2021,ES 17711351 T,2017-03-09,DK PA201670147 A;;IB 2017051387 W,2016-03-14,Método de supervisión de la condición de una o más turbinas eólicas y partes de las mismas y ejecución de una alarma instantánea cuando sea necesario,"Un método de supervisión de la condición de un WTG (generador de turbina eólica) (12) que comprende acciones de: - recopilar al menos los siguientes conjuntos de datos con cronomarcadores: A) mediciones de producción de energía del generador; B) mediciones de estado mecánico; C) mediciones de dirección de la góndola; D) medición de condiciones meteorológicas, incluidas al menos mediciones de la condición del viento; E) y medición de par - sincronizar y procesar los conjuntos de datos para proporcionar al menos i) Información de estado del rotor/de la pala ii) Información de producción de energía del generador iii) Información de estado de la torre - clasificar la información i), ii) y iii) en al menos los siguientes estados de funcionamiento: - o normal de funcionamiento o - o no normal de funcionamiento, y dicha acción de sincronización se realiza en al menos un sistema de sincronización para sincronizar datos recopilados y cronomarcados.",VENTUS ENG GMBH,LYSGAARD LARS;;LÜBKER POUL ANKER SKAARUP,,https://lens.org/180-396-563-747-767,Granted Patent,no,0,0,17,17,0,F03D7/0204;;F03D17/00;;G01P5/26;;F03D7/02;;F03D17/00;;G01P5/26;;F03D7/0204;;G01P5/26;;F03D17/00;;Y02E10/72;;F03D7/0204;;G05B2219/2619;;F05B2270/8041;;G01M11/081;;G01N2021/8854;;F03D17/00;;F03D7/0224;;F03D7/042;;F05B2220/30;;F05B2220/706;;F05B2260/80;;F05B2270/1033;;G06T7/001,F03D7/02;;F03D17/00;;G01P5/26,,0,0,,,,ACTIVE
26,US,A1,US 2016/0192070 A1,098-489-383-595-015,2016-06-30,2016,US 201514956492 A,2015-12-02,US 201514956492 A;;US 201462096691 P,2014-12-24,LOUDSPEAKER PROTECTION AGAINST EXCESSIVE EXCURSION,"Systems and methods for loudspeaker protection against excessive excursion are described. In an illustrative, non limiting embodiment, a method may include splitting an input signal into two or more signals, each of the two or more signals within a given frequency band; independently selecting between a power attenuation or an excursion attenuation for each of the two or more signals; independently applying the selected power attenuation or excursion attenuation to each of the two or more signals; combining the attenuated two or more signals into an output signal; and providing the output signal to a loudspeaker.",TEXAS INSTRUMENTS INC,BJOERN-JOSEFSEN ANKER;;RISBO LARS;;CHRISTIANSEN THEIS,TEXAS INSTRUMENTS INCORPORATED (2016-01-15),https://lens.org/098-489-383-595-015,Patent Application,yes,8,5,2,2,0,G10L19/018;;G10L19/018;;G10L21/034;;G10L21/034;;H04R3/007;;H04R3/007;;H03G7/002;;H03G7/002;;H03G9/025;;H03G9/025;;H04R3/002;;H04R3/002;;H04R29/001;;H04R29/001,H04R3/00;;G10L19/018;;G10L19/02;;H04R29/00,,0,0,,,,ACTIVE
27,US,B2,US 9967663 B2,185-218-545-877-357,2018-05-08,2018,US 201514956492 A,2015-12-02,US 201514956492 A;;US 201462096691 P,2014-12-24,Loudspeaker protection against excessive excursion,"Systems and methods for loudspeaker protection against excessive excursion are described. In an illustrative, non limiting embodiment, a method may include splitting an input signal into two or more signals, each of the two or more signals within a given frequency band; independently selecting between a power attenuation or an excursion attenuation for each of the two or more signals; independently applying the selected power attenuation or excursion attenuation to each of the two or more signals; combining the attenuated two or more signals into an output signal; and providing the output signal to a loudspeaker.",TEXAS INSTRUMENTS INC,BJOERN-JOSEFSEN ANKER;;RISBO LARS;;CHRISTIANSEN THEIS,TEXAS INSTRUMENTS INCORPORATED (2016-01-15),https://lens.org/185-218-545-877-357,Granted Patent,yes,8,2,2,2,0,G10L19/018;;G10L19/018;;G10L21/034;;G10L21/034;;H04R3/007;;H04R3/007;;H03G7/002;;H03G7/002;;H03G9/025;;H03G9/025;;H04R3/002;;H04R3/002;;H04R29/001;;H04R29/001,H04R3/00;;G10L19/018;;G10L21/034;;H03G7/00;;H03G9/02;;H04R29/00,,0,0,,,,ACTIVE
28,US,B2,US 7279965 B2,067-382-672-546-178,2007-10-09,2007,US 15095205 A,2005-06-13,US 15095205 A,2005-06-13,Reduction of audible artifacts in an audio system,"An audio system includes a switch mode amplifier that provides an output signal at an output for driving a load based on at least one control signal. A control system provides the at least one control signal to control the amplifier according to an operating mode of the audio system. In a first mode, the control system providing the at least one control signal to actively control an equivalent output impedance at the output of the amplifier, gradually adjusting the equivalent output impedance from a high-impedance state to a low impedance state, so as to mitigate a voltage drop across the load (e.g., including one or more speakers) when the amplifier is activated to a second mode corresponding to the low impedance state.",HANSEN THOMAS HOLM;;RISBO LARS;;BJOERN-JOSEFSEN ANKER,HANSEN THOMAS HOLM;;RISBO LARS;;BJOERN-JOSEFSEN ANKER,TEXAS INSTRUMENTS INCORPORATED (2005-06-07),https://lens.org/067-382-672-546-178,Granted Patent,yes,2,33,2,2,0,H03F1/305;;H03F1/305;;H03F1/08;;H03F1/08;;H03F3/68;;H03F3/68;;H03F2200/351;;H03F2200/351,H03F3/38,330/10;;330/251,3,0,,,"Apogee Technology, Inc., ""Applying the DDX-8000 in Binary Mode"", (date unknown), pp. 1-16.;;""STA500, 30V 3.5A Quad Power Half Bridge"", Jul. 2003, ST Micro electronics, pp. 1-10.;;""CS4360 24-Bit, 192 kHz 6-channel D/A Converter"", http://www.cirrus.com, Jul. 2004, Cirrus Logic, Inc. pp. 1-37.",ACTIVE
29,US,A1,US 2016/0057533 A1,120-267-854-571-282,2016-02-25,2016,US 201514827265 A,2015-08-14,US 201514827265 A;;US 201462037426 P,2014-08-14,ELECTROMECHANICAL SYSTEM WITH PREDICTIVE BACK-EMF PROTECTION,"A predictive back-emf protection methodology for an electromechanical system, including a signal processor that processes a source signal to provide a modified source signal, a driver that converts the modified source signal to a drive signal, and an electromechanical transducer that generates, from the drive signal, a transducer response, and a back-emf signal coupled back to the driver output. A predictive back-emf generator (such as a routine in the signal processor) is characterized by a back-emf transfer function (linear parameterized model of the electromechanical transducer) for transforming an input signal into a transform back-emf representation of a back-emf signal predicted by the back-emf transfer function as a response of the electromechanical transducer to such input signal. The signal processor processes the source signal based on the transform back-emf representation to generate the modified source signal input to the driver. An example application is limiting peaking current in an audio system.",TEXAS INSTRUMENTS INC,RISBO LARS;;BJØRN-JOSEFSEN ANKER;;MADSEN KIM N,TEXAS INSTRUMENTS INCORPORATED (2015-08-14),https://lens.org/120-267-854-571-282,Patent Application,yes,2,0,2,2,0,H04R3/007;;H04R3/007;;H04R3/00;;H04R29/001;;H04R2203/00,H04R3/00,,0,0,,,,ACTIVE
30,US,B2,US 10313787 B2,133-580-079-832-068,2019-06-04,2019,US 201514827265 A,2015-08-14,US 201514827265 A;;US 201462037426 P,2014-08-14,Electromechanical system with predictive back-EMF protection,"A predictive back-emf protection methodology for an electromechanical system, including a signal processor that processes a source signal to provide a modified source signal, a driver that converts the modified source signal to a drive signal, and an electromechanical transducer that generates, from the drive signal, a transducer response, and a back-emf signal coupled back to the driver output. A predictive back-emf generator (such as a routine in the signal processor) is characterized by a back-emf transfer function (linear parameterized model of the electromechanical transducer) for transforming an input signal into a transform back-emf representation of a back-emf signal predicted by the back-emf transfer function as a response of the electromechanical transducer to such input signal. The signal processor processes the source signal based on the transform back-emf representation to generate the modified source signal input to the driver. An example application is limiting peaking current in an audio system.",TEXAS INSTRUMENTS INC,RISBO LARS;;BJØRN-JOSEFSEN ANKER;;MADSEN KIM N,TEXAS INSTRUMENTS INCORPORATED (2015-08-14),https://lens.org/133-580-079-832-068,Granted Patent,yes,2,1,2,2,0,H04R3/007;;H04R3/007;;H04R3/00;;H04R29/001;;H04R2203/00,H03G11/00;;H04R3/00;;H04R29/00,,0,0,,,,ACTIVE
31,US,B2,US 7773358 B2,155-380-560-497-579,2010-08-10,2010,US 33502806 A,2006-01-19,US 33502806 A;;US 68228605 P,2005-05-18,Output current control and overload protection in digital audio amplifiers,"Overcurrent and overload protection for the power output of a pulse-width-modulated digital audio system is disclosed. The overcurrent protection circuitry includes a latch that is set in responsive to output current from the power output stage that exceeds an overcurrent threshold; the output of the latch gates the pulse-width-modulated control signal to block power output for the remainder of the current pulse-width-modulated cycle; upon the end of the cycle, or the beginning of the next, the latch is cleared to enable power output in that next cycle. Overload protection is provided by circuitry including counters for counting the relative number of overcurrent cycles to normal, non-overcurrent cycles, and generating an overload signal to block power output in the event of too frequent overcurrent cycles.",TEXAS INSTRUMENTS INC,NEESGAARD CLAUS NIELS;;RISBO LARS;;BJOERN-JOSEFSEN ANKER,TEXAS INSTRUMENTS INCORPORATED (2006-01-10),https://lens.org/155-380-560-497-579,Granted Patent,yes,9,9,2,2,0,H03F1/52;;H03F3/183;;H03F3/217;;H03F3/68;;H03F2200/426;;H03F1/52;;H03F3/68;;H03F3/183;;H03F2200/426;;H03F3/217,H02H3/08,361/93.1;;361/18;;361/93.2;;361/93.9,4,1,009-187-375-875-947,10.1109/esscirc.2003.1257190,"Pulse Width Modulator; Aug. 1, 1982. IBM Technical Disclosure Bulletin, vol. 25 Issue 3A. pp. 1057-1058.;;Brotton,""Sound advice for Class D amplifiers"", EDN (Apr. 28, 2005), pp. 65-70.;;Berkhout, ""Integrated Overcurrent Protection for Class D Power Stages"", 29th European Solid-State Circuits Conference: ESSCIRC 2003 (Sep. 2003), Paper C30.2.;;""TK2150: Stereo 200W (6 ohm) Class-T Digital Audio Amplifier Driver Using Digital Power Processing (TM) Technology"" (Tripath Technology, Inc., 2003).",ACTIVE
32,US,A1,US 2006/0262473 A1,154-712-340-375-184,2006-11-23,2006,US 33502806 A,2006-01-19,US 33502806 A;;US 68228605 P,2005-05-18,Output current control and overload protection in digital audio amplifiers,"Overcurrent and overload protection for the power output of a pulse-width-modulated digital audio system is disclosed. The overcurrent protection circuitry includes a latch that is set in responsive to output current from the power output stage that exceeds an overcurrent threshold; the output of the latch gates the pulse-width-modulated control signal to block power output for the remainder of the current pulse-width-modulated cycle; upon the end of the cycle, or the beginning of the next, the latch is cleared to enable power output in that next cycle. Overload protection is provided by circuitry including counters for counting the relative number of overcurrent cycles to normal, non-overcurrent cycles, and generating an overload signal to block power output in the event of too frequent overcurrent cycles.",TEXAS INSTRUMENTS INC,NEESGAARD CLAUS N;;RISBO LARS;;BJORN-JOSEFSEN ANKER,TEXAS INSTRUMENTS INCORPORATED (2006-01-10),https://lens.org/154-712-340-375-184,Patent Application,yes,9,24,2,2,0,H03F1/52;;H03F3/183;;H03F3/217;;H03F3/68;;H03F2200/426;;H03F1/52;;H03F3/68;;H03F3/183;;H03F2200/426;;H03F3/217,H02H3/08,361/93.1,0,0,,,,ACTIVE
33,US,A1,US 2006/0279354 A1,045-473-313-097-660,2006-12-14,2006,US 15095205 A,2005-06-13,US 15095205 A,2005-06-13,Reduction of audible artifacts in an audio system,"An audio system includes a switch mode amplifier that provides an output signal at an output for driving a load based on at least one control signal. A control system provides the at least one control signal to control the amplifier according to an operating mode of the audio system. In a first mode, the control system providing the at least one control signal to actively control an equivalent output impedance at the output of the amplifier, gradually adjusting the equivalent output impedance from a high-impedance state to a low impedance state, so as to mitigate a voltage drop across the load (e.g., including one or more speakers) when the amplifier is activated to a second mode corresponding to the low impedance state.",TEXAS INSTRUMENTS INC,HANSEN THOMAS H;;RISBO LARS;;BJORN-JOSEFSEN ANKER,TEXAS INSTRUMENTS INCORPORATED (2005-06-07),https://lens.org/045-473-313-097-660,Patent Application,yes,2,29,2,2,0,H03F1/305;;H03F1/305;;H03F1/08;;H03F1/08;;H03F3/68;;H03F3/68;;H03F2200/351;;H03F2200/351,H03F3/38,330/10,0,0,,,,ACTIVE
34,US,A1,US 2011/0267210 A1,138-333-901-273-090,2011-11-03,2011,US 76962910 A,2010-04-28,US 76962910 A,2010-04-28,Shaping Inter-Symbol-Interference in Sigma Delta Converter,A signal converting system is described that has a multi-segment digital to analog converter coupled to one or more error shaping loops. Each error shaping loop includes a quantizer with a feedback loop configured to generate a control signal responsive to a stream of symbols and to an error signal. Each error shaping loop also includes an inter-symbol-interference (ISI) shaping loop coupled to receive the control signal and to produce an ISI portion of the error signal that is responsive to inter-symbol transition rate.,RISBO LARS;;HEZAR RAHMI;;KELLECI BURAK;;BJOERN-JOSEFSEN ANKER,RISBO LARS;;HEZAR RAHMI;;KELLECI BURAK;;BJOERN-JOSEFSEN ANKER,TEXAS INSTRUMENTS INCORPORATED (2010-04-23),https://lens.org/138-333-901-273-090,Patent Application,yes,0,10,2,2,0,H03M7/3006;;H03M7/3006;;H03M1/0668;;H03M1/0668;;H03M1/74;;H03M1/74;;H03M3/502;;H03M3/502,H03M1/00;;H03M1/66;;H03M3/00,341/110;;341/143;;341/144,0,0,,,,ACTIVE
35,DE,D1,DE 69005308 D1,098-540-772-152-841,1994-01-27,1994,DE 69005308 T,1990-08-24,DK 420289 A;;DK 9000220 W,1989-08-25,VERFAHREN ZUR HERSTELLUNG VON LIGNOCELLULOSEPULPE.,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN,,https://lens.org/098-540-772-152-841,Granted Patent,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
36,US,B2,US 8144043 B2,173-531-380-523-774,2012-03-27,2012,US 76962910 A,2010-04-28,US 76962910 A,2010-04-28,Shaping inter-symbol-interference in sigma delta converter,A signal converting system is described that has a multi-segment digital to analog converter coupled to one or more error shaping loops. Each error shaping loop includes a quantizer with a feedback loop configured to generate a control signal responsive to a stream of symbols and to an error signal. Each error shaping loop also includes an inter-symbol-interference (ISI) shaping loop coupled to receive the control signal and to produce an ISI portion of the error signal that is responsive to inter-symbol transition rate.,RISBO LARS;;HEZAR RAHMI;;KELLECI BURAK;;BJOERN-JOSEFSEN ANKER;;TEXAS INSTRUMENTS INC,RISBO LARS;;HEZAR RAHMI;;KELLECI BURAK;;BJOERN-JOSEFSEN ANKER,TEXAS INSTRUMENTS INCORPORATED (2010-04-23),https://lens.org/173-531-380-523-774,Granted Patent,yes,3,12,2,2,0,H03M7/3006;;H03M7/3006;;H03M1/0668;;H03M1/0668;;H03M1/74;;H03M1/74;;H03M3/502;;H03M3/502,H03M1/66,341/144;;341/143;;341/152,2,1,158-662-267-576-950,10.1109/4.748184,"T. Shui, R. Schreier, and F. Hudson, ""Mismatch Shaping for a Current-Mode Multibit Delta-Sigma DAC"", IEEE Journal of Solid-State Circuits, vol. 34, No. 3, Mar. 1999.;;""The Data Conversion Handbook"" edited by Walt Kester, Chapter 3: Data Converter Architectures, ""Analog-Digital Conversion"", pp. 3.1-3.140 (1-142), Newnes, 2005.",ACTIVE
37,BG,B1,BG 61607 B1,195-929-893-877-197,1998-01-30,1998,BG 9974195 A,1995-06-22,DK 9300434 W;;DK 155292 A,1992-12-23,PURINE DERIVATIVES,"Compounds have been synthetized, having the formulawhere X is halogen, trifluoromethyl, cyano, C1-6-alkoxy,C1-6-alkylthio, C1-6-alkylamino or C1-6-dialkylamino, R1 & R4 arehydrogen, C1-6-alkyl with a straight or branching carbon chain ortrifluoromethyl, or R1 & R4 together form cycloalkyl ring, Y is 0,S, SO2, N-H or N-alkyl, R5 in a given case is substitutedheterocycle, R6 & R7 are hydrogen, benzoly or C1-6-alkanoyl, ortheiir pharmaceutically acceptable salts. The derivatives or theirsalts find application for the treatment of diseases of thecentral nervous system and of the cardiovascular system.",NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS J;;SHEARDOWN MALCOLM;;HANSEN ANKER J,,https://lens.org/195-929-893-877-197,Granted Patent,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,EXPIRED
38,CN,A,CN 113597443 A,075-904-973-686-954,2021-11-02,2021,CN 202080018290 A,2020-03-05,EP 19160963 A;;EP 2020055825 W,2019-03-06,FOAMABLE POLYOLEFIN COMPOSITION PROVIDING INCREASED FLEXIBILITY,"The invention relates to a foamable polymer composition comprising a polyolefin polymer which polyolefin polymer does not bear silane moieties and comprises 20 to 99.99 wt.% linear low density polyethylene, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of citric acid and/or derivatives of citric acid or mixtures thereof. Further the invention relates to a foamable polymer composition comprising a polyolefin polymer, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of expandable polymeric microspheres, and the composition does not comprise fluororesin. Further the invention relates to a foamed polymer composition obtained by foaming this foamable polymer composition. Further the invention relates to the use of the foamable composition or the foamed polymer composition for a layer of a cable and a cable comprising at least one layer which comprises the foamable polymer composition or the foamed polymer composition.",BOREALIS AG,HJARTFORS ANNA;;WANNERSKOG ASA;;ANKER MARTIN;;EFRAIMSSON LARS;;NILSSON ANDREAS,,https://lens.org/075-904-973-686-954,Patent Application,no,5,0,7,7,0,C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;C08J9/0023;;H01B3/441;;H01B13/142;;C08K2201/019;;C08J2203/02;;C08J9/08;;C08J2323/06;;C08J9/0038;;C08J9/0061;;C08J2423/06;;C08J9/32;;C08J2203/22;;C08J9/08;;C08J9/32;;C08J2203/02;;C08J2207/06;;C08J2323/06;;C08K5/092;;C08K5/098;;C08K5/11;;C08K5/521;;C08K7/22;;C08K2201/019;;H01B3/441;;H01B13/142,C08J9/00;;C08J9/16;;C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;H01B3/44;;H01B13/14,,0,0,,,,PENDING
39,SK,A3,SK 82695 A3,086-923-923-831-917,1996-04-03,1996,SK 82695 A,1993-12-21,DK 155292 A;;DK 9300434 W,1992-12-23,PURINE DERIVATIVES,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS J S;;SHEARDOWN MALCOLM;;HANSEN ANKER,,https://lens.org/086-923-923-831-917,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;A61K31/7042;;A61K31/7052;;C07H1/00;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,PENDING
40,EP,A1,EP 4256286 A1,173-165-304-332-805,2023-10-11,2023,EP 21844015 A,2021-12-23,EP 21155897 A;;EP 2021087487 W,2021-02-09,ROTOR BLADE MONITORING ARRANGEMENT,,SIEMENS GAMESA RENEWABLE ENERGY AS,BERNHAMMER LARS OLIVER;;FREMMELEV MADS ANKER;;LADPLI PURIM;;ORLOWITZ ESBEN,,https://lens.org/173-165-304-332-805,Patent Application,yes,0,0,4,4,0,G01M5/0033;;G01M5/0066;;G01M5/0016;;G01M7/00;;G01H1/006;;Y02E10/72,G01H1/00;;G01M7/00,,0,0,,,,PENDING
41,WO,A1,WO 2022/171350 A1,177-775-131-328-923,2022-08-18,2022,EP 2021087487 W,2021-12-23,EP 21155897 A,2021-02-09,ROTOR BLADE MONITORING ARRANGEMENT,"The invention describes a wind turbine rotor blade monitoring arrangement (1) comprising an electrodynamic exciter (10) mounted on the rotor blade (20); an excitation unit (11) configured to generate an excitation signal (110) for the electrodynamic exciter (10); a force sensor (10F) configured to measure force (100) imparted to the rotor blade (20) during operation of the electrodynamic exciter (10), which force sensor (10F) is collocated with the electrodynamic exciter (10); a vibration sensor (12) arranged on the rotor blade (20) at a distance from the electrodynamic exciter (10); and an evaluation unit (13) configured to infer a health status of the rotor blade (20) on the basis of a vibration sensor output (120) and the measured force (100). The invention further describes a method of monitoring the health status of a wind turbine rotor blade (20).",SIEMENS GAMESA RENEWABLE ENERGY AS,BERNHAMMER LARS OLIVER;;FREMMELEV MADS ANKER;;LADPLI PURIM;;ORLOWITZ ESBEN,,https://lens.org/177-775-131-328-923,Patent Application,yes,4,1,4,4,0,G01M5/0033;;G01M5/0066;;G01M5/0016;;G01M7/00;;G01H1/006;;Y02E10/72,G01H1/00;;G01M7/00,,0,0,,,,PENDING
42,EP,A1,EP 4264042 A1,044-204-334-600-489,2023-10-25,2023,EP 21836169 A,2021-12-14,EP 21155898 A;;EP 2021085676 W,2021-02-09,WIND TURBINE ROTOR BLADE,,SIEMENS GAMESA RENEWABLE ENERGY AS,BERNHAMMER LARS OLIVER;;FREMMELEV MADS ANKER;;LADPLI PURIM;;ORLOWITZ ESBEN,,https://lens.org/044-204-334-600-489,Patent Application,yes,0,0,4,4,0,F03D17/00;;F05B2220/709;;F05B2270/821;;G01L1/16;;G01M5/0016;;G01M5/0083;;Y02E10/72,F03D17/00;;G01P15/09,,0,0,,,,PENDING
43,EP,A1,EP 3935105 A1,151-746-305-058-93X,2022-01-12,2022,EP 20707283 A,2020-03-05,EP 19160963 A;;EP 2020055825 W,2019-03-06,FOAMABLE POLYOLEFIN COMPOSITION PROVIDING INCREASED FLEXIBILITY,,BOREALIS AG,HJÄRTFORS ANNA;;WANNERSKOG ÅSA;;ANKER MARTIN;;EFRAIMSSON LARS;;NILSSON ANETTE,BOREALIS AG (2022-03-09),https://lens.org/151-746-305-058-93X,Patent Application,yes,0,0,7,7,0,C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;C08J9/0023;;H01B3/441;;H01B13/142;;C08K2201/019;;C08J2203/02;;C08J9/08;;C08J2323/06;;C08J9/0038;;C08J9/0061;;C08J2423/06;;C08J9/32;;C08J2203/22;;C08J9/08;;C08J9/32;;C08J2203/02;;C08J2207/06;;C08J2323/06;;C08K5/092;;C08K5/098;;C08K5/11;;C08K5/521;;C08K7/22;;C08K2201/019;;H01B3/441;;H01B13/142,C08J9/00;;C08J9/16;;C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;H01B3/44;;H01B13/14,,0,0,,,,PENDING
44,WO,A1,WO 2020/178381 A1,144-605-262-066-100,2020-09-10,2020,EP 2020055825 W,2020-03-05,EP 19160963 A,2019-03-06,FOAMABLE POLYOLEFIN COMPOSITION PROVIDING INCREASED FLEXIBILITY,"The invention relates to a foamable polymer composition comprising a polyolefin polymer which polyolefin polymer does not bear silane moieties and comprises 20 to 99.99 wt.% linear low density polyethylene, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of citric acid and/or derivatives of citric acid or mixtures thereof. Further the invention relates to a foamable polymer composition comprising a polyolefin polymer, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of expandable polymeric microspheres, and the composition does not comprise fluororesin. Further the invention relates to a foamed polymer composition obtained by foaming this foamable polymer composition. Further the invention relates to the use of the foamable composition or the foamed polymer composition for a layer of a cable and a cable comprising at least one layer which comprises the foamable polymer composition or the foamed polymer composition.",BOREALIS AG,HJÄRTFORS ANNA;;WANNERSKOG ÅSA;;ANKER MARTIN;;EFRAIMSSON LARS;;NILSSON ANETTE,,https://lens.org/144-605-262-066-100,Patent Application,yes,8,1,7,7,0,C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;C08J9/0023;;H01B3/441;;H01B13/142;;C08K2201/019;;C08J2203/02;;C08J9/08;;C08J2323/06;;C08J9/0038;;C08J9/0061;;C08J2423/06;;C08J9/32;;C08J2203/22;;C08J9/08;;C08J9/32;;C08J2203/02;;C08J2207/06;;C08J2323/06;;C08K5/092;;C08K5/098;;C08K5/11;;C08K5/521;;C08K7/22;;C08K2201/019;;H01B3/441;;H01B13/142,C08J9/00;;C08J9/16;;C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;H01B3/44;;H01B13/14,,1,1,095-992-323-677-640,10.1002/mame.201100400,"ELLEN CHAN ET AL: ""Novel Thermally Conductive Thermoplastic/Ceramic Composite Foams"", MACROMOLECULAR MATERIALS AND ENGINEERING., vol. 297, no. 10, 1 October 2012 (2012-10-01), DE, pages 1014 - 1020, XP055471111, ISSN: 1438-7492, DOI: 10.1002/mame.201100400",PENDING
45,AU,B2,AU 2020/233273 B2,005-450-979-026-209,2023-04-13,2023,AU 2020/233273 A,2020-03-05,EP 19160963 A;;EP 2020055825 W,2019-03-06,Foamable polyolefin composition providing increased flexibility,"The invention relates to a foamable polymer composition comprising a polyolefin polymer which polyolefin polymer does not bear silane moieties and comprises 20 to 99.99 wt.% linear low density polyethylene, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of citric acid and/or derivatives of citric acid or mixtures thereof. Further the invention relates to a foamable polymer composition comprising a polyolefin polymer, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of expandable polymeric microspheres, and the composition does not comprise fluororesin. Further the invention relates to a foamed polymer composition obtained by foaming this foamable polymer composition. Further the invention relates to the use of the foamable composition or the foamed polymer composition for a layer of a cable and a cable comprising at least one layer which comprises the foamable polymer composition or the foamed polymer composition.",BOREALIS AG,HJÄRTFORS ANNA;;WANNERSKOG ÅSA;;ANKER MARTIN;;EFRAIMSSON LARS;;NILSSON ANETTE,,https://lens.org/005-450-979-026-209,Granted Patent,no,2,0,7,7,0,C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;C08J9/0023;;H01B3/441;;H01B13/142;;C08K2201/019;;C08J2203/02;;C08J9/08;;C08J2323/06;;C08J9/0038;;C08J9/0061;;C08J2423/06;;C08J9/32;;C08J2203/22;;C08J9/08;;C08J9/32;;C08J2203/02;;C08J2207/06;;C08J2323/06;;C08K5/092;;C08K5/098;;C08K5/11;;C08K5/521;;C08K7/22;;C08K2201/019;;H01B3/441;;H01B13/142,C08J9/00;;C08J9/16;;C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;H01B3/44;;H01B13/14,,1,1,095-992-323-677-640,10.1002/mame.201100400,"CHAN E. et al., 'Novel Thermally Conductive Thermoplastic/Ceramic Composite Foams', Macromol. Mater. Eng. 2012, Vol. 297, pages 1014–1020",ACTIVE
46,EP,A1,EP 4040119 A1,018-636-305-602-967,2022-08-10,2022,EP 21155897 A,2021-02-09,EP 21155897 A,2021-02-09,ROTOR BLADE MONITORING ARRANGEMENT,"The invention describes a wind turbine rotor blade monitoring arrangement (1) comprising an electrodynamic exciter (10) mounted on the rotor blade (20); an excitation unit (11) configured to generate an excitation signal (110) for the electrodynamic exciter (10); a force sensor (10F) configured to measure force (100) imparted to the rotor blade (20) during operation of the electrodynamic exciter (10), which force sensor (10F) is collocated with the electrodynamic exciter (10); a vibration sensor (12) arranged on the rotor blade (20) at a distance from the electrodynamic exciter (10); and an evaluation unit (13) configured to infer a health status of the rotor blade (20) on the basis of a vibration sensor output (120) and the measured force (100). The invention further describes a method of monitoring the health status of a wind turbine rotor blade (20).
",SIEMENS GAMESA RENEWABLE ENERGY AS,BERNHAMMER LARS OLIVER;;FREMMELEV MADS ANKER;;LADPLI PURIM;;ORLOWITZ ESBEN,,https://lens.org/018-636-305-602-967,Patent Application,yes,3,1,4,4,0,G01M5/0033;;G01M5/0066;;G01M5/0016;;G01M7/00;;G01H1/006;;Y02E10/72,G01H1/00;;G01M7/00,,0,0,,,,DISCONTINUED
47,AU,A1,AU 2020/233273 A1,087-495-210-900-730,2021-10-28,2021,AU 2020/233273 A,2020-03-05,EP 19160963 A;;EP 2020055825 W,2019-03-06,Foamable polyolefin composition providing increased flexibility,"The invention relates to a foamable polymer composition comprising a polyolefin polymer which polyolefin polymer does not bear silane moieties and comprises 20 to 99.99 wt.% linear low density polyethylene, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of citric acid and/or derivatives of citric acid or mixtures thereof. Further the invention relates to a foamable polymer composition comprising a polyolefin polymer, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of expandable polymeric microspheres, and the composition does not comprise fluororesin. Further the invention relates to a foamed polymer composition obtained by foaming this foamable polymer composition. Further the invention relates to the use of the foamable composition or the foamed polymer composition for a layer of a cable and a cable comprising at least one layer which comprises the foamable polymer composition or the foamed polymer composition.",BOREALIS AG,HJÄRTFORS ANNA;;WANNERSKOG ÅSA;;ANKER MARTIN;;EFRAIMSSON LARS;;NILSSON ANETTE,,https://lens.org/087-495-210-900-730,Patent Application,no,0,0,7,7,0,C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;C08J9/0023;;H01B3/441;;H01B13/142;;C08K2201/019;;C08J2203/02;;C08J9/08;;C08J2323/06;;C08J9/0038;;C08J9/0061;;C08J2423/06;;C08J9/32;;C08J2203/22;;C08J9/08;;C08J9/32;;C08J2203/02;;C08J2207/06;;C08J2323/06;;C08K5/092;;C08K5/098;;C08K5/11;;C08K5/521;;C08K7/22;;C08K2201/019;;H01B3/441;;H01B13/142,C08J9/00;;C08J9/16;;C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;H01B3/44;;H01B13/14,,0,0,,,,ACTIVE
48,EP,A1,EP 4039971 A1,124-820-491-662-578,2022-08-10,2022,EP 21155898 A,2021-02-09,EP 21155898 A,2021-02-09,WIND TURBINE ROTOR BLADE,"The invention describes a wind turbine rotor blade (20) comprising a reinforcement element (20C) embedded in the body of the rotor blade (20) and extending in a longitudinal direction of the rotor blade; a number of piezo-electric transducers (10) arranged between the leading edge (LE) of the rotor blade (20) and the reinforcement element (20C); a number of piezo-electric transducers (10) arranged between the reinforcement element (20C) and the trailing edge (TE) of the rotor blade (20); and a connector arrangement (12) configured to apply an excitation signal (10B, 10C) to any one of the piezo-electric transducers (10), and to transmit a sensed signal (10B s1 , 10B s2 , 10C s1 , 10C s2 ) from any one of the piezo-electric transducers (10) to an evaluation module (142). The invention further describes a wind turbine (2) comprising a number of such rotor blades (20); and a method of measuring strain in a reinforcement element (20C) arranged in such a rotor blade (20).
",SIEMENS GAMESA RENEWABLE ENERGY AS,BERNHAMMER LARS OLIVER;;FREMMELEV MADS ANKER;;LADPLI PURIM;;ORLOWITZ ESBEN,,https://lens.org/124-820-491-662-578,Patent Application,yes,4,0,4,4,0,F03D17/00;;F05B2220/709;;F05B2270/821;;G01L1/16;;G01M5/0016;;G01M5/0083;;Y02E10/72,F03D17/00;;G01P15/09,,0,0,,,,DISCONTINUED
49,BG,A,BG 99741 A,112-981-954-061-210,1996-04-30,1996,BG 9974195 A,1995-06-22,DK 9300434 W;;DK 155292 A,1992-12-23,PURINE DERIVATIVES,"Compounds have been synthetized, having the formula where X is halogen, trifluoromethyl, cyano, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkylamino or C1-6-dialkylamino, R1 & R4 are hydrogen, C1-6-alkyl with a straight or branching carbon chain or trifluoromethyl, or R1 & R4 together form cycloalkyl ring, Y is 0, S, SO2, N-H or N-alkyl, R5 in a given case is substituted heterocycle, R6 & R7 are hydrogen, benzoly or C1-6-alkanoyl, or theiir pharmaceutically acceptable salts. The derivatives or their salts find application for the treatment of diseases of the central nervous system and of the cardiovascular system.",NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS J;;SHEARDOWN MALCOLM;;HANSEN ANKER J,,https://lens.org/112-981-954-061-210,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,EXPIRED
50,WO,A1,WO 2022/171334 A1,150-486-608-436-016,2022-08-18,2022,EP 2021085676 W,2021-12-14,EP 21155898 A,2021-02-09,WIND TURBINE ROTOR BLADE,"The invention describes a wind turbine rotor blade (20) comprising a reinforcement element (20C) embedded in the body of the rotor blade (20) and extending in a longitudinal direction of the rotor blade; a number of piezo-electric transducers (10) arranged between the leading edge (LE) of the rotor blade (20) and the reinforcement element (20C); a number of piezo-electric transducers (10) arranged between the reinforcement element (20C) and the trailing edge (TE) of the rotor blade (20); and a connector arrangement (12) configured to apply an excitation signal (10B, 10C) to any one of the piezo-electric transducers (10), and to transmit a sensed signal (10BS1, 10BS2, 10CS1, 10CS2) from any one of the piezo-electric transducers (10) to an evaluation module (142). The invention further describes a wind turbine (2) comprising a number of such rotor blades (20); and a method of measuring strain in a reinforcement element (20C) arranged in such a rotor blade (20).",SIEMENS GAMESA RENEWABLE ENERGY AS,BERNHAMMER LARS OLIVER;;FREMMELEV MADS ANKER;;LADPLI PURIM;;ORLOWITZ ESBEN,,https://lens.org/150-486-608-436-016,Patent Application,yes,3,0,4,4,0,F03D17/00;;F05B2220/709;;F05B2270/821;;G01L1/16;;G01M5/0016;;G01M5/0083;;Y02E10/72,F03D17/00;;G01P15/09,,0,0,,,,PENDING
51,EP,A1,EP 3705513 A1,059-725-521-690-393,2020-09-09,2020,EP 19160963 A,2019-03-06,EP 19160963 A,2019-03-06,FOAMABLE POLYOLEFIN COMPOSITION PROVIDING INCREASED FLEXIBILITY,"The invention relates to a foamable polymer composition comprising a polyolefin polymer which polyolefin polymer does not bear silane moieties and comprises 20 to 99.99 wt.% linear low density polyethylene, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of citric acid and/or derivatives of citric acid or mixtures thereof. Further the invention relates to a foamable polymer composition comprising a polyolefin polymer, and a blowing agent in an amount of 0.01 to 3 wt.% based on the total foamable polymer composition, wherein the blowing agent consists of expandable polymeric microspheres, and the composition does not comprise fluororesin. Further the invention relates to a foamed polymer composition obtained by foaming this foamable polymer composition. Further the invention relates to the use of the foamable composition or the foamed polymer composition for a layer of a cable and a cable comprising at least one layer which comprises the foamable polymer composition or the foamed polymer composition.",BOREALIS AG,HJÄRTFORS ANNA;;WANNERSKOG ÅSA;;ANKER MARTIN;;EFRAIMSSON LARS;;NILSSON ANETTE,BOREALIS AG (2022-03-09),https://lens.org/059-725-521-690-393,Patent Application,yes,10,0,7,7,0,C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;C08J9/0023;;H01B3/441;;H01B13/142;;C08K2201/019;;C08J2203/02;;C08J9/08;;C08J2323/06;;C08J9/0038;;C08J9/0061;;C08J2423/06;;C08J9/32;;C08J2203/22;;C08J9/08;;C08J9/32;;C08J2203/02;;C08J2207/06;;C08J2323/06;;C08K5/092;;C08K5/098;;C08K5/11;;C08K5/521;;C08K7/22;;C08K2201/019;;H01B3/441;;H01B13/142,C08J9/00;;C08J9/16;;C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;H01B3/44;;H01B13/14,,1,1,095-992-323-677-640,10.1002/mame.201100400,"ELLEN CHAN ET AL: ""Novel Thermally Conductive Thermoplastic/Ceramic Composite Foams"", MACROMOLECULAR MATERIALS AND ENGINEERING., vol. 297, no. 10, 1 October 2012 (2012-10-01), DE, pages 1014 - 1020, XP055471111, ISSN: 1438-7492, DOI: 10.1002/mame.201100400",PENDING
52,US,A1,US 2022/0135758 A1,169-212-140-628-11X,2022-05-05,2022,US 202017434430 A,2020-03-05,EP 19160963 A;;EP 2020055825 W,2019-03-06,FOAMABLE POLYOLEFIN COMPOSITION PROVIDING INCREASED FLEXIBILITY,"The invention relates to a foamable polymer composition comprising a polyolefin polymer which polyolefin polymer does not bear silane moieties and comprises 20 to 99.99 wt. % linear low density polyethylene, and a blowing agent in an amount of 0.01 to 3 wt. % based on the total foamable polymer composition, wherein the blowing agent consists of citric acid and/or derivatives of citric acid or mixtures thereof. Further the invention relates to a foamable polymer composition comprising a polyolefin polymer, and a blowing agent in an amount of 0.01 to 3 wt. % based on the total foamable polymer composition, wherein the blowing agent consists of expandable polymeric microspheres, and the composition does not comprise fluororesin. Further the invention relates to a foamed polymer composition obtained by foaming this foamable polymer composition. Further the invention relates to the use of the foamable composition or the foamed polymer composition for a layer of a cable and a cable comprising at least one layer which comprises the",BOREALIS AG,HJARTFORS ANNA;;WANNERSKOG ASA;;ANKER MARTIN;;EFRAIMSSON LARS;;NILSSON ANETTE,BOREALIS AG (2021-08-09),https://lens.org/169-212-140-628-11X,Patent Application,yes,0,0,7,7,0,C08K5/092;;C08K5/098;;C08K5/11;;C08K7/22;;C08J9/0023;;H01B3/441;;H01B13/142;;C08K2201/019;;C08J2203/02;;C08J9/08;;C08J2323/06;;C08J9/0038;;C08J9/0061;;C08J2423/06;;C08J9/32;;C08J2203/22;;C08J9/08;;C08J9/32;;C08J2203/02;;C08J2207/06;;C08J2323/06;;C08K5/092;;C08K5/098;;C08K5/11;;C08K5/521;;C08K7/22;;C08K2201/019;;H01B3/441;;H01B13/142,C08J9/08;;C08J9/32;;C08K5/092;;C08K5/098;;C08K5/11;;C08K5/521;;C08K7/22;;H01B3/44;;H01B13/14,,0,0,,,,PENDING
53,PT,A,PT 95094 A,027-677-648-198-879,1991-04-18,1991,PT 9509490 A,1990-08-24,DK 420289 A,1989-08-25,PROCESSO PARA O TRATAMENTO DE POLPA LIGNOCELULOSICA,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/027-677-648-198-879,Patent Application,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
54,WO,A1,WO 1991/002839 A1,132-441-086-749-135,1991-03-07,1991,DK 9000220 W,1990-08-24,DK 420289 A,1989-08-25,PROCESS FOR TREATMENT OF LIGNOCELLULOSIC PULP,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/132-441-086-749-135,Patent Application,yes,1,30,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,3,1,070-718-550-259-060,10.1002/bit.260320214;;18584740,"VIIKARI L. et al, ""Fourth International Symposium on Wood and Pulping Chemistry"" Paris (1987), p. 151-154, see especially page 154, column 1, line 11 - column 2, line 25.;;CHAUVET J.-M. et al, ""Fourth International Symposium on Wood and Pulping Chemistry"", Paris (1987), p. 325-327, see especially page 326, column 1, line 27 - column 2, line 16.;;Biotechnology and Bioengineering, Vol. 32, July 1988 M.G. PAICE et al: ""Viscosity-Enhancing Bleaching of Hardwood Kraft Pulp with Xylanase from a Cloned Gene"", see page 235 - page 239 especially page 237, column 1, line 1 - line 20.",PATENTED
55,WO,A1,WO 1994/014832 A1,192-753-205-018-650,1994-07-07,1994,DK 9300434 W,1993-12-21,DK 155292 A,1992-12-23,PURINE DERIVATIVES,"A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein X is halogen, trifluoromethyl, cyano, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkylamino or C1-6-dialkylamino; R?1 and R4¿ are H or straight or branched C¿1-6?-alkyl or trifluoromethyl or R?1 and R4¿ together form a cycloalkyl ring; Y is O, S, SO¿2?, NH or N-alkyl; R?5¿ is selected from optionally substituted heterocycles; R?6 and R7¿ are hydrogen, benzoyl or C¿1-6?-alkanoyl. The compounds have been found useful for treating central nervous system and cardiovascular ailments.",NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/192-753-205-018-650,Patent Application,yes,5,9,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;A61K31/7042;;A61K31/7052;;C07H1/00;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,PENDING
56,AT,T1,AT E98713 T1,081-027-270-083-060,1994-01-15,1994,AT 90913469 T,1990-08-24,DK 420289 A;;DK 9000220 W,1989-08-25,VERFAHREN ZUR HERSTELLUNG VON LIGNOCELLULOSEPULPE.,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/081-027-270-083-060,Granted Patent,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,DISCONTINUED
57,AU,A,AU 1994/058093 A,076-308-510-247-686,1994-07-19,1994,AU 1994/058093 A,1993-12-21,DK 155292 A;;DK 9300434 W,1992-12-23,Purine derivatives,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/076-308-510-247-686,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,EXPIRED
58,US,A1,US 2009/0116654 A1,120-477-257-508-715,2009-05-07,2009,US 35162709 A,2009-01-09,US 35162709 A;;US 98826804 A,2004-11-12,ON-THE-FLY INTRODUCTION OF INTER-CHANNEL DELAY IN A PULSE-WIDTH-MODULATION AMPLIFIER,"A multiple-channel audio processor ( 10 ) and an associated plurality of power stages ( 22 ) in an audio system are disclosed. The audio processor ( 10 ) includes a plurality of audio amplifier channels ( 22 ), each of which includes a pulse-code-modulation (PCM) to pulse-width-modulation (PWM) conversion function ( 25 ), which generates PWM signals for application to the plurality of power stages ( 22 ). The audio amplifier channels ( 20 ) each also include an interchannel delay function ( 28 ) for delaying the PWM edges relative to other channels ( 20 ), for reducing noise. The audio amplifier channels ( 20 ) each also include delay adjust circuitry ( 32 ) for gradually increasing and decreasing the interchannel delay of the channel ( 20 ) on startup and shutdown. This permits a single control terminal (VALID) at the processor to globally enable and disable all of the power stages ( 22 ).",TEXAS INSTRUMENTS INC,HANSEN THOMAS H;;BJOERN-JOSEFSEN ANKER;;RISBO LARS;;ROBERSON DOUGLAS A,,https://lens.org/120-477-257-508-715,Patent Application,yes,5,12,3,3,0,H03F3/211;;H03F3/2173;;H03F3/68;;H03F2200/331;;H03F3/2173;;H03F3/211;;H03F3/68;;H03F2200/331,H04R5/00,381/28,0,0,,,,DISCONTINUED
59,NZ,A,NZ 259323 A,175-681-890-624-096,1996-06-25,1996,NZ 25932393 A,1993-12-21,DK 155292 A,1992-12-23,"N-SUBSTITUTED ADENOSINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF",,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/175-681-890-624-096,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;A61K31/7042;;A61K31/7052;;C07H1/00;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,PENDING
60,PT,B,PT 95094 B,090-229-660-374-121,1997-05-28,1997,PT 9509490 A,1990-08-24,DK 420289 A,1989-08-25,PROCESSO PARA O TRATAMENTO DE POLPA LIGNOCELULOSICA,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/090-229-660-374-121,Granted Patent,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
61,US,A1,US 2006/0103458 A1,155-715-720-340-733,2006-05-18,2006,US 98826804 A,2004-11-12,US 98826804 A,2004-11-12,On-the-fly introduction of inter-channel delay in a pulse-width-modulation amplifier,"A multiple-channel audio processor ( 10 ) and an associated plurality of power stages ( 22 ) in an audio system are disclosed. The audio processor ( 10 ) includes a plurality of audio amplifier channels ( 22 ), each of which includes a pulse-code-modulation (PCM) to pulse-width-modulation (PWM) conversion function ( 25 ), which generates PWM signals for application to the plurality of power stages ( 22 ). The audio amplifier channels ( 20 ) each also include an interchannel delay function ( 28 ) for delaying the PWM edges relative to other channels ( 20 ), for reducing noise. The audio amplifier channels ( 20 ) each also include delay adjust circuitry ( 32 ) for gradually increasing and decreasing the interchannel delay of the channel ( 20 ) on startup and shutdown. This permits a single control terminal (VALID) at the processor to globally enable and disable all of the power stages ( 22 ).",TEXAS INSTRUMENTS INC,HANSEN THOMAS H;;BJORN-JOSEFSEN ANKER;;RISBO LARS;;ROBERSON DOUGLAS A,TEXAS INSTRUMENTS INCORPORATED (2004-12-03),https://lens.org/155-715-720-340-733,Patent Application,yes,5,58,3,3,0,H03F3/211;;H03F3/2173;;H03F3/68;;H03F2200/331;;H03F3/2173;;H03F3/211;;H03F3/68;;H03F2200/331,H03F3/68;;H03F3/38,330/10;;X33012400R,0,0,,,,ACTIVE
62,PL,B1,PL 175029 B1,001-180-410-236-719,1998-10-30,1998,PL 30961093 A,1993-12-21,DK 155292 A;;DK 9300434 W,1992-12-23,PURINE DERIVATIVES,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS J S;;SHEARDOWN MALCOLM;;HANSEN ANKER J,,https://lens.org/001-180-410-236-719,Granted Patent,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;A61K31/7042;;C07H1/00;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,EXPIRED
63,FI,A0,FI 953127 A0,052-565-891-488-622,1995-06-22,1995,FI 953127 A,1995-06-22,DK 155292 A;;DK 9300434 W,1992-12-23,Puriinijohdannaisia,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/052-565-891-488-622,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,DISCONTINUED
64,NZ,A,NZ 235039 A,068-547-425-780-02X,1991-12-23,1991,NZ 23503990 A,1990-08-24,DK 420289 A,1989-08-25,"TREATMENT OF CHEMICAL PULP WITH AN ALKALINE XYLANASE ABOVE PH 7.5, FOLLOWED BY CHLORINE TREATMENT","The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/068-547-425-780-02X,Patent Application,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,PENDING
65,US,A,US 5683989 A,141-827-839-589-294,1997-11-04,1997,US 50481195 A,1995-07-20,US 50481195 A;;US 16909793 A,1993-12-17,"Treatment of ischemias by administration of 2,N6-substituted adenosines","The present invention relates to compounds of formula I ##STR1## wherein X is amino, C.sub.1-6 -alkylamino, di-C.sub.1-6 -alkylamino; R.sup.1 is H, straight or branched C.sub.1-6 -alkyl or trifluoromethyl; R.sup.4 is H or straight or branched C.sub.1-6 -alkyl; or R.sup.1 and R.sup.4 together form a cyclobutyl, cyclopentyl or cyclohexyl ring; Y is O, S, SO.sub.2, N--H or N-alkyl; R.sup.5 is selected from optionally substituted heterocycles; R.sup.6 is hydrogen, benzoyl or C.sub.1-6 -alkanoyl and R.sup.7 is hydrogen, benzoyl or C.sub.1-6 -alkanoyl; or a pharmaceutically acceptable salt thereof. The compounds have been found useful for treating central nervous system and cardiovascular ailments.",NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/141-827-839-589-294,Granted Patent,yes,12,13,1,1,0,C07H19/16;;C07H19/16,C07H19/16,514/46;;536/27.61;;536/27.62;;536/27.63;;536/27.7,7,6,024-568-677-872-437;;070-030-673-251-274;;107-357-537-215-434;;094-482-067-870-153;;109-479-316-354-13X;;086-362-526-870-245,10.1021/jm00159a020;;3018244;;10.1039/c39760000851;;10.1002/jlac.197619760417;;10.1055/s-1982-29896;;7255176;;10.1016/b978-0-12-701901-7.50007-0,"Olsson et al. N 6 Substituted N Alkyladenosine 5 uronamides: Bifunctional Ligands Having Recognition Groups for A1 and A2 Adenosine Receptors, J. Med. Chem. , 29(9), 1683 1689 (1986).;;Cadogan et al., On the Formation of Benzenediazonium Chloride in Gomberg Hey Type Reactions of Diazonium Salts with Bromotrichloromethane, Carbon Tetrachloride, and Chloroform. The Solution of a Long standing Mechanistic Puzzle, J. Chem. Soc. Chem. Comm. , 1976, 851 852.;;Vorbr u ggen et al., Einfach neue Synthese von N 6 Substituierten Adenosinen und Adeninen sowie ihrer 2 Amino and 2 Hydroxyderivate, Liebigs Ann. Chem. , 1976, 745 761.;;Nair et al.(I), Utility of Purinyl Radicals in the Synthesis of Base Modified Nucleosides and Alkylpurines: 6 Amino Group Replacement by H, CL, Br, and I, J. Organic Chem. , 45(20), 3936 3974 (1980).;;Nair et al. (II), Modification of Nucleic Acid Bases via Radical Intermediates: Synthesis of Dihalogenated Purine Nucleosides , Synthesis , 1982, 832 834.;;Koster et al., Some Improvements in the Synthesis of DNA of Biological Interest, Nucleic Acids Research, Symposium Series No. 7 , IRL Press Ltd., 1980, London, U.K., pp. 39 60.;;Goodman, Chemical Syntheses and Transformations of Nucleosides, Ch. 2 in Basic Principles in Nucleic Acid Chemistry , Academic Press, New York, 1974, pp. 94 208, only pp. 153 154 and subsequent pages with reference citations supplied.",EXPIRED
66,AU,A,AU 1990/063584 A,144-267-106-233-06X,1991-04-03,1991,AU 1990/063584 A,1990-08-24,DK 420289 A,1989-08-25,PROCESS FOR TREATMENT OF LIGNOCELLULOSIC PULP,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/144-267-106-233-06X,Patent Application,no,0,1,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
67,HU,A,HU T72409 A,192-269-915-453-353,1996-04-29,1996,HU 9501856 A,1993-12-21,DK 155292 A,1992-12-23,"PURINE DERIVATIVES, THEIR PREPARATION AND APPLICATION",,NOVO NORDISK AS,HANSEN ANKER JON;;KNUTSEN LARS JACOB STRAY;;LAU JESPER;;SHEARDOWN MALCOLM,,https://lens.org/192-269-915-453-353,Unknown,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,DISCONTINUED
68,ZA,B,ZA 893733 B,093-026-186-632-638,1990-02-28,1990,ZA 893733 A,1989-05-18,DK 270488 A,1988-05-18,"AZACYCLIC CARBOXYLIC ACID DERIVATIVES,THEIR PREPARATION AND USE","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO INDUSTRI AS,KNUTSEN LARS JACOB STRAY;;LARS JACOB STRAY KNUTSEN;;ANDERSEN KNUD ERIK;;KNUD ERIK ANDERSEN;;JORGENSEN ANKER STEEN;;ANKER STEEN JORGENSEN;;SONNEWALD URSULA;;URSULA SONNEWALD,,https://lens.org/093-026-186-632-638,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
69,EP,A1,EP 0675896 A1,052-803-517-732-817,1995-10-11,1995,EP 94903747 A,1993-12-21,DK 9300434 W;;DK 155292 A,1992-12-23,PURINE DERIVATIVES.,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/052-803-517-732-817,Patent Application,yes,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,DISCONTINUED
70,AU,B2,AU 690532 B2,063-228-553-448-777,1998-04-30,1998,AU 1994/058093 A,1993-12-21,DK 155292 A;;DK 9300434 W,1992-12-23,Purine derivatives,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/063-228-553-448-777,Granted Patent,no,3,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,EXPIRED
71,NO,D0,NO 952508 D0,042-605-433-020-521,1995-06-22,1995,NO 952508 A,1995-06-22,DK 155292 A;;DK 9300434 W,1992-12-23,Purinderivater,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/042-605-433-020-521,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;C07H1/00;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,PENDING
72,US,A,US 5484774 A,144-341-323-276-640,1996-01-16,1996,US 16909793 A,1993-12-17,DK 155292 A,1992-12-23,"2, N6-disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias","A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, trifluoromethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, C.sub.1-6 -alkylamino or C.sub.1-6 -dialkylamino; R.sup.1 and R.sup.4 are H or straight or branched C.sub.1-6 -alkyl or trifluoromethyl or R.sup.1 and R.sup.4 together form a cycloalkyl ring; Y is O, S, SO.sub.2, NH or N-alkyl; R.sup.5 is selected from optionally substituted heterocycles. R.sup.6 and R.sup.7 are hydrogen, benzoyl or C.sub.1-6 -alkanoyl. The compounds have been found useful for treating central nervous system and cardiovascular ailments.",NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS J S;;SHEARDOWN MALCOLM;;HANSEN ANKER J,NOVO NORDISK A/S (1994-01-25),https://lens.org/144-341-323-276-640,Granted Patent,yes,4,4,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;A61K31/7042;;C07H1/00;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,514/46;;536/27.62;;536/27.63;;536/27.7,7,6,024-568-677-872-437;;070-030-673-251-274;;107-357-537-215-434;;094-482-067-870-153;;109-479-316-354-13X;;086-362-526-870-245,10.1021/jm00159a020;;3018244;;10.1039/c39760000851;;10.1002/jlac.197619760417;;10.1055/s-1982-29896;;7255176;;10.1016/b978-0-12-701901-7.50007-0,"Olsson et al., N 6 Substituted N Alkyladenosine 5 uronamides: Bifunctional Ligands Having Recognition Groups for A1 and A2 Adenosine Receptors, J. Med. Chem., 29(9), 1683 1689 (1986).;;Cadogan et al., On the Formation of Benzenediazonium Chloride in Gomberg Hey Type Reactions of Diazonium Salts with Bromotrichloromethane, Carbon Tetrachloride, and Chloroform. The Solution of a Long standing Mechanistic Puzzle, J. Chem. Soc. Chem. Comm., 1976, 851 852.;;Vorbr gen et al., Einfach neue Synthese von N 6 Substituierten Adenosinen und Adeninen sowie ihrer 2 Amino and 2 Hydroxyderivate, Liebigs Ann. Chem., 1976, 745 761.;;Nair et al.(I), Utility of Purinyl Radicals in the Synthesis of Base Modified Nucleosides and Alkylpurines: 6 Amino Group Replacement by H, Cl, Br, and I, J. Organic Chem., 45(20), 3936 3974 (1980).;;Nair et al. (II), Modification of Nucleic Acid Bases via Radical Intermediates: Synthesis of Dihalogenated Purine Nucleosides , Synthesis, 1982, 832 834.;;Koster et al., Some Improvements in the Synthesis of DNA of Biological Interest, Nucleic Acids Research, Symposium Series No. 7, IRL Press Ltd., 1980, London, U.K., pp. 39 60.;;Goodman, Chemical Syntheses and Transformations of Nucleosides, Ch. 2 in Basic Principles in Nucleic Acid Chemistry, Academic Press, New York, 1974, pp. 94 208, only pp. 153 154 and subsequent pages with reference citations supplied.",EXPIRED
73,DK,D0,DK 420289 D0,156-279-233-371-792,1989-08-25,1989,DK 420289 A,1989-08-25,DK 420289 A,1989-08-25,FREMGANGSMAADE TIL BEHANDLING AF LIGNOCELLULOSEPULP,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/156-279-233-371-792,Patent Application,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,DISCONTINUED
74,ZA,B,ZA 939663 B,178-272-520-240-679,1995-06-23,1995,ZA 939663 A,1993-12-23,DK 155292 A,1992-12-23,Chemical compounds their preparation and use,,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;LAU JESPER;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/178-272-520-240-679,Granted Patent,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;A61K31/7042;;C07H1/00;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,EXPIRED
75,ES,T3,ES 2047950 T3,041-139-682-938-921,1994-03-01,1994,ES 90913469 T,1990-08-24,DK 420289 A,1989-08-25,PROCEDIMIENTO PARA EL TRATAMIENTO DE PASTA QUIMICA LIGNOCELULOSICA.,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/041-139-682-938-921,Granted Patent,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
76,NO,D0,NO 920734 D0,101-621-806-452-537,1992-02-24,1992,NO 920734 A,1992-02-24,DK 420289 A;;DK 9000220 W,1989-08-25,FREMGANGSMAATE FOR BEHANDLING AV LIGNOCELLULOSEMASSE,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/101-621-806-452-537,Patent Application,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
77,EP,A1,EP 0489104 A1,026-325-611-441-104,1992-06-10,1992,EP 90913469 A,1990-08-24,DK 420289 A,1989-08-25,PROCESS FOR TREATMENT OF LIGNOCELLULOSIC PULP.,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/026-325-611-441-104,Patent Application,yes,0,1,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
78,EP,B1,EP 0489104 B1,008-732-621-197-016,1993-12-15,1993,EP 90913469 A,1990-08-24,DK 420289 A,1989-08-25,PROCESS FOR TREATMENT OF LIGNOCELLULOSIC PULP.,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F,,https://lens.org/008-732-621-197-016,Granted Patent,yes,1,5,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,3,0,,,"Viikari L. et al, ""Fourth International Symposium on Wood and Pulping Chemistry"", Paris (1987), p. 151-154, see especially page 154, column 1, line 11 - column 2, line 25;;Chauvet J.-M. et al, ""Fourth International Symposium on Wood and Pulping Chemistry"", Paris (1987), p. 325-327, see especially page 326, column 1, line 27 - column 2, line 16.;;Biotechnology and Bioengineering, Vol. 32, July 1988 M.G. Paice et al: ""Viscosity-Enhancing Bleaching of Hardwood Kraft Pulp with Xylanase from a Cloned Gene"", see page 235-page 239 especially page 237, column 1, line 1-line 20",EXPIRED
79,FI,A,FI 953127 A,118-907-790-239-272,1995-08-21,1995,FI 953127 A,1995-06-22,DK 155292 A;;DK 9300434 W,1992-12-23,Puriinijohdannaisia,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/118-907-790-239-272,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,DISCONTINUED
80,PL,A1,PL 309610 A1,029-560-469-006-986,1995-10-30,1995,PL 30961093 A,1993-12-21,DK 155292 A;;DK 9300434 W,1992-12-23,PURINE DERIVATIVES,,NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/029-560-469-006-986,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;C07H1/00;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,EXPIRED
81,CA,A1,CA 2152341 A1,049-012-497-968-072,1994-07-07,1994,CA 2152341 A,1993-12-21,DK 155292 A,1992-12-23,PURINE DERIVATIVES,"A compound of formula (I), or a pharmaceutically salt thereof, wherein X is halogen, trifluoromethyl, cyano, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkylamino or C1-6-dialkylamino; R1 and R4 are H or straight or branched C1-6-alkyl or trifluoromethyl or R1 and R4 together form a cycloakyl ring; Y is O, S, SO2, NH or N-alkyl; R5 is selected from optionally substituted heterocycles: R6 and R7 are hydrogen, benzoyl or C1-6-alkanoyl. The compounds have been found useful for treating central nervous system and cardiovascular ailments.",NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/049-012-497-968-072,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,DISCONTINUED
82,HU,D0,HU 9501856 D0,170-816-229-332-721,1995-08-28,1995,HU 9501856 A,1993-12-21,DK 155292 A,1992-12-23,PURINE DERIVATIVES,,NOVO NORDISK AS,LAU JESPER;;SHEARDOWN MALCOLM;;HANSEN ANKER JON;;KNUTSEN LARS JACOB STRAY,,https://lens.org/170-816-229-332-721,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,DISCONTINUED
83,NO,L,NO 952508 L,182-975-445-769-366,1995-08-22,1995,NO 952508 A,1995-06-22,DK 155292 A;;DK 9300434 W,1992-12-23,Purinderivater,"Forbindelse med formel (I) (I) -6 O¿R1 eller et farmasøytisk akseptabelt salt derav, hvor X er halogen, trifluor- metyl, cyan, Cj_6-alkoksy, C^-alkyltio, C^alkylamino eller Cj.j-dialkylamino; R1 og R4 er H eller rettkjedet eller forgrenet Cj.j-alkyl eller trifluor- metyl, eller R1 og R4 danner til sammen en sykloalkylring; Y er O, S, SO2, NH eller N-alkyl; R5 er valgt fra even- tuelt substituerte heterosykliske ringer; og R6 og R7 er hydrogen, benzoyl eller Cj.t-alkanoyl. Forbindelsene er blitt funnet anvendbare for behandling av sentralnervesystem- og hjerte- og karlidelser.",NOVO NORDISK AS,LAU JESPER;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/182-975-445-769-366,Abstract,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,A61K31/70;;A61K31/7042;;A61K31/7052;;C07H1/00;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,PENDING
84,US,B2,US 7492217 B2,198-267-757-889-635,2009-02-17,2009,US 98826804 A,2004-11-12,US 98826804 A,2004-11-12,On-the-fly introduction of inter-channel delay in a pulse-width-modulation amplifier,"A multiple-channel audio processor ( 10 ) and an associated plurality of power stages ( 22 ) in an audio system are disclosed. The audio processor ( 10 ) includes a plurality of audio amplifier channels ( 22 ), each of which includes a pulse-code-modulation (PCM) to pulse-width-modulation (PWM) conversion function ( 25 ), which generates PWM signals for application to the plurality of power stages ( 22 ). The audio amplifier channels ( 20 ) each also include an interchannel delay function ( 28 ) for delaying the PWM edges relative to other channels ( 20 ), for reducing noise. The audio amplifier channels ( 20 ) each also include delay adjust circuitry ( 32 ) for gradually increasing and decreasing the interchannel delay of the channel ( 20 ) on startup and shutdown. This permits a single control terminal (VALID) at the processor to globally enable and disable all of the power stages ( 22 ).",TEXAS INSTRUMENTS INC,HANSEN THOMAS HOLM;;BJOERN-JOSEFSEN ANKER;;RISBO LARS;;ROBERSON DOUGLAS A,TEXAS INSTRUMENTS INCORPORATED (2004-12-03),https://lens.org/198-267-757-889-635,Granted Patent,yes,5,29,3,3,0,H03F3/211;;H03F3/2173;;H03F3/68;;H03F2200/331;;H03F3/2173;;H03F3/211;;H03F3/68;;H03F2200/331,H03F3/38,330/10;;381/71.1;;381/94.5,0,0,,,,ACTIVE
85,ES,T3,ES 2058383 T3,001-849-308-753-586,1994-11-01,1994,ES 89108850 T,1989-05-17,DK 270488 A,1988-05-18,"DERIVADOS DE ACIDOS CARBOXILICOS AZACICLICOS, SU PREPARACION Y USO.","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/001-849-308-753-586,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
86,EP,A3,EP 0374801 A3,033-274-476-347-719,1991-08-07,1991,EP 89123400 A,1989-12-18,DK 704488 A,1988-12-19,NOVEL N-SUSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS,"Novel  N -substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the  N -substituent, the compounds thus having the general for­mula I
   wherein R¹ and R² are the same or different and each re­presents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents se­lected among the following atoms or groups: hydrogen, ha­logen, C₁₋₆-alkyl, C₁₋₆-alkoxy or cyano; R³ and R⁴ each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R⁵ and R⁶ each represents hydrogen or may - when m is 2 - together represent a bond, and R⁷ is OH or C₁₋₈-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R⁸ is H and C₁₋₄-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.  ",NOVO-NORDISK A/S,"KNUTSEN, LARS JACOB STRAY;;JORGENSEN,ANKER STEEN;;ANDERSEN, KNUD ERIK;;SONNEWALD, URSULA",,https://lens.org/033-274-476-347-719,Search Report,yes,2,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,1,1,041-648-445-932-193,2535204,"Drug Design and Delivery, Vol. 4(3), 1989, pages 205-215, Harwood Academic Publishers GmbH; E. FALCH et al.: ""Gaba uptake inhibitors containing mono- and diarylmethoxyalkyl N-substituents""",EXPIRED
87,DK,A,DK 639989 A,045-395-634-081-386,1990-08-21,1990,DK 639989 A,1989-12-18,DK 639989 A;;DK 704488 A,1988-12-19,NYE N-SUBSTITUEREDE AZAHETEROCYKLISKE CARBOXYLSYRER,"N-substituted azaheterocyclic carboxylic acids and esters thereof, where an ether group constitutes a part of the N- substituent, having the general formula <IMAGE> where R1 and R2 are identical or different and each separately represents phenyl, 2-thienyl, 3-thienyl, 2-pyrrolyl or 3-pyrrolyl which is substituted by one or more substituents selected from the following atoms or groups: H, halogen, C1-C6-alkyl, C1-C6-alkoxy or cyano; R3 and R4 are each separately H or together form a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R5 and R6 are each separately H or, when m is 2, can together form a bond, and R7 is OH or C1-C8-alkoxy, p is 0, 1 or 2, q is 0, 1 or 2, R8 is H and C1-4-alkyl, are prepared by different processes. The compounds are potent inhibitors of GABA uptake from the synaptic cleft and are well-suited for treating anxiety, pain, epilepsy and muscle or movement diseases, inter alia.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/045-395-634-081-386,Patent Application,no,0,0,4,33,0,,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
88,US,A,US 5229404 A,000-694-137-417-501,1993-07-20,1993,US 80490391 A,1991-12-06,US 80490391 A;;DK 270488 A;;US 35015189 A;;US 55424690 A,1988-05-18,Azacyclic carboxylic acid derivatives and their preparation and use,"Novel O-alkylated oximes of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA re-uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS J S;;ANDERSEN KNUD E;;JORGENSEN ANKER S;;SONNEWALD URSULA,,https://lens.org/000-694-137-417-501,Granted Patent,yes,5,0,1,37,0,C07D401/12;;C07D401/12;;C07D211/60;;C07D211/60;;C07D211/78;;C07D211/78;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,514/357;;514/399;;514/400;;514/427;;514/524;;514/640;;546/333;;548/561;;548/332.5;;548/326.5;;558/418;;564/256,1,0,,,Rossi et al. p Dialchilaminoetilchetossimne . . . Farma Ed. Sci XIX 688 702 (1964).,EXPIRED
89,AU,A,AU 1989/034845 A,035-799-621-442-929,1989-11-23,1989,AU 1989/034845 A,1989-05-16,DK 270488 A,1988-05-18,"AZACYCLIC CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO INDUSTRI AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/035-799-621-442-929,Patent Application,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
90,ES,T3,ES 2099067 T3,097-288-878-182-67X,1997-05-16,1997,ES 89123400 T,1989-12-18,DK 704488 A,1988-12-19,NUEVOS ACIDOS CARBOXILICOS AZAHETEROCICLICOS SUSTITUIDOS EN N.,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/097-288-878-182-67X,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
91,PT,B,PT 92628 B,157-373-748-467-950,1995-09-12,1995,PT 9262889 A,1989-12-19,DK 704488 A,1988-12-19,PROCESSO DE PREPARACAO DE ACIDOS CARBOXILICOS AZA-HETEROCICLICOS N-SUBSTITUIDOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,ANDERSEN KNUD ERIK;;KNUDSEN LARS JACOBS STRAY;;SONNEWALD URSULA;;JORGENSEN ANKER STEEN,,https://lens.org/157-373-748-467-950,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D211/32;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
92,CZ,A3,CZ 164295 A3,035-497-827-857-552,1996-01-17,1996,CZ 164295 A,1993-12-21,DK 155292 A,1992-12-23,PURINE DERIVATIVES,,NOVO NORDISK AS,LAU JESPER ROSENVAENGET;;KNUTSEN LARS JACOB STRAY;;SHEARDOWN MALCOLM;;HANSEN ANKER JON,,https://lens.org/035-497-827-857-552,Patent Application,no,0,0,24,24,0,A61K31/70;;C07H19/16;;A61P25/00;;A61P43/00;;A61P9/00;;C07H19/16;;A61K31/706;;A61K31/7056;;A61K31/70;;C07H19/16,C07H1/00;;A61K31/70;;A61K31/7042;;A61K31/7052;;A61K31/7076;;A61P9/00;;A61P25/00;;A61P43/00;;C07H19/16;;C07H19/167,,0,0,,,,PENDING
93,PT,A,PT 90607 A,072-934-320-832-430,1989-11-30,1989,PT 9060789 A,1989-05-18,DK 270488 A,1988-05-18,PROCESSO DE PREPARACAO DE DERIVADOS DE ACIDOS AZACICLICOCARBOXILICOS,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,ANDERSEN KNUD ERIK;;KNUDSEN LARS JACOBS STRAY;;SONNEWALD URSULA;;JORGENSEN ANKER STEEN,,https://lens.org/072-934-320-832-430,Patent Application,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
94,NO,D0,NO 891970 D0,162-885-621-050-584,1989-05-16,1989,NO 891970 A,1989-05-16,DK 270488 A,1988-05-18,FREMGANGSMAATE FOR FREMSTILLING AV AZACYKLISKE CARBOXYLSYREDERIVATER.,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO INDUSTRI AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/162-885-621-050-584,Patent Application,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
95,GR,T3,GR 3023379 T3,000-844-756-973-970,1997-08-29,1997,GR 970401032 T,1997-05-09,DK 704488 A,1988-12-19,Novel N-sustituted azaheterocyclic carboxylic acids,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/000-844-756-973-970,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
96,FI,C,FI 93955 C,000-799-072-527-507,1995-06-26,1995,FI 892388 A,1989-05-18,DK 270488 A,1988-05-18,Menetelmä terapeuttisesti käyttökelpoisten O-substituoitujen oksiimijohdannaisten valmistamiseksi,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/000-799-072-527-507,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
97,DE,T2,DE 68927875 T2,113-173-620-421-248,1997-06-26,1997,DE 68927875 T,1989-12-18,DK 704488 A,1988-12-19,N-substituierte azaheterocyclische Carbonsäuren,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/113-173-620-421-248,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
98,DK,D0,DK 639989 D0,053-830-318-883-858,1989-12-18,1989,DK 639989 A,1989-12-18,DK 639989 A;;DK 704488 A,1988-12-19,NYE N-SUBSTITUEREDE AZAHETEROCYKLISKE CARBOXYLSYRER,,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/053-830-318-883-858,Patent Application,no,0,0,4,33,0,,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
99,PT,A,PT 92628 A,110-276-268-351-81X,1990-06-29,1990,PT 9262889 A,1989-12-19,DK 704488 A,1988-12-19,PROCESSO DE PREPARACAO DE ACIDOS CARBOXILICOS AZA-HETEROCICLICOS N-SUBSTITUIDOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,ANDERSEN KNUD ERIK;;KNUDSEN LARS JACOBS STRAY;;SONNEWALD URSULA;;JORGENSEN ANKER STEEN,,https://lens.org/110-276-268-351-81X,Patent Application,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D211/32;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
100,AT,T1,AT E110064 T1,029-386-108-462-459,1994-09-15,1994,AT 89108850 T,1989-05-17,DK 270488 A,1988-05-18,"AZACYCLISCHE CARBONSÄUREDERIVATE,IHRE HERSTELLUNG UND VERWENDUNG.","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/029-386-108-462-459,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,DISCONTINUED
101,DK,B,DK 165366 B,163-263-563-136-848,1992-11-16,1992,DK 639989 A,1989-12-18,DK 639989 A;;DK 704488 A,1988-12-19,"3-Piperidinecarboxylic acids or 3-tetrahydropyridine carboxylic acids which are N-substituted by a diphenyl-, dithienyl- or phenyl-thienyl-substituted ether group, a process for preparing them, and pharmaceutical preparations which comprise the compounds",,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/163-263-563-136-848,Patent Application,no,0,0,4,33,0,,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
102,JP,A,JP H02223551 A,038-072-030-012-566,1990-09-05,1990,JP 32746389 A,1989-12-19,DK 704488 A,1988-12-19,NEW N-SUBSTITUTED AZA HETEROCYCLIC CARBOXYLIC ACIDS,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/038-072-030-012-566,Patent Application,no,0,1,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;C07D211/32;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
103,DK,A,DK 231489 A,111-818-689-541-03X,1989-11-19,1989,DK 231489 A,1989-05-12,DK 231489 A;;DK 270488 A,1988-05-18,"AZACYKLISKE CARBOXYLSYREDERIVATER, DERES FREMSTILLING OG ANVENDELSE","Novel O-alkylated oximes of the general formula I <IMAGE> where A is <IMAGE> or <IMAGE> where R1 and R2 are optionally substituted aromatic or heteroaromatic rings, R3 is hydrogen or lower alkyl, R4 is a nitrogen-containing substituted ring or an amino group which carries a substituted ring, and n and m, independently of each other, are 0, 1 or 2, are potent inhibitors of GABA reabsorption from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/111-818-689-541-03X,Patent Application,no,0,0,4,37,0,,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
104,FI,A0,FI 892388 A0,105-483-160-401-409,1989-05-18,1989,FI 892388 A,1989-05-18,DK 270488 A,1988-05-18,Menetelmä terapeuttisesti käyttökelpoisten O-substituoitujen oksiimijohdannaisten valmistamiseksi,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO INDUSTRI AS,KNUTSEN LARS JAKOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/105-483-160-401-409,Patent Application,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
105,PT,B,PT 90607 B,132-497-500-363-370,1995-03-01,1995,PT 9060789 A,1989-05-18,DK 270488 A,1988-05-18,"PROCESSO PARA A PREPARACAO DE DERIVADOS DE ACIDOS AZACICLICOCARBOXILICOS, NOMEADAMENTE DE OXIMAS O-SUBSTITUIDAS","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,ANDERSEN KNUD ERIK;;KNUDSEN LARS JACOBS STRAY;;SONNEWALD URSULA;;JORGENSEN ANKER STEEN,,https://lens.org/132-497-500-363-370,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
106,NZ,A,NZ 231836 A,180-375-158-394-408,1992-11-25,1992,NZ 23183689 A,1989-12-18,DK 704488 A,1988-12-19,N-SUBSTITUTED 5- OR 6-MEMBERED AZAHETEROCYCLIC RING CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUDSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/180-375-158-394-408,Patent Application,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D211/32;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
107,AU,B2,AU 622178 B2,006-484-102-442-048,1992-04-02,1992,AU 1989/034845 A,1989-05-16,DK 270488 A,1988-05-18,"AZACYCLIC CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/006-484-102-442-048,Granted Patent,no,2,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
108,NO,L,NO 895093 L,068-434-049-319-254,1990-06-20,1990,NO 895093 A,1989-12-18,DK 704488 A,1988-12-19,FREMGANGSMAATE FOR FREMSTILLING AV N-SUBSTITUERTE AZAHETEROCKLISKE CARBOXYLSYRER.,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/068-434-049-319-254,Abstract,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;A61K31/415;;C07D211/32;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
109,NO,L,NO 891970 L,099-314-193-680-392,1989-11-20,1989,NO 891970 A,1989-05-16,DK 270488 A,1988-05-18,FREMGANGSMAATE FOR FREMSTILLING AV AZACYKLISKE CARBOXYLSYREDERIVATER.,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO INDUSTRI AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/099-314-193-680-392,Abstract,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
110,NO,C,NO 177262 C,124-735-261-821-776,1995-08-16,1995,NO 891970 A,1989-05-16,DK 270488 A,1988-05-18,"Analogifremgangsmåte for fremstilling av terapeutisk aktive, O-substituerte oximer","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS;;NOVO INDUSTRI AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/124-735-261-821-776,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
111,NO,B,NO 177262 B,121-366-143-927-019,1995-05-08,1995,NO 891970 A,1989-05-16,DK 270488 A,1988-05-18,"Analogifremgangsmåte for fremstilling av terapeutisk aktive, O-substituerte oximer","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS;;NOVO INDUSTRI AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/121-366-143-927-019,Unknown,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
112,NO,B,NO 177672 B,172-712-130-424-93X,1995-07-24,1995,NO 895093 A,1989-12-18,DK 704488 A,1988-12-19,"Analogifremgangsmåte for fremstilling av terapeutisk aktive, N-substituerte azaheterocykliske karboksylsyrer og estere derav","Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/172-712-130-424-93X,Unknown,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;A61K31/415;;C07D211/32;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
113,EP,A1,EP 0342635 A1,071-891-306-645-635,1989-11-23,1989,EP 89108850 A,1989-05-17,DK 270488 A,1988-05-18,"Azacyclic carboxylic acid derivatives, their preparation and use.","Novel  O -alkylated oximes of the general formula I
   wherein R¹ and R² are optionally substituted aromatic or heteroaromatic rings, R³ is hydrogen or lower alkyl, R⁴ is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m indepen­dently are 0, 1 or 2, are potent inhibitors of GABA re­uptake from the synaptic cleft.  ",NOVO INDUSTRI AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,NOVO NORDISK A/S (1991-10-02);;NOVO-NORDISK A/S (1991-04-03),https://lens.org/071-891-306-645-635,Patent Application,yes,9,10,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,1,0,,,CHEMICAL ABSTRACTS,EXPIRED
114,AU,B2,AU 634992 B2,122-139-335-396-335,1993-03-11,1993,AU 1989/046889 A,1989-12-18,DK 704488 A,1988-12-19,N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO-NORDISK A/S,LARS JACOB STRAY KNUDSEN;;ANKER STEEN JORGENSEN;;KNUD ERIK ANDERSEN;;URSULA SONNEWALD,,https://lens.org/122-139-335-396-335,Granted Patent,no,2,1,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
115,DK,D0,DK 270488 D0,181-353-385-945-088,1988-05-18,1988,DK 270488 A,1988-05-18,DK 270488 A,1988-05-18,HIDTIL UKENDTE O-SUBSTITUEREDE KETOXIMER,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO INDUSTRI AS,KNUTZEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/181-353-385-945-088,Patent Application,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,DISCONTINUED
116,DK,C,DK 165366 C,013-378-169-684-986,1993-04-05,1993,DK 639989 A,1989-12-18,DK 639989 A;;DK 704488 A,1988-12-19,"3-PIPERIDINCARBOXYLSYRER ELLER 3-TETRAHYDROPYRIDIN-CARBOXYLSYRER, N-SUBSTITUERET MED EN DI-PHENYL-,DI-THIENYL- ELLER PHENYL-THIENYL-SUBSTITUERET AETERGRUPPE, FREMGANGSMAADE TIL FREMSTILLING DERAF, SAMT FARMACEUTISKE PRAEPARATER INDEHOLDENDE FORBINDELSERNE",,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/013-378-169-684-986,Granted Patent,no,0,0,4,33,0,,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
117,DE,D1,DE 68917517 D1,082-115-626-073-055,1994-09-22,1994,DE 68917517 T,1989-05-17,DK 270488 A,1988-05-18,"Azacyclische Carbonsäurederivate,ihre Herstellung und Verwendung.","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/082-115-626-073-055,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
118,NO,D0,NO 895093 D0,131-414-147-480-126,1989-12-18,1989,NO 895093 A,1989-12-18,DK 704488 A,1988-12-19,FREMGANGSMAATE FOR FREMSTILLING AV N-SUBSTITUERTE AZAHETEROCKLISKE CARBOXYLSYRER.,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/131-414-147-480-126,Patent Application,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;C07D211/32;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
119,DE,D1,DE 68927875 D1,145-720-825-189-05X,1997-04-24,1997,DE 68927875 T,1989-12-18,DK 704488 A,1988-12-19,N-substituierte azaheterocyclische Carbonsäuren,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/145-720-825-189-05X,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
120,FI,A,FI 892388 A,189-895-084-261-552,1989-11-19,1989,FI 892388 A,1989-05-18,DK 270488 A,1988-05-18,Menetelmä terapeuttisesti käyttökelpoisten O-substituoitujen oksiimijohdannaisten valmistamiseksi,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO INDUSTRI AS,KNUTSEN LARS JAKOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/189-895-084-261-552,Patent Application,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
121,AU,A,AU 1989/046889 A,080-119-799-530-053,1990-06-21,1990,AU 1989/046889 A,1989-12-18,DK 704488 A,1988-12-19,N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUDSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/080-119-799-530-053,Patent Application,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
122,US,A,US 5039685 A,115-847-537-950-369,1991-08-13,1991,US 35015189 A,1989-05-10,DK 270488 A,1988-05-18,"Azacyclic carboxylic acid derivatives, their preparation and use","Novel O-alkylated oximes of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS J S;;ANDERSEN KNUD E;;JORGENSEN ANKER S;;SONNEWALD URSULA,NOVO NORDISK A/S (1990-06-20);;NOVO INDUSTRI A/S NOVO ALLE (1989-04-17),https://lens.org/115-847-537-950-369,Granted Patent,yes,1,3,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,514/326;;546/214;;546/212;;546/221;;546/225;;546/227;;549/474;;549/476;;549/481;;549/484;;549/488;;549/61;;549/62;;549/63;;549/65;;549/68;;549/75;;548/527;;548/517;;514/461;;514/471;;514/473;;514/438;;514/444;;514/445;;514/446;;514/447;;514/326;;514/327;;514/330;;514/315;;514/422,0,0,,,,EXPIRED
123,ZA,B,ZA 899736 B,185-980-864-909-736,1990-09-26,1990,ZA 899736 A,1989-12-19,DK 704488 A,1988-12-19,N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/185-980-864-909-736,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;C07D211/32;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
124,FI,B,FI 93955 B,008-025-313-614-639,1995-03-15,1995,FI 892388 A,1989-05-18,DK 270488 A,1988-05-18,Menetelmä terapeuttisesti käyttökelpoisten O-substituoitujen oksiimijohdannaisten valmistamiseksi,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/008-025-313-614-639,Patent Application,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
125,PH,A,PH 26373 A,025-334-206-139-102,1992-06-01,1992,PH 38628 A,1989-05-05,DK 270488 A,1988-05-18,Azacyclic carboxylic acid derivatives,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/025-334-206-139-102,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
126,FI,A0,FI 896084 A0,055-492-059-660-206,1989-12-19,1989,FI 896084 A,1989-12-19,DK 704488 A,1988-12-19,Menetelmä uusien terapeuttisesti käyttökelpoisten N-substituoitujen atsaheterosyklisten karboksyylihappojen valmistamiseksi,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/055-492-059-660-206,Patent Application,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
127,AT,T1,AT E150455 T1,087-164-054-852-987,1997-04-15,1997,AT 89123400 T,1989-12-18,DK 704488 A,1988-12-19,N-SUBSTITUIERTE AZAHETEROCYCLISCHE CARBONSÄUREN,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/087-164-054-852-987,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,DISCONTINUED
128,DK,B,DK 165292 B,166-344-454-561-857,1992-11-02,1992,DK 231489 A,1989-05-12,DK 231489 A;;DK 270488 A,1988-05-18,"3-Piperidinecarboxylic acids and 3- tetrahydropyridinecarboxylic acids which are N- substituted by alkyl ethers of oximes, and pharmaceutical preparations which comprise the compounds",,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/166-344-454-561-857,Patent Application,no,0,0,4,37,0,,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
129,NZ,A,NZ 229136 A,004-190-066-009-91X,1992-01-29,1992,NZ 22913689 A,1989-05-16,DK 270488 A,1988-05-18,HETEROCYCLICALLY-SUBSTITUTED OXIMES AND PHARMACEUTICAL COMPOSITIONS,"Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/004-190-066-009-91X,Patent Application,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
130,DK,C,DK 165292 C,036-432-750-593-569,1993-03-22,1993,DK 231489 A,1989-05-12,DK 231489 A;;DK 270488 A,1988-05-18,"3-PIPERIDINCARBOXYLSYRER OG 3-TETRAHYDROPYRIDINCARBOXYLSYRER, N-SUBSTITUEREDE MED ALKYLETHERE AF OXIMER, SAMT FARMACEUTISKE PRAEPARATER INDEHOLDENDE FORBINDELSERNE",,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/036-432-750-593-569,Granted Patent,no,0,0,4,37,0,,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
131,NO,C,NO 177672 C,040-668-318-228-883,1995-11-01,1995,NO 895093 A,1989-12-18,DK 704488 A,1988-12-19,"Analogifremgangsmåte for fremstilling av terapeutisk aktive, N-substituerte azaheterocykliske karboksylsyrer og estere derav","Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/040-668-318-228-883,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;A61K31/415;;C07D211/32;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
132,US,A,US 5071859 A,105-297-541-188-497,1991-12-10,1991,US 45080589 A,1989-12-14,DK 704488 A,1988-12-19,N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND PHARMACEUTICAL USES,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy or cyano; R.sup.3 and R.sup.4 each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R.sup.5 and R.sup.6 each represents hydrogen or may--when m is 2--together represent a bond, and R.sup.7 is OH or C.sub.1 -C.sub.8 -alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R.sup.8 is H and C.sub.1 -C.sub.4 -alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",KNUDSEN LARS JACOB S;;JORGENSEN ANKER S;;ANDERSEN KNUD E;;SONNEWALD URSULA,KNUDSEN LARS JACOB S;;JORGENSEN ANKER S;;ANDERSEN KNUD E;;SONNEWALD URSULA,NOVO NORDISK A/S A CORP. OF DENMARK (1990-01-03),https://lens.org/105-297-541-188-497,Granted Patent,yes,8,23,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;C07D211/32;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,514/326;;514/330;;514/336;;514/343;;514/356;;514/422;;514/428;;546/208;;546/212;;546/213;;546/227;;546/281;;546/284;;546/318;;548/518;;548/527;;548/572,4,2,029-471-284-115-25X;;003-244-922-726-036,2973980;;10.1016/0920-1211(87)90012-x;;10.1016/b978-0-12-013317-8.50009-5,"Krogsgaard Larsen et al., Epilepsy Res. 1 (1987), 77 93.;;Krogsgaard Larsen et al., Advances in Drug Research, 17 (1988), 381 456.;;Krogsgaard Larsen et al., Progress in Medicinal Chemistry 22 (1985) 68 111.;;Yunger et al., Pharm. Exp. Therap. 228 (1984) 109, 1983.",EXPIRED
133,DK,D0,DK 231489 D0,112-364-059-659-327,1989-05-12,1989,DK 231489 A,1989-05-12,DK 231489 A;;DK 270488 A,1988-05-18,"AZACYKLISKE CARBOXYLSYREDERIVATER, DERES FREMSTILLING OG ANVENDELSE",,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JOERGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/112-364-059-659-327,Patent Application,no,0,0,4,37,0,,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
134,EP,B1,EP 0374801 B1,171-539-540-467-630,1997-03-19,1997,EP 89123400 A,1989-12-18,DK 704488 A,1988-12-19,Novel N-sustituted azaheterocyclic carboxylic acids,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/171-539-540-467-630,Granted Patent,yes,2,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,1,0,,,"DRUG DESIGN AND DELIVERY, vol. 4(3), 1989, pp. 205-215, Harwood Academic Publishers GmbH; E. FLACH et al.: ""Gaba uptake inhibitors containing mono- and diarylmethoxyalkyl N-substituents""",EXPIRED
135,EP,B1,EP 0342635 B1,179-004-669-509-889,1994-08-17,1994,EP 89108850 A,1989-05-17,DK 270488 A,1988-05-18,"Azacyclic carboxylic acid derivatives, their preparation and use.","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,NOVO NORDISK A/S (1991-10-02);;NOVO-NORDISK A/S (1991-04-03),https://lens.org/179-004-669-509-889,Granted Patent,yes,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,1,0,,,"CHEMICAL ABSTRACTS vol.,77, no. 21, 20 November 1972, page 400, abstract no. 139518h, Columbus, Ohio, USA; A. BUZAS et al.: ""Synthesis and pharmacological properties of oxime esters and ethers. 3. New m-(trifluoromethyl)benzyl methyl ketone derivatives"" & Chim. Ther, 1972, vol. 7, no. 2, pages 140-142.",EXPIRED
136,US,A,US 5214054 A,078-055-917-473-888,1993-05-25,1993,US 55424690 A,1990-07-17,US 55424690 A;;DK 270488 A;;US 35015189 A,1988-05-18,Azacyclic carboxylic acid derivatives and their preparation and use,"Novel O-alkylated oximes of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS J S;;ANDERSEN KNUD E;;JORGENSEN ANKER S;;SONNEWALD URSULA,NOVO NORDISK A/S (1990-06-20);;NOVO NORDISK A/S (CHANGED INTO) (1991-04-14),https://lens.org/078-055-917-473-888,Granted Patent,yes,6,0,1,37,0,C07D401/12;;C07D401/12;;C07D211/60;;C07D211/60;;C07D211/78;;C07D211/78;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,514/318;;514/317;;514/326;;546/193;;546/207;;546/208;;546/210;;546/227,1,0,,,"Racagni et al. GABA and Endocrine Function Adv. Biochem. Psychopharm. 42 5 6, 103 108 (1986).",EXPIRED
137,EP,A2,EP 0374801 A2,089-398-876-153-370,1990-06-27,1990,EP 89123400 A,1989-12-18,DK 704488 A,1988-12-19,Novel N-sustituted azaheterocyclic carboxylic acids.,"Novel  N -substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the  N -substituent, the compounds thus having the general for­mula I
   wherein R¹ and R² are the same or different and each re­presents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents se­lected among the following atoms or groups: hydrogen, ha­logen, C₁₋₆-alkyl, C₁₋₆-alkoxy or cyano; R³ and R⁴ each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R⁵ and R⁶ each represents hydrogen or may - when m is 2 - together represent a bond, and R⁷ is OH or C₁₋₈-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R⁸ is H and C₁₋₄-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.  ",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JORGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/089-398-876-153-370,Patent Application,yes,0,6,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
138,DE,T2,DE 68917517 T2,092-055-461-844-923,1994-12-15,1994,DE 68917517 T,1989-05-17,DK 270488 A,1988-05-18,"Azacyclische Carbonsäurederivate,ihre Herstellung und Verwendung.","Novel O-alkylated oximes of the general formula I <CHEM> wherein R<1> and R<2> are optionally substituted aromatic or heteroaromatic rings, R<3> is hydrogen or lower alkyl, R<4> is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/092-055-461-844-923,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
139,US,A,US 5214057 A,102-386-967-740-061,1993-05-25,1993,US 74732291 A,1991-08-20,US 74732291 A;;DK 704488 A;;US 45080584 A,1984-12-14,N-substituted azaheterocyclic carboxylic acids,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl- or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy or cyano; R.sup.3 and R.sup.4 each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R.sup.5 and R.sup.6 each represents hydrogen or may--when m is 2--together represent a bond, and R.sup.7 is OH or C.sub.1-8 -alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R.sup.8 is H and C.sub.1-4 -alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUDSEN LARS JACOB S;;JORGENSEN ANKER S;;ANDERSEN KNUD E;;SONNEWALD URSULA,,https://lens.org/102-386-967-740-061,Granted Patent,yes,2,1,1,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;C07D409/12;;C07D211/78;;C07D409/14;;C07D211/60,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,514/330;;546/227,0,0,,,,EXPIRED
140,FI,B,FI 93951 B,129-348-152-472-134,1995-03-15,1995,FI 896084 A,1989-12-19,DK 704488 A,1988-12-19,Menetelmä uusien terapeuttisesti käyttökelpoisten N-substituoitujen atsaheterosyklisten karboksyylihappojen valmistamiseksi,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/129-348-152-472-134,Patent Application,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
141,US,A,US 5231106 A,172-374-700-319-308,1993-07-27,1993,US 80490291 A,1991-12-06,US 80490291 A;;DK 270488 A;;US 35015189 A;;US 55424690 A,1988-05-18,Azacyclic carboxylic acid derivatives and their preparation and use,"Novel O-alkylated oximes of the general formula I ##STR1## or ##STR2## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS J S;;ANDERSEN KNUD E;;JORGENSEN ANKER S;;SONNEWALD URSULA,,https://lens.org/172-374-700-319-308,Granted Patent,yes,3,16,1,37,0,A61K31/40;;A61K31/44;;C07D401/12;;C07D207/10;;C07D233/64;;C07C2601/14;;A61K31/40;;A61K31/44;;C07D207/10;;C07D401/12,A61K31/40;;A61K31/44;;C07D207/10;;C07D401/12,514/340;;514/397;;514/422;;546/275;;548/518;;548/314.7,1,0,,,"Rossi et al., Dialkylaminoethylketoximes . . . , CA 61: 10545g (1964).",EXPIRED
142,DK,D0,DK 704488 D0,010-138-548-284-649,1988-12-19,1988,DK 704488 A,1988-12-19,DK 704488 A,1988-12-19,NYE N-SUBSTITUEREDE AZAHETEROCYKLISKE CARBOXYLSYRER,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO INDUSTRI AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/010-138-548-284-649,Patent Application,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,DISCONTINUED
143,CA,C,CA 2005919 C,044-483-944-212-12X,1997-01-07,1997,CA 2005919 A,1989-12-19,DK 704488 A,1988-12-19,N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I (I) wherein R1 and R2 are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R3 and R4 each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m i8 1 and n is 0 when m is 2; R5 and R6 each represents hydrogen or may - when m is 2 together represent a bond, and R7 is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/044-483-944-212-12X,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,D126002927   M;;1670228    S;;1670233    S;;26002789   S;;260027925  S;;26002794   S;;2600294    S;;26003255   S,0,0,,,,EXPIRED
144,FI,C,FI 93951 C,036-759-023-939-783,1995-06-26,1995,FI 896084 A,1989-12-19,DK 704488 A,1988-12-19,Menetelmä uusien terapeuttisesti käyttökelpoisten N-substituoitujen atsaheterosyklisten karboksyylihappojen valmistamiseksi,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;JOERGENSEN ANKER STEEN;;ANDERSEN KNUD ERIK;;SONNEWALD URSULA,,https://lens.org/036-759-023-939-783,Granted Patent,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
145,CA,C,CA 1337123 C,187-630-061-808-301,1995-09-26,1995,CA 599974 A,1989-05-17,DK 270488 A,1988-05-18,"AZACYCLIC CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE","Novel O-alkylated oximes of the general formula I <IMG> (I) wherein A is <IMG> or <IMG> wherein R1 and R2 are optionally substituted aromatic or heteroaromatic rings, R3 is hydrogen or lower alkyl, R4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;ANDERSEN KNUD ERIK;;JORGENSEN ANKER STEEN;;SONNEWALD URSULA,,https://lens.org/187-630-061-808-301,Granted Patent,no,0,0,30,37,0,C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/20;;C07D295/04;;C07D401/12;;C07D211/60;;C07D409/14;;C07D409/12;;C07D211/78,A61K31/4427;;A61K31/4433;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/20;;C07C251/58;;C07D211/60;;C07D211/78;;C07D401/12;;C07D409/12;;C07D409/14,D42600278    M;;1670208    S;;2600250    S;;26002794   S;;26002927   S;;2600294    S;;26003065   S,0,0,,,,EXPIRED
146,CA,A1,CA 2005919 A1,189-992-653-981-977,1990-06-19,1990,CA 2005919 A,1989-12-19,DK 704488 A,1988-12-19,N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS,"Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I <CHEM> wherein R<1> and R<2> are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy or cyano; R<3> and R<4> each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R<5> and R<6> each represents hydrogen or may - when m is 2 - together represent a bond, and R<7> is OH or C1-8-alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R<8> is H and C1-4-alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.",NOVO NORDISK AS,KNUTSEN LARS J S;;JORGENSEN ANKER S;;ANDERSEN KNUD E;;SONNEWALD URSULA,,https://lens.org/189-992-653-981-977,Patent Application,no,0,0,28,33,0,C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D409/12;;C07D211/78;;C07D211/60;;C07D409/14,C07D211/32;;A61K31/40;;A61K31/415;;A61K31/445;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;C07D207/08;;C07D211/60;;C07D211/78;;C07D409/12;;C07D409/14,D126002927   M;;1670228    S;;1670233    S;;26002789   S;;260027925  S;;26002794   S;;2600294    S;;26003255   S,0,0,,,,EXPIRED
147,WO,A2,WO 2015/086738 A2,094-895-705-129-761,2015-06-18,2015,EP 2014077358 W,2014-12-11,EP 13196620 A,2013-12-11,HIV VACCINE,"The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel compositions of HIV-specific vaccine peptides.",BIONOR IMMUNO AS,HØIE LARS H;;LUNDEMOSE ANKER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT,,https://lens.org/094-895-705-129-761,Patent Application,yes,0,6,2,2,22,A61K39/21,A61K39/00,,0,0,,,,PENDING
148,WO,A3,WO 2015/086738 A3,182-130-784-857-948,2015-08-06,2015,EP 2014077358 W,2014-12-11,EP 13196620 A,2013-12-11,HIV VACCINE,"The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel compositions of HIV-specific vaccine peptides.",BIONOR IMMUNO AS,HØIE LARS H;;LUNDEMOSE ANKER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT,,https://lens.org/182-130-784-857-948,Search Report,yes,3,0,2,2,0,A61K39/21,A61K39/21,,2,1,067-317-889-178-82X,24525316;;10.1016/s1473-3099(13)70343-8,"ANKER LUNDEMOSE: ""Exploring the Path Towards a Functional Cure for HIV"", 27 November 2013 (2013-11-27), XP055134825, Retrieved from the Internet <URL:http://www.bionorpharma.com/filestore/BionorNov2013.pdf> [retrieved on 20140814];;RICHARD B POLLARD ET AL: ""Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial"", THE LANCET INFECTIOUS DISEASES, vol. 14, no. 4, 1 April 2014 (2014-04-01), pages 291 - 300, XP055134453, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(13)70343-8",PENDING
149,US,A1,US 2004/0239417 A1,035-953-093-655-527,2004-12-02,2004,US 76836504 A,2004-01-29,US 76836504 A;;US 94502701 A,2001-08-31,Amplifiers,"
   A digital amplifier includes a noise shaper and a dither generator arranged to introduce noise to the shaper. The generator uses a seed value derived from a state variable of the shaper. 
",KOWKUTLA VENKATESWAR R.;;ZHAO SHIFENG;;OSSA LUIS E.;;BELL KENNETH M.;;JOSEFSEN ANKER;;RISBO LARS,KOWKUTLA VENKATESWAR R;;ZHAO SHIFENG;;OSSA LUIS E;;BELL KENNETH M;;JOSEFSEN ANKER;;RISBO LARS,TEXAS INSTRUMENTS INCORPORATED (2006-04-21),https://lens.org/035-953-093-655-527,Patent Application,yes,4,14,2,2,0,H03M7/3008;;H03M7/3008;;H03F3/2171;;H03F3/2171;;H03F3/2173;;H03F3/2173;;H03M7/3042;;H03M7/3042,H03F3/217;;H03M7/36,330 1,0,0,,,,EXPIRED
150,US,B2,US 7071752 B2,120-664-179-948-582,2006-07-04,2006,US 76836504 A,2004-01-29,US 76836504 A;;US 94502701 A,2001-08-31,Amplifiers,A digital amplifier includes a noise shaper and a dither generator arranged to introduce noise to the shaper. The generator uses a seed value derived from a state variable of the shaper.,TEXAS INSTRUMENTS INC,KOWKUTLA VENKATESWAR R;;ZHAO SHIFENG;;OSSA LUIS E;;BELL KENNETH M;;JOSEFSEN ANKER;;RISBO LARS,TEXAS INSTRUMENTS INCORPORATED (2006-04-21),https://lens.org/120-664-179-948-582,Granted Patent,yes,4,7,2,2,0,H03M7/3008;;H03M7/3008;;H03F3/2171;;H03F3/2171;;H03F3/2173;;H03F3/2173;;H03M7/3042;;H03M7/3042,G06F1/04;;H03F3/217;;H03M7/36,327/291;;327/299,0,0,,,,EXPIRED
151,WO,A1,WO 2005/014028 A1,117-501-136-611-58X,2005-02-17,2005,DK 2004000532 W,2004-08-09,DK PA200301151 A;;US 49530003 P,2003-08-08,INTERLEUKIN-20 FOR TREATING AND DIAGNOSING CONDITIONS ASSOCIATED WITH NEOVASCULARISATION,"Use of IL-20 or an analogue, active fragment or derivative thereof for the manufacture of a medicament for the promotion of neovascularisation. Use of an antagonist of IL-20 or an analogue, active fragment or derivative thereof for the manufacture of a medicament for the inhibition of neovascularisation. A method of diagnosing a state of disease involving neovascularisation by analysing the IL-20 activity.",NOVO NORDISK AS;;OLSEN UFFE BANG;;HANSEN ANKER JON;;ROEMER JOHN;;HASSELAGER ERIK;;CLAUSEN JES THORN;;IVERSEN LARS FOGH,OLSEN UFFE BANG;;HANSEN ANKER JON;;ROEMER JOHN;;HASSELAGER ERIK;;CLAUSEN JES THORN;;IVERSEN LARS FOGH,,https://lens.org/117-501-136-611-58X,Patent Application,yes,16,3,5,5,0,A61K38/20;;A61K38/20;;A61P17/02;;A61P35/00;;A61P43/00,A61K38/20,,8,3,022-999-463-942-964;;086-422-362-097-461;;064-896-046-385-273,12941841;;12667095;;10.1517/14728222.7.2.165;;10.1111/j.1523-1747.2003.12626.x;;14675174,"RAMESH RAJAGOPAL ET AL: ""Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor."", CANCER RESEARCH. 15 AUG 2003, vol. 63, no. 16, 15 August 2003 (2003-08-15), pages 5105 - 5113, XP002302973, ISSN: 0008-5472;;DATABASE WPI Section Ch Week 200430, Derwent World Patents Index; Class B04, AN 2004-320878, XP002302975;;DATABASE PHIN [online] 19 January 2001 (2001-01-19), XP002302974, retrieved from STN Database accession no. 2001:2367;;RICH BENJAMIN E: ""IL-20: a new target for the treatment of inflammatory skin disease."", EXPERT OPINION ON THERAPEUTIC TARGETS. APR 2003, vol. 7, no. 2, April 2003 (2003-04-01), pages 165 - 174, XP009038159, ISSN: 1472-8222;;ROMER J ET AL: ""Expression of mRNA for IL - 20 and its receptor complexes in psoriatic plaques and their regulation upon cyclosporin A treatment."", BR.J.DERMATOL. (147, NO. 5, 1063-64) 1 REF. CODEN: BJDEAZ ISSN: 0366-2845 AV - NOVO NORDISK, COPENHAGEN, DENMARK., 2002, XP009038256;;ROMER J ET AL: ""Epidermal overexpression of Interleukin-19 and -20 mRNA in psoriatic skin disappears after short term treatment with cyclosporine A or calcipotriol"", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 121, no. 6, 6 December 2003 (2003-12-06), USA, pages 1306 - 1311, XP001203454;;SMEETS T J M (REPRINT) ET AL: ""Interleukin - 20 is expressed in inflamed synovium of patients with psoriatic arthritis and rheumatoid arthritis"", ARTHRITIS AND RHEUMATISM, VOL. 48, NO. 9, SUPP. [S], PP. S57-S57. MA 21. PUBLISHER: WILEY-LISS, DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA. ISSN: 0004-3591., September 2003 (2003-09-01), XP009038258;;DATABASE WPI Section Ch Week 200379, Derwent World Patents Index; Class B04, AN 2003-854360, XP002302976",PENDING
152,US,A1,US 2006/0188476 A1,117-077-500-163-980,2006-08-24,2006,US 34243306 A,2006-01-30,US 34243306 A;;DK PA200301151 A;;DK 2004000532 W;;US 49530003 P,2003-08-08,Interleukin 20 (IL-20) and its use in neovascularisation,The invention provides a novel method of regulating neovascularisation.,NOVO NORDISK AS,OLSEN UFFE B;;HANSEN ANKER J;;ROMER JOHN;;HASSELAGER ERIK;;CLAUSEN JES T;;IVERSEN LARS F,,https://lens.org/117-077-500-163-980,Patent Application,yes,7,18,5,5,2,A61K38/20;;A61K38/20;;A61P17/02;;A61P35/00;;A61P43/00,A61K38/20,424/85.2,0,0,,,,DISCONTINUED
153,AU,B2,AU 635070 B2,185-539-627-335-110,1993-03-11,1993,AU 1990/063584 A,1990-08-24,DK 420289 A,1989-08-25,PROCESS FOR TREATMENT OF LIGNOCELLULOSIC PULP,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK A/S,LARS SAABY PEDERSEN;;STEEN SKJOLD-JOERGENSEN;;LISBETH ANKER;;HELEN F. AUSTIN;;BRUCE ZAMOST;;DANA DURRSCHMIDT ELM,,https://lens.org/185-539-627-335-110,Granted Patent,no,3,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
154,ZA,B,ZA 9811565 B,070-402-574-805-686,1999-06-17,1999,ZA 9811565 A,1998-12-17,DK 147997 A,1997-12-17,Novel pyridine and pyrimidine derivatives,,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;LUNDEMOSE ANKER G;;JEPPESEN CLAUS BEKKER;;SORENSEN ANDERS ROBERT;;DANIELSEN GILLIAN MARY,,https://lens.org/070-402-574-805-686,Granted Patent,no,0,0,4,4,0,C07D471/04,C07D471/04,,0,0,,,,EXPIRED
155,AU,A,AU 1999/015562 A,129-145-504-240-960,1999-07-05,1999,AU 1999/015562 A,1998-12-11,DK 147997 A;;DK 9800549 W,1997-12-17,Novel pyridine and pyrimidine derivatives,,NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;LUNDEMOSE ANKER G;;JEPPESEN CLAUS BEKKER;;SORENSEN ANDERS ROBERT;;DANIELSEN GILLIAN MARY,,https://lens.org/129-145-504-240-960,Patent Application,no,0,0,4,4,0,C07D471/04,C07D471/04,,0,0,,,,DISCONTINUED
156,BR,A,BR 9007608 A,147-824-370-762-743,1992-08-25,1992,BR 9007608 A,1990-08-24,DK 420289 A;;DK 9000220 W,1989-08-25,PROCESSO PARA TRATAMENTO DE POLPA QUIMICA LIGNOCELULOSICA,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F;;ZAMOST BRUCE;;ELM DANA DURRSCHMIDT,,https://lens.org/147-824-370-762-743,Patent Application,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,DISCONTINUED
157,WO,A8,WO 1999/031098 A8,090-217-746-843-568,1999-08-26,1999,DK 9800549 W,1998-12-11,DK 147997 A,1997-12-17,NOVEL PYRIDINE AND PYRIMIDINE DERIVATIVES,"A novel class of substituted pyridine and pyrimidine derivatives, methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of disorders in which a reduction of the blood glucose is beneficial. The derivatives are particularly useful for the treatment and/or prevention of non-insulin dependent diabetes mellitus (NIDDM).",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;LUNDEMOSE ANKER G;;JEPPESEN CLAUS BEKKER;;SOERENSEN ANDERS ROBERT;;DANIELSEN GILLIAN MARY,,https://lens.org/090-217-746-843-568,Patent Application,no,0,0,4,4,0,C07D471/04,C07D471/04,,0,0,,,,PENDING
158,CA,A1,CA 2065244 A1,041-683-265-628-446,1991-02-26,1991,CA 2065244 A,1990-08-24,DK 420289 A,1989-08-25,PROCESS FOR TREATMENT OF LIGNOCELLULOSIC PULP,"2065244 9102839 PCTABS00003 The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,ZAMOST BRUCE;;SKJOLD-JOERGENSEN STEEN;;AUSTIN HELEN F;;ELM DANA D;;PEDERSEN LARS S;;ANKER LISBETH,,https://lens.org/041-683-265-628-446,Patent Application,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,DISCONTINUED
159,NO,C,NO 175948 C,105-961-847-770-474,1995-01-04,1995,NO 920734 A,1992-02-24,DK 420289 A;;DK 9000220 W,1989-08-25,Fremgangsmåte for behandling av lignocellulosemasse,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F;;ZAMOST BRUCE;;ELM DANA DURRSCHMIDT,,https://lens.org/105-961-847-770-474,Granted Patent,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
160,EP,A2,EP 2087905 A2,118-763-274-903-608,2009-08-12,2009,EP 09158227 A,2004-08-09,EP 04739029 A;;DK PA200301151 A;;US 49530003 P,2003-08-08,Interleukin-20 for treating and diagnosing conditions associated with neovascularisation,The invention provides a novel method of regulating neovascularisation.,NOVO NORDISK AS,OLSEN UFFE BANG;;HANSEN ANKER JON;;ROEMER JOHN;;HASSELAGER ERIK;;CLAUSEN JES THORN;;IVERSEN LARS FOGH,,https://lens.org/118-763-274-903-608,Patent Application,yes,19,0,5,5,0,A61K38/20;;A61K38/20;;A61P17/02;;A61P35/00;;A61P43/00,A61K38/20;;G01N33/53,,44,24,005-530-610-119-448;;000-961-207-300-362;;059-766-301-817-277;;117-182-182-798-861;;021-049-880-398-044;;054-167-555-136-715;;018-694-084-068-187;;033-154-485-941-377;;021-301-666-722-431;;046-475-261-047-666;;023-969-505-910-047;;021-693-018-511-818;;056-456-509-029-170;;016-273-136-051-718;;097-970-813-772-582;;034-994-084-014-896;;085-764-009-624-439;;042-235-850-564-946;;004-720-259-087-901;;072-724-329-457-870;;141-785-095-849-82X;;050-936-820-840-171;;074-012-785-057-034;;034-064-980-590-436,10.1016/s0092-8240(86)90010-8;;3580642;;10.1007/bf02462326;;10.4049/jimmunol.167.7.3545;;11564763;;10.1016/s1471-4906(01)02149-4;;11929132;;2990908;;10.1002/j.1460-2075.1985.tb03741.x;;pmc554302;;10.1016/0378-1119(88)90005-4;;3047011;;10.1016/1046-5928(91)90057-p;;1821793;;10.1126/science.2471267;;2471267;;pmc51688;;2034689;;10.1073/pnas.88.10.4498;;1549776;;10.1126/science.1549776;;1569578;;10.1016/0022-2836(92)90457-u;;1511746;;10.1016/0014-5793(92)80739-4;;10.1126/science.3388019;;3388019;;10.1073/pnas.86.7.2152;;2928323;;pmc286869;;10.1016/0378-1119(86)90398-7;;3803923;;10.1089/dna.1988.7.127;;3282853;;10.3109/03008209609028888;;8835843;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;2156132;;10.1016/0076-6879(90)83007-v;;10.1016/c2009-0-02655-5;;6374086;;10.3109/03639049209046327;;10.1023/a:1018929224005;;8140042;;10.1016/0011-2240(88)90054-5;;12669032;;10.1038/nm848,"SAMBROOK; FRITSCH; MANIATIS: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR;;SAMBROOK ET AL.: ""DNA Cloning: A Practical Approach"", vol. I, II, 1985;;""Oligonucleotide Synthesis"", 1984;;""Nucleic Acid Hybridization"", 1985;;""Transcription And Translation"", 1984;;""Animal Cell Culture"", 1986;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;B. PERBAL, A PRACTICAL GUIDE TO MOLECULAR CLONING, 1984;;""Remington's Pharmaceutical Sciences"", 1996, MACK PUBLISHING CO.;;ALTSCHUL ET AL., BULL. MATH. BIO., vol. 48, 1986, pages 603 616;;HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992;;DUMOUTIER ET AL., J. IMMOL, vol. 167, 2001, pages 3545 - 3549;;FICKENSCHER ET AL., TRENDS IMMUNOL, vol. 23, 2002, pages 89 - 96;;NILSSON ET AL., EMBO J., vol. 4, 1985, pages 1075;;NILSSON ET AL., METHODS ENZYMOL., vol. 198, 1991, pages 3;;SMITH; JOHNSON, GENE, vol. 67, 1988, pages 31;;FORD ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 2, 1991, pages 95 107;;CUN-NINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;BASS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4498 - 4502;;VOS, SCIENCE, vol. 255, 1992, pages 306 312;;SMITH ET AL., J. MOD. BIOD., vol. 224, 1992, pages 899 904;;WLODAVER, FEES LETT., vol. 309, 1992, pages 59 64;;REIDHAAR; OLSON; SAUER, SCIENCE, vol. 241, 1988, pages 53 57;;BOWIE; SAUER, PROC. NAT1. ACAD. SCI. USA, vol. 86, 1989, pages 2152 - 2156;;LOWMAN ET AL., BIO- CHEM., vol. 30, 1991, pages 10832 - 10837;;DERBYSHIRE ET AL., GENE, vol. 46, 1986, pages 145;;NER ET AL., DNA, vol. 7, 1988, pages 127;;TUAN ET AL., CONNECTIVE TISSUE RESEARCH, vol. 34, 1996, pages 1 9;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR;;D.J. LIPMAN: ""Improved Tools for Biological Sequence Analysis"", PNAS, vol. 85, 1988, pages 2444 - 2448;;W.R. PEARSON: ""Rapid and Sensitive Sequence Comparison with FASTP and FASTA"", METHODS IN ENZYMOLOGY, vol. 183, 1990, pages 63 - 98;;""More Gene Manipulations in Fungi"", 1991, ACADEMIC PRESS;;REMINGTON: ""The Science and Practise of Pharmacy"", 1995;;REMINGTON: ""The Science and Practice of Pharmacy"", 1995;;WILLIAMS; POLLI, J. PARENTERAL SCI. TECHNOL., vol. 38, 1984, pages 48 - 59;;MASTERS; ESSEZ, U.K.: ""Spray-Drying Handbook"", 1991, LONGMAN SCIENTIFIC AND TECHNICAL, pages: 491 - 676;;BROADHEAD ET AL., DRUG DEVEL. IND. PHARM., vol. 18, 1992, pages 1169 - 1206;;MUMENTHALER ET AL., PHARM. RES., vol. 11, 1994, pages 12 - 20;;CARPENTER; CROWE, CRYOBIOLOGY, vol. 25, 1988, pages 459 - 470;;ROSER, BIOPHARM., vol. 4, 1991, pages 47 - 53;;""Handbook of Pharmaceutical Controlled Release"", 2000, MARCEL DEKKER;;""Drug and the Pharmaceutical Sciences vol. 99: Protein Formulation and Delivery"", vol. 99, 2000, MARCEL DEKKER;;AHERN. T.J.; MAN- NING M.C.: ""Stability of Protein Pharmaceuticals"", 1992, PLENUM PRESS;;CAO RH ET AL., NATURE MEDICINE, vol. 9, no. 5, 2003, pages 604 - 613",DISCONTINUED
161,FI,A0,FI 920798 A0,149-322-628-669-320,1992-02-24,1992,FI 920798 A,1992-02-24,DK 420289 A;;DK 9000220 W,1989-08-25,PROCESS FOER BEHANDLING AV LIGNOCELLULOSAMASSA.,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F;;ELM DANA DURRSCHMIDT;;ZAMOST BRUCE,,https://lens.org/149-322-628-669-320,Patent Application,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,DISCONTINUED
162,NO,B,NO 175948 B,040-665-990-868-201,1994-09-26,1994,NO 920734 A,1992-02-24,DK 420289 A;;DK 9000220 W,1989-08-25,Fremgangsmåte for behandling av lignocellulosemasse,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F;;ZAMOST BRUCE;;ELM DANA DURRSCHMIDT,,https://lens.org/040-665-990-868-201,Unknown,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
163,WO,A1,WO 1999/031098 A1,147-772-243-827-901,1999-06-24,1999,DK 9800549 W,1998-12-11,DK 147997 A,1997-12-17,NOVEL PYRIDINE AND PYRIMIDINE DERIVATIVES,"A novel class of substituted pyridine and pyrimidine derivatives, methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of disorders in which a reduction of the blood glucose is beneficial. The derivatives are particularly useful for the treatment and/or prevention of non-insulin dependent diabetes mellitus (NIDDM).",NOVO NORDISK AS,KNUTSEN LARS JACOB STRAY;;LUNDEMOSE ANKER G;;JEPPESEN CLAUS BEKKER;;SOERENSEN ANDERS ROBERT;;DANIELSEN GILLIAN MARY,,https://lens.org/147-772-243-827-901,Patent Application,yes,0,2,4,4,0,C07D471/04,C07D471/04,,1,1,050-665-373-186-582,10.1016/s0223-5234(96)80006-7,"EUR. J. MED. CHEM., Volume 31, 1996, A. DA SETTIMO et al., ""Synthesis of Pyrrolo(3,4-c)Pyridine Derivatives Possessing an Acid Group and Their In Vitro and In Vivo Evaluation as Aldose Reductase Inhibitors"", pages 49-58.",PENDING
164,DK,T3,DK 0489104 T3,181-235-222-134-232,1994-04-18,1994,DK 90913469 T,1990-08-24,DK 420289 A,1989-08-25,Fremgangsmåde til behandling af lignocellulosepulp,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F;;ZAMOST BRUCE;;ELM DANA DURRSCHMIDT,,https://lens.org/181-235-222-134-232,Granted Patent,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
165,NO,L,NO 920734 L,113-821-835-148-368,1992-02-24,1992,NO 920734 A,1992-02-24,DK 420289 A;;DK 9000220 W,1989-08-25,FREMGANGSMAATE FOR BEHANDLING AV LIGNOCELLULOSEMASSE,"The process comprises treatment of the pulp with an alkaline xylanase at pH values above 7.5 with subsequent treatment of the thus treated pulp with chlorine with a multiple for active chlorine of 0.20 or less in the first chlorination stage. In this manner the necessary time for the enzymatic pretreatment can be reduced, and furthermore the need for the amount of active chlorine in the first chlorination stage is reduced.",NOVO NORDISK AS,PEDERSEN LARS SAABY;;SKJOLD-JOERGENSEN STEEN;;ANKER LISBETH;;AUSTIN HELEN F;;ZAMOST BRUCE;;ELM DANA DURRSCHMIDT,,https://lens.org/113-821-835-148-368,Abstract,no,0,0,22,22,0,C12P19/14;;D21C5/005,C12P19/14;;C12S3/08;;D21C5/00;;D21C9/10;;D21C9/12,,0,0,,,,EXPIRED
166,EP,A1,EP 1653995 A1,134-823-380-814-926,2006-05-10,2006,EP 04739029 A,2004-08-09,DK 2004000532 W;;DK PA200301151 A;;US 49530003 P,2003-08-08,INTERLEUKIN-20 FOR TREATING AND DIAGNOSING CONDITIONS ASSOCIATED WITH NEOVASCULARISATION,,NOVO NORDISK AS,OLSEN UFFE BANG;;HANSEN ANKER JON;;ROMER JOHN;;HASSELAGER ERIK;;CLAUSEN JES THORN;;IVERSEN LARS FOGH,,https://lens.org/134-823-380-814-926,Patent Application,yes,0,0,5,5,0,A61K38/20;;A61K38/20;;A61P17/02;;A61P35/00;;A61P43/00,A61K38/20,,1,0,,,See references of WO 2005014028A1,DISCONTINUED
167,IN,A,IN 2774KON2014 A,050-369-112-735-938,2015-05-08,2015,IN 2774KON2014 A,2014-12-02,US 201261656242 P;;US 201361768905 P;;EP 2013061752 W,2012-06-06,VACCINE,"The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and/or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and/or a reservoir purging agent,such as a histone deacetylase (HDAC) inhibitor.",BIONOR IMMUNO AS,HØIE LARS;;LUNDEMOSE ANKER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SØRENSEN BIRGER,,https://lens.org/050-369-112-735-938,Patent Application,no,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K39/21,,0,0,,,,PENDING
168,EP,A1,EP 2858667 A1,176-779-220-487-506,2015-04-15,2015,EP 13730828 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 2013061750 W,2012-06-06,HIV VACCINE,,BIONOR IMMUNO AS,SØRENSEN BIRGER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT;;HØIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,,https://lens.org/176-779-220-487-506,Patent Application,yes,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,14,8,075-889-606-900-215;;007-472-424-906-413;;126-138-973-529-869;;107-646-518-618-845;;126-138-973-529-869;;078-045-984-755-501;;078-045-984-755-501;;045-407-550-913-363,22339485;;10.3109/00365548.2011.653581;;10.1089/088922202320935438;;12487807;;20721838;;10.1186/1742-4690-9-s1-i16;;20721838;;22732922;;pmc3491743;;10.1093/infdis/jis412;;22732922;;pmc3491743;;10.1093/infdis/jis412;;10.1016/j.clim.2009.09.009;;19889582;;pmc2818410,"LIND A ET AL: ""Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4+ and CD8+ T cell responses lasting more than seven years"", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, SCANDINAVIAN UNIVERSITY PRESS, OSLO, NO, vol. 44, no. 8, 1 August 2012 (2012-08-01), pages 566 - 572, XP008157946, ISSN: 0036-5548, DOI: 10.3109/00365548.2011.653581;;ASJÖ B ET AL: ""Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy"", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 18, no. 18, 10 December 2002 (2002-12-10), pages 1357 - 1365, XP002687385, ISSN: 0889-2229, DOI: 10.1089/088922202320935438;;JONES TAFF: ""Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection"", CURRENT OPINION IN INVESTIGATIONAL DRUGS, THOMSON REUTERS (SCIENTIFIC) LTD, LONDON, UK, vol. 11, no. 8, 1 August 2010 (2010-08-01), pages 964 - 970, XP009181003, ISSN: 2040-3429;;JENNIFER LEVIN: ""Successfully results from clinical study with Vacc-4x and Endocine | FiercePharma"", 17 May 2012 (2012-05-17), XP055284267, Retrieved from the Internet <URL:http://www.fiercepharma.com/vaccines/successfully-results-from-clinical-study-vacc-4x-and-endocine> [retrieved on 20160628];;SEAN R HOSEIN: ""Norwegian HIV vaccine-Very modest results seen in recent clinical trial"", 21 February 2012 (2012-02-21), XP055284277, Retrieved from the Internet <URL:http://www.catie.ca/en/printpdf/catienews/2012-02-21/norwegian-hiv-vaccine-very-modest-results-seen-recent-clinical-trial> [retrieved on 20160628];;ANONYMOUS: ""PA || Current HIV News"", 3 May 2012 (2012-05-03), XP055284279, Retrieved from the Internet <URL:http://www.positivelyaware.com/archives/2012/news_briefs/news_briefs_12_03_01.shtml> [retrieved on 20160628];;SANTIAGO MORENO: ""Anti-latency agents to purge HIV reservoirs"", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 9, no. Suppl 1, 25 May 2012 (2012-05-25), pages I16, XP021095794, ISSN: 1742-4690, DOI: 10.1186/1742-4690-9-S1-I16;;T JONES: ""Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection."", CURR OPIN INVESTIG DRUGS, vol. 11, no. 8, 11 August 2010 (2010-08-11), pages 964 - 970, XP055431415;;J. BLAZKOVA ET AL: ""Effect of Histone Deacetylase Inhibitors on HIV Production in Latently Infected, Resting CD4+ T Cells From Infected Individuals Receiving Effective Antiretroviral Therapy"", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 206, no. 5, 25 June 2012 (2012-06-25), CHICAGO, IL., pages 765 - 769, XP055431479, ISSN: 0022-1899, DOI: 10.1093/infdis/jis412;;Blazkova, Abstract 108 ""Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy."" Keystone Symposia HIV Eradicatin March 2012, Poster Abstracts, Frontiers in HIV Pathogenesis, Tuesday;;ROUTY J P ET AL: ""Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy"", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 134, no. 2, 1 February 2010 (2010-02-01), pages 140 - 147, XP026827613, ISSN: 1521-6616, [retrieved on 20091104];;ANONYMOUS: ""NCT00659789 on 2012_02_02: ClinicalTrials.gov Archive"", 2 February 2012 (2012-02-02), XP055431651, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT00659789/2012_02_02> [retrieved on 20171204];;ANONYMOUS: ""Clinical Reseacrh Protocol: IMMUNOTHERAPY OF HIV-INFECTED PATIENTS: A single-blinded, randomized, immunogenicity, pilot study of intranasal administration of Vacc-4x with Endocine as adjuvant."", 20 May 2012 (2012-05-20), Retrieved from the Internet <URL:https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=2ahUKEwiDmrOAxO_dAhUKKFAKHZZ-APIQFjACegQIBxAC&url=http%3A%2F%2Fjournals.plos.org%2Fplosone%2Farticle%2Ffile%3Ftype%3Dsupplementary%26id%3Dinfo%3Adoi%2F10.1371%2Fjournal.pone.0112556.s002&usg=AOvVaw1s1XfbFEkFjVy6bCgL-5g4> [retrieved on 20181005];;See also references of WO 2013182660A1",DISCONTINUED
169,EP,A2,EP 3967323 A2,124-465-258-504-203,2022-03-16,2022,EP 21176262 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 13730828 A;;EP 2013061750 W,2012-06-06,HIV VACCINE,"The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.
",BIONOR IMMUNO AS,SØRENSEN BIRGER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT;;HØIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,,https://lens.org/124-465-258-504-203,Patent Application,yes,52,0,24,24,69,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,73,56,021-312-792-828-011;;008-019-015-818-595;;006-655-500-310-036;;031-788-303-706-950;;006-482-646-188-149;;016-074-634-735-109;;065-305-126-448-376;;069-025-475-478-505;;049-267-952-264-152;;011-557-917-823-306;;117-203-049-791-548;;069-025-475-478-505;;042-204-626-457-327;;127-706-827-894-461;;077-532-829-551-519;;006-574-964-805-278;;162-646-650-680-173;;042-235-850-564-946;;025-502-903-207-115;;056-201-471-905-934;;028-862-168-091-90X;;070-318-972-823-861;;004-080-056-048-328;;049-697-084-003-824;;006-071-768-855-708;;058-263-944-579-750;;008-586-279-961-02X;;038-651-946-063-60X;;040-564-054-665-636;;012-233-267-251-566;;029-889-648-056-624;;100-643-690-081-324;;101-556-508-196-784;;040-248-991-014-497;;000-488-828-478-314;;077-902-281-227-830;;033-734-546-562-460;;013-156-923-422-168;;041-869-100-449-381;;154-131-435-813-225;;060-678-743-599-049;;100-232-061-503-962;;097-299-492-311-452;;088-674-448-033-446;;040-803-392-303-107;;026-100-922-350-309;;095-009-613-240-195;;016-452-999-291-294;;005-538-767-286-70X;;026-794-989-787-512;;064-865-149-673-057;;067-172-489-998-955;;157-974-914-113-933;;002-815-825-053-992;;002-815-825-053-992;;015-606-173-288-411,9780250;;10.1086/314436;;10.1007/bf00918790;;1708780;;1673465;;10.1093/infdis/163.5.959;;10.1093/infdis/168.6.1523;;7504036;;9728534;;10.1086/515378;;8617980;;7730654;;10.1089/aid.2007.0194;;18544021;;10.1006/viro.1994.1293;;7514319;;1715361;;9367954;;10.1126/science.278.5342.1447;;0009367954;;10.1089/aid.2007.0194;;18544021;;3127726;;10.1038/332323a0;;9415445;;10.1093/protein/10.8.949;;10.1038/nbt1142;;16151406;;10.1038/321522a0;;3713831;;10.1016/0959-440x(92)90091-k;;2156132;;10.1016/0076-6879(90)83007-v;;10.1385/1-59259-192-2:185;;10547837;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1146/annurev-pharmtox-061008-103129;;18851703;;pmc2481506;;10.1016/j.jmb.2008.04.049;;18508079;;pmc3372706;;10.1016/j.vaccine.2012.04.084;;22575167;;21723901;;10.1016/j.vaccine.2011.06.070;;7660002;;7919109;;10.1016/0753-3322(94)90080-9;;10.1182/blood.v89.9.3129;;9129015;;19416838;;10.1073/pnas.0903181106;;pmc2674105;;10.1016/s0140-6736(01)06957-4;;10.3410/f.1002866.32207;;11747915;;17652518;;pmc1937553;;10.1073/pnas.0703342104;;10723627;;10.1080/0738-859991229170;;10.1371/journal.pone.0003116;;18776936;;pmc2525815;;10.1080/10611860801900462;;18446607;;10.1016/j.vaccine.2008.05.074;;18599166;;17558426;;10.1016/j.vaccine.2007.12.038;;18272264;;18501482;;10.1016/j.vaccine.2008.04.023;;16054274;;10.1016/j.vaccine.2005.06.018;;19008380;;10.1099/vir.0.2008/005470-0;;10.2174/157016208785861195;;pmc2683678;;18855649;;10.1126/science.1165706;;19265012;;10.1371/journal.pone.0018270;;pmc3071729;;21483687;;pmc52816;;1682922;;10.1073/pnas.88.21.9838;;8765505;;10.1021/jm9603328;;10.1016/s0960-894x(98)00475-2;;9873600;;10.1146/annurev.immunol.15.1.617;;9143702;;10.1016/s0024-3205(96)00502-4;;9000640;;1471428;;10.1016/0264-410x(92)90106-t;;10.1016/s0040-4020(00)00305-7;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;10.1111/j.1399-3011.1990.tb00939.x;;2191922;;10.1016/s0040-4039(00)91864-1;;22718823;;10.1128/jvi.00472-12;;pmc3416114;;22718823;;10.1128/jvi.00472-12;;pmc3416114;;10.1016/s0140-6736(05)67098-5;;16099290;;pmc1894952,"SOMMERFELT, RECENT TRANSLATIONAL RESEARCH IN HIV/AIDS, 2011, pages 493 - 510, ISBN: ISBN 979-953-307-189-2;;LOOMIS-PRICE ET AL., J. INF. DIS., vol. 178, 1998, pages 1306 - 1316;;WARREN RQ ET AL., J. CLIN. IMMUNOL, vol. 11, 1991, pages 13 - 21;;LIFSON ET AL., J. INF. DIS, vol. 163, 1991, pages 959 - 965;;WONG ET AL., J. INF. DIS, vol. 168, 1993, pages 1523 - 1527;;LIEGLER ET AL., J. INFEC. DIS., vol. 178, 1998, pages 669 - 79;;GOUGEON ET AL., J. IMMUNOL., vol. 156, 1996, pages 3509 - 20;;MURO-CACHO ET AL., J. IMMUNOL., vol. 154, 1995, pages 5555 - 66;;EASTERBROOK ET AL., J. INFECT., vol. 28, 1999, pages 71 - 73;;CADOGAN ET AL., AIDS RESEARCH AND HUMAN RETORVIRUSES, vol. 24, 2008, pages 845 - 855;;ZWART G. ET AL., VIROLOGY, vol. 201, June 1994 (1994-06-01), pages 285 - 93;;JOHNSON R.P. ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 5, 1 September 1991 (1991-09-01), pages 1512 - 1521;;ROSENBERG E.S. ET AL., SCIENCE, vol. 278, 21 November 1997 (1997-11-21), pages 1447 - 1450;;LAKE D.F. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 23, 8 November 1994 (1994-11-08), pages 10849 - 53;;KLENERMAN P., NATURE, vol. 369, no. 6479, 2 June 1994 (1994-06-02), pages 355;;CADOGAN ET AL., AIDS RES AND HUM RETROVIRUSES, vol. 24, 2008, pages 845 - 55;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PROTEIN ENG, vol. 10, 1997, pages 949 - 57;;HOLLIGERHUDSON, NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 1136;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;PEARSON, METHODS ENZYMOL, vol. 183, 1990, pages 63 - 98;;PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;ALTSCHUL ET AL., NUCLEIC ACIDS RES, vol. 25, 1997, pages 3389 - 402;;JENNINGSBACHMANN, ANN. REV. PHARMACOL. TOXICOL., vol. 49, 2009, pages 303 - 26;;PEABODY ET AL., J. MOL. BIOL., vol. 380, 2008, pages 252 - 63;;BARTON ET AL., CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 93, no. 1, 2013, pages 46 - 561;;HUNG CY ET AL.: ""An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection"", VACCINE, 2012;;KOLLESSERY G ET AL.: ""Tumor-specific peptide based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model"", VACCINE, vol. 29, 2011, pages 5904 - 10, XP028248487, DOI: 10.1016/j.vaccine.2011.06.070;;SALIOU P, REV. PRAT., vol. 45, 1995, pages 1492 - 1496;;ROESTENBERG M ET AL., PLOS ONE, vol. 3, no. 12, 18 December 2008 (2008-12-18), pages e3960;;RELYVELD ECHERMANN JC, BIOMED PHARMACOTHER, vol. 48, no. 2, 1994, pages 79 - 83;;HSU FJ ET AL., BLOOD, vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 3129 - 35;;GALLI G ET AL., PROC NATL ACAD SCI USA., vol. 106, no. 19, 27 April 2009 (2009-04-27), pages 7962 - 7;;BOJANG KA ET AL., LANCET, vol. 358, no. 9297, 8 December 2001 (2001-12-08), pages 1927 - 34;;ODUNSI K ET AL., PROC NATL ACAD SCI USA., vol. 104, no. 31, 25 July 2007 (2007-07-25), pages 12837 - 42;;PATEL GBSPROTT GD, CRIT REV BIOTECHNOL, vol. 19, no. 4, 1999, pages 317 - 57;;AGGER EM ET AL., PLOS ONE, vol. 3, no. 9, 8 September 2008 (2008-09-08), pages e3116;;KIRBY DJ ET AL., J DRUG TARGET, vol. 16, no. 4, May 2008 (2008-05-01), pages 282 - 93;;FLORINDO HF ET AL., VACCINE, vol. 26, no. 33, 17 June 2008 (2008-06-17), pages 4168 - 77;;SUN HX ET AL., VACCINE, 28 May 2009 (2009-05-28);;GUY B, NAT REV MICROBIOL, vol. 5, no. 7, July 2007 (2007-07-01), pages 505 - 17;;VANDEPAPELIERE P ET AL., VACCINE, vol. 26, no. 10, 14 January 2008 (2008-01-14), pages 1375 - 86;;GHOCHIKYAN A ET AL., VACCINE, vol. 24, no. 13, 5 December 2005 (2005-12-05), pages 2275 - 82;;XIE Y ET AL., VACCINE, vol. 26, no. 27-28, 1 May 2008 (2008-05-01), pages 3452 - 60;;CHUNG YC ET AL., VACCINE, vol. 26, no. 15, 25 February 2008 (2008-02-25), pages 1855 - 62;;MAIER M ET AL., VACCINE, vol. 23, no. 44, 25 October 2005 (2005-10-25), pages 5149 - 59;;SUNDLING C ET AL., J GEN VIROL, vol. 89, December 2008 (2008-12-01), pages 2954 - 64;;ALEXAKI ET AL., CURR. HIV RES, vol. 6, 2008, pages 388 - 400;;RICHMAN ET AL., SCIENCE, vol. 323, 2009, pages 1304 - 1307;;KOVOCHICH ET AL., PLOS ONE, vol. 6, no. 4, 2011, pages e18270;;PANTALEO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 9838 - 42;;FOX ET AL., J. INFECT. DIS., vol. 164, 1991, pages 1051 - 57;;MARRIOTT, J.B. ET AL., EXPERT OPIN. BIOL. THER., vol. 4, 2001, pages 1 - 8;;G.W. MULLER ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 17, 1996, pages 3238 - 3240;;G.W. MULLER ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, 1998, pages 2669 - 2674;;L.G. CORRAL ET AL., ANN. RHEUM. DIS., vol. 58, 1999, pages 1107 - 1113;;DONNELLY JJ, ANNU. REV. IMMUNOL., vol. 15, 1997, pages 617 - 648;;DONNELLY JJ ET AL., LIFE SCIENCES, vol. 60, 1997, pages 163 - 172;;WALKER PD, VACCINE, vol. 10, 1992, pages 977 - 990;;SCHUTZ A ET AL., TETRAHEDRON, vol. 56, 9 June 2000 (2000-06-09), pages 3889 - 3891;;ATHERTON ET AL., J. CHEM. SOC. CHEM COMMUN, 1978, pages 539;;W.C. CHANP.D. WHITE: ""Solid Phase Peptide Synthesis - A Practical Approach"", 2000, OXFORD UNIVERSITY PRESS INC.;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;BARANYMERRIFIELD: ""Peptides, Analysis, Synthesis, Biology"", vol. 2, 1980, ACAD.PRESS;;KNEIB-CORONIERMULLEN, INT. J. PEPTIDE PROTEIN RES., vol. 30, 1987, pages 705 - 739;;FIELDSNOBLE, INT.J.PEPTIDE PROTEIN RES., vol. 35, 1990, pages 161 - 214;;AKAJI ET AL., TETRAHEDRON LETTER, vol. 33, no. 8, 1992, pages 1073 - 1076;;KEERSMAECKER ET AL., J. VIROL., vol. 86, 2012, pages 9351 - 9360;;BRENDA DE KEERSMAECKERSABINE D. ALLARDPATRICK LACORRIK SCHOTSKRIS THIELEMANSJOERI L. AERTS: ""Expansion of Polyfunctional HIV-Specific T Cells upon Stimulation with mRNA Electroporated Dendritic Cells in the Presence of Immunomodulatory Drugs"", J. VIROL., vol. 86, 20 June 2012 (2012-06-20), pages 9351 - 9360, XP055132916, DOI: 10.1128/JVI.00472-12;;LEHRMAN ET AL., THE LANCET, vol. 366, 2005, pages 549 - 555;;SHEPPARD, J.CHEM.SOC., CHEM. COMMUN., 1978, pages 539",DISCONTINUED
170,HK,A1,HK 1208150 A1,132-236-572-317-909,2016-02-26,2016,HK 15108547 A,2015-09-01,EP 2013061752 W;;US 201261656242 P;;US 201361768905 P,2012-06-06,VACCINE,,BIONOR IMMUNO AS,HIE LARS;;LUNDEMOSE ANKER;;KVIST MATS;;HOVDEN ARNT OVE;;GRNVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SRENSEN BIRGER,,https://lens.org/132-236-572-317-909,Patent Application,no,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K/,,0,0,,,,PENDING
171,WO,A1,WO 2013/182662 A1,160-607-670-783-693,2013-12-12,2013,EP 2013061752 W,2013-06-06,US 201261656242 P;;US 201361768905 P,2012-06-06,VACCINE,"The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and/or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and/or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.",BIONOR IMMUNO AS,HOEIE LARS;;LUNDEMOSE ANKER;;OEKVIST MATS;;HOVDEN ARNT OVE;;GROENVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SOERENSEN BIRGER,,https://lens.org/160-607-670-783-693,Patent Application,yes,73,9,24,24,69,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,86,61,088-605-909-621-20X;;083-760-682-906-160;;050-162-387-635-663;;023-317-419-342-908;;065-374-812-374-601;;060-678-743-599-049;;100-232-061-503-962;;097-299-492-311-452;;088-674-448-033-446;;040-803-392-303-107;;026-100-922-350-309;;021-312-792-828-011;;008-019-015-818-595;;006-655-500-310-036;;031-788-303-706-950;;006-482-646-188-149;;016-074-634-735-109;;065-305-126-448-376;;077-532-829-551-519;;006-574-964-805-278;;042-204-626-457-327;;162-646-650-680-173;;042-235-850-564-946;;025-502-903-207-115;;056-201-471-905-934;;028-862-168-091-90X;;070-318-972-823-861;;004-080-056-048-328;;049-697-084-003-824;;006-071-768-855-708;;008-586-279-961-02X;;038-651-946-063-60X;;040-564-054-665-636;;012-233-267-251-566;;029-889-648-056-624;;100-643-690-081-324;;101-556-508-196-784;;040-248-991-014-497;;000-488-828-478-314;;077-902-281-227-830;;033-734-546-562-460;;013-156-923-422-168;;041-869-100-449-381;;154-131-435-813-225;;095-009-613-240-195;;016-452-999-291-294;;058-263-944-579-750;;005-538-767-286-70X;;065-386-713-665-591;;064-638-684-564-725;;096-049-594-310-196;;088-605-909-621-20X;;048-057-623-080-06X;;014-696-433-147-048;;023-587-284-643-526;;064-865-149-673-057;;067-172-489-998-955;;157-974-914-113-933;;002-815-825-053-992;;002-815-825-053-992;;015-606-173-288-411,pmc3501645;;22406268;;10.1016/j.immuni.2012.01.014;;10.1016/j.vaccine.2006.07.034;;16971027;;10.1038/icb.2011.95;;22083528;;pmc3105138;;10.2119/molmed.2011.00076;;21424110;;10.5772/1753;;10.2174/157016208785861195;;pmc2683678;;18855649;;10.1126/science.1165706;;19265012;;10.1371/journal.pone.0018270;;pmc3071729;;21483687;;pmc52816;;1682922;;10.1073/pnas.88.21.9838;;8765505;;10.1021/jm9603328;;10.1016/s0960-894x(98)00475-2;;9873600;;9780250;;10.1086/314436;;10.1007/bf00918790;;1708780;;1673465;;10.1093/infdis/163.5.959;;10.1093/infdis/168.6.1523;;7504036;;9728534;;10.1086/515378;;8617980;;7730654;;10.1038/nbt1142;;16151406;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1016/0959-440x(92)90091-k;;2156132;;10.1016/0076-6879(90)83007-v;;10.1385/1-59259-192-2:185;;10547837;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1146/annurev-pharmtox-061008-103129;;18851703;;pmc2481506;;10.1016/j.jmb.2008.04.049;;18508079;;pmc3372706;;10.1016/j.vaccine.2012.04.084;;22575167;;21723901;;10.1016/j.vaccine.2011.06.070;;7919109;;10.1016/0753-3322(94)90080-9;;10.1182/blood.v89.9.3129;;9129015;;19416838;;10.1073/pnas.0903181106;;pmc2674105;;10.1016/s0140-6736(01)06957-4;;10.3410/f.1002866.32207;;11747915;;17652518;;pmc1937553;;10.1073/pnas.0703342104;;10723627;;10.1080/0738-859991229170;;10.1371/journal.pone.0003116;;18776936;;pmc2525815;;10.1080/10611860801900462;;18446607;;10.1016/j.vaccine.2008.05.074;;18599166;;17558426;;10.1016/j.vaccine.2007.12.038;;18272264;;18501482;;10.1016/j.vaccine.2008.04.023;;16054274;;10.1016/j.vaccine.2005.06.018;;19008380;;10.1099/vir.0.2008/005470-0;;10.1146/annurev.immunol.15.1.617;;9143702;;10.1016/s0024-3205(96)00502-4;;9000640;;7660002;;1471428;;10.1016/0264-410x(92)90106-t;;10.1002/jcb.20532;;16088937;;10.1002/jcb.22185;;pmc2766855;;19459166;;10.1155/2011/475641;;21188171;;pmc3004414;;pmc3501645;;22406268;;10.1016/j.immuni.2012.01.014;;10.3410/f.1165504.628500;;10.1172/jci39199;;pmc2769176;;10.3410/f.1165504.723055;;19805909;;10.1182/blood-2007-06-097907;;17881634;;21992606;;pmc3215964;;10.1186/1742-4690-8-80;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;10.1111/j.1399-3011.1990.tb00939.x;;2191922;;10.1016/s0040-4039(00)91864-1;;22718823;;10.1128/jvi.00472-12;;pmc3416114;;22718823;;10.1128/jvi.00472-12;;pmc3416114;;10.1016/s0140-6736(05)67098-5;;16099290;;pmc1894952,"LIANG SHAN ET AL: ""Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation"", IMMUNITY, CELL PRESS, US, vol. 36, no. 3, 5 January 2012 (2012-01-05), pages 491 - 501, XP028475174, ISSN: 1074-7613, [retrieved on 20120227], DOI: 10.1016/J.IMMUNI.2012.01.014;;BIONOR PHARMA ASA: ""First Human Clinical Study of HIV Vaccine Vacc-C5 Approved to Begin"", 29 May 2012 (2012-05-29), pages 1 - 5, XP002714661, Retrieved from the Internet <URL:http://www.bloomberg.com/article/2012-05-29/aAPWrFGgXY00.html> [retrieved on 20131007];;BIONOR PHARMA: ""New Clinical Trial, HIV Vacc-4x in Combination With Revlimid (lenalidomide)"", 25 November 2011 (2011-11-25), pages 1 - 2, XP002714662, Retrieved from the Internet <URL:http://www.bionorpharma.com/en/News/2011/Scientific/New+clinical+trial,+HIV+Vacc-4x+in+combination+with+Revlimid%C2%AE+%28Lenalidomide%29.b7C_wljQ2f.ips> [retrieved on 20131002];;BIONOR PHARMA: ""HIV Therapeutic Vaccine Vacc-4x 'lowered viral load in patients off A'"", 15 February 2012 (2012-02-15), pages 1 - 3, XP002714663, Retrieved from the Internet <URL:http://www.natap.org/2012/newsUpdates/021512_03.htm> [retrieved on 20131007];;ROMAS GELEZIUNAS, PH.D: ""Gilead HIV Eradication Program"", 25 May 2012 (2012-05-25), pages 1 - 28, XP002714664, Retrieved from the Internet <URL:http://www.isheid.com/presentations/vendredi/12-30/geleziunas/Geleziunas.pdf> [retrieved on 20131002];;""Vaccination may be key for true elimination of HIV-1"", 8 March 2012 (2012-03-08), pages 1 - 1, XP002714665, Retrieved from the Internet <URL:http://www.eurekalert.org/pub_releases/2012-03/cp-vmb030812.php> [retrieved on 20131001];;QIU ET AL: ""Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag"", VACCINE, ELSEVIER LTD, GB, vol. 25, no. 2, 8 December 2006 (2006-12-08), pages 253 - 263, XP005798939, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2006.07.034;;SRUTISRIVATSAN: ""Researchers Make Progress In Learning How To Activate Latent HIV (CROI 2012)"", 28 March 2012 (2012-03-28), pages 1 - 3, XP002714666, Retrieved from the Internet <URL:http://www.aidsbeacon.com/news/2012/03/28/researchers-make-progress-in-learning-how-to-activate-latent-hiv-aids-croi-2012/> [retrieved on 20131001];;WIGHTMAN FIONA ET AL: ""HDAC inhibitors in HIV"", IMMUNOLOGY AND CELL BIOLOGY, NATURE PUBLISHING GROUP, AU, vol. 90, no. 1, 1 January 2012 (2012-01-01), pages 47 - 54, XP008160750, ISSN: 1440-1711, [retrieved on 20111115], DOI: 10.1038/ICB.2011.95;;MATALON SHAY ET AL: ""Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir"", MOLECULAR MEDICINE (BALTIMORE), vol. 17, no. 5-6, May 2011 (2011-05-01), pages 466 - 472, XP002714668, ISSN: 1076-1551;;SOMMERFELT: ""Recent Translational Research in HIV/AIDS"", 2011, pages: 493 - 510;;ALEXAKI ET AL., CURR. HIV RES., vol. 6, 2008, pages 388 - 400;;RICHMAN ET AL., SCIENCE, vol. 323, 2009, pages 1304 - 1307;;KOVOCHICH ET AL., PLOS ONE, vol. 6, no. 4, 2011, pages E18270;;PANTALEO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 9838 - 42;;FOX ET AL., J. INFECT. DIS., vol. 164, 1991, pages 1051 - 57;;MARRIOTT, J.B. ET AL., EXPERT OPIN. BIOL. THER., vol. 4, 2001, pages 1 - 8;;G.W. MULLER ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 17, 1996, pages 3238 - 3240;;G.W. MULLER ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, 1998, pages 2669 - 2674;;L.G. CORRAL ET AL., ANN. RHEUM. DIS., vol. 58, no. I, 1999, pages 1107 - 1113;;LOOMIS- PRICE ET AL., J. INF DIS., vol. 178, 1998, pages 1306 - 1316;;WARREN RQ, CLIN IMMUNOL, vol. 11, 1991, pages 13 - 21;;LIFSON ET AL., J. INF. DIS, vol. 163, 1991, pages 959 - 965;;WONG ET AL., J.INF. DIS, vol. 168, 1993, pages 1523 - 1527;;LIEGLER ET AL., J. INFEC. DIS., vol. 178, 1998, pages 669 - 79;;GOUGEON ET AL., J. IMMUNOL, vol. 156, 1996, pages 3509 - 20;;MURO-CACHO ET AL., J. IMMUNOL, vol. 154, 1995, pages 5555 - 66;;EASTERBROOK ET AL., J. INFECT, vol. 28, 1999, pages 71 - 73;;HARLOW ET AL.: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;III ET AL., PROTEIN ENG, vol. 10, 1997, pages 949 - 57;;HOLLIGER; HUDSON, NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 1136;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98;;PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402;;JENNINGS; BACHMANN, ANN REV PHARMACOL. TOXICOL., vol. 49, 2009, pages 303 - 26;;PEABODY ET AL., J. MOL. BIOL., vol. 380, 2008, pages 252 - 63;;HUNG CY ET AL.: ""An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection"", VACCINE, 2012;;KOLLESSERY G ET AL.: ""Tumor- specific peptide based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model"", VACCINE, vol. 29, 2011, pages 5904 - 10;;DUNCAN E.S. STEWART-TULL: ""The Theory and Practical Application of Adjuvants"", 1995, JOHN WILEY & SONS LTD;;GREGORIADIS G ET AL.: ""Vaccines: New Generationn Immunological Adjuvants"", 1995, PLENUM PRESS;;ROESTENBERG M ET AL., PLOS ONE, vol. 3, no. 12, 18 December 2008 (2008-12-18), pages E3960;;RELYVELD E; CHERMANN JC, BIOMED PHARMACOTHER., vol. 48, no. 2, 1994, pages 79 - 83;;HSU FJ ET AL., BLOOD, vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 3129 - 35;;GALLI G ET AL., PROC NATL ACAD SCI U S A., vol. 106, no. 19, 27 April 2009 (2009-04-27), pages 7962 - 7;;BOJANG KA ET AL., LANCET, vol. 358, no. 9297, 8 December 2001 (2001-12-08), pages 1927 - 34;;ODUNSI K ET AL., PROC NATL ACAD SCI USA., vol. 104, no. 31, 25 July 2007 (2007-07-25), pages 12837 - 42;;PATEL GB; SPROTT GD, CRIT REV BIOTECHNOL., vol. 19, no. 4, 1999, pages 317 - 57;;AGGER EM ET AL., PLOS ONE, vol. 3, no. 9, 8 September 2008 (2008-09-08), pages E3116;;KIRBY DJ ET AL., J DRUG TARGET., vol. 16, no. 4, May 2008 (2008-05-01), pages 282 - 93;;FLORINDO HF ET AL., VACCINE, vol. 26, no. 33, 17 June 2008 (2008-06-17), pages 4168 - 77;;SUN HX ET AL., VACCINE, 28 May 2009 (2009-05-28);;GUY B, NAT REV MICROBIOL., vol. 5, no. 7, July 2007 (2007-07-01), pages 505 - 17;;VANDEPAPELIERE P ET AL., VACCINE, vol. 26, no. 10, 14 January 2008 (2008-01-14), pages 1375 - 86;;GHOCHIKYAN A ET AL., VACCINE, vol. 24, no. 13, 5 December 2005 (2005-12-05), pages 2275 - 82;;XIE Y ET AL., VACCINE, vol. 26, no. 27-28, 1 May 2008 (2008-05-01), pages 3452 - 60;;CHUNG YC ET AL., VACCINE, vol. 26, no. 15, 25 February 2008 (2008-02-25), pages 1855 - 62;;MAIER M ET AL., VACCINE, vol. 23, no. 44, 25 October 2005 (2005-10-25), pages 5149 - 59;;SUNDLING C ET AL., J GEN VIROL., vol. 89, December 2008 (2008-12-01), pages 2954 - 64;;DONNELLY JJ ET AL., ANNU. REV. IMMUNOL., vol. 15, 1997, pages 617 - 648;;DONNELLY JJ ET AL., LIFE SCIENCES, vol. 60, 1997, pages 163 - 172;;SALIOU P, REV. PRAT., vol. 45, 1995, pages 1492 - 1496;;WALKER PD, VACCINE, vol. 10, 1992, pages 977 - 990;;SCHUTZ A ET AL., TETRAHEDRON, vol. 56, no. 24, 9 June 2000 (2000-06-09), pages 3889 - 3891;;DOKMANOVIC; MARKS, J. CELL. BIOCHEM., vol. 96, 2005, pages 293 - 304;;MARKS; XU, J. CELL. BIOCHEM., vol. 107, 2009, pages 600 - 608;;FEDERICO; BAGELLA, J. BIOMED. BIOTECHNOL, 2011, pages 475641;;BARTON ET AL., CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 93, no. 1, 2013, pages 46 - 561;;SHAN ET AL., IMMUNITY, vol. 36, no. 3, 2012, pages 491 - 501;;YANG ET AL., J CLIN INVEST., vol. 119, no. 11, 2009, pages 3473 - 3486;;SALEH ET AL., BLOOD, vol. 110, 2007, pages 4161 - 4;;SALEH ET AL., RETROVIROLOGY, vol. 8, 2011, pages 80;;ATHERTON ET AL., J. CHEM. SOC. CHEM COMMUN, 1978, pages 539;;W.C. CHAN; P.D. WHITE: ""Solid Phase Peptide Synthesis - A Practical Approach"", 2000, OXFORD UNIVERSITY PRESS INC.;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;BARANY; MERRIFIELD: ""Peptides, Analysis, Synthesis, Biology"", vol. 2, 1980, ACAD.PRESS;;KNEIB-CORONIER; MULLEN, INT. J. PEPTIDE PROTEIN RES., vol. 30, 1987, pages 705 - 739;;FIELDS; NOBLE, INT.J.PEPTIDE PROTEIN RES., vol. 35, 1990, pages 161 - 214;;AKAJI ET AL., TETRAHEDRON LETTER, vol. 33, no. 8, 1992, pages 1073 - 1076;;KEERSMAECKER ET AL., J. VIROL., vol. 86, 2012, pages 9351 - 9360;;BRENDA DE KEERSMAECKER; SABINE D. ALLARD; PATRICK LACOR; RIK SCHOTS; KRIS THIELEMANS; JOERI L. AERTS, J. VIROL, 20 June 2012 (2012-06-20), pages 9351 - 9360;;LEHRMAN ET AL., THE LANCET, vol. 366, 2005, pages 549 - 555;;SHEPPARD, J.CHEM.SOC., CHEM. COMMUN., 1978, pages 539",PENDING
172,EP,A1,EP 2858665 A1,158-674-679-793-108,2015-04-15,2015,EP 13727203 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 2013061752 W,2012-06-06,VACCINE,,BIONOR IMMUNO AS,HØIE LARS;;LUNDEMOSE ANKER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SØRENSEN BIRGER,,https://lens.org/158-674-679-793-108,Patent Application,yes,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,0,0,,,,DISCONTINUED
173,HK,A1,HK 1207829 A1,178-640-583-576-037,2016-02-12,2016,HK 15108546 A,2015-09-01,EP 2013061750 W;;US 201261656242 P;;US 201361768905 P,2012-06-06,HIV VACCINE,,BIONOR IMMUNO AS,SRENSEN BIRGER;;KVIST MATS;;HOVDEN ARNT OVE;;GRNVOLD MAJA SOMMERFELT;;HIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,,https://lens.org/178-640-583-576-037,Patent Application,no,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K/,,0,0,,,,PENDING
174,AU,A1,AU 2013/273481 A1,117-461-973-619-913,2014-12-18,2014,AU 2013/273481 A,2013-06-06,US 201361768905 P;;US 201261656242 P;;EP 2013061750 W,2012-06-06,HIV vaccine,"The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.",BIONOR IMMUNO AS,SORENSEN BIRGER;;OKVIST MATS;;HOVDEN ARNT OVE;;GRONVOLD MAJA SOMMERFELT;;HOIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,,https://lens.org/117-461-973-619-913,Patent Application,no,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,0,0,,,,INACTIVE
175,US,A1,US 2015/0132255 A1,096-977-637-334-617,2015-05-14,2015,US 201314405302 A,2013-06-06,US 201314405302 A;;US 201261656242 P;;US 201361768905 P;;EP 2013061750 W,2012-06-06,HIV VACCINE,"The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.",BIONOR IMMUNO AS,SORENSEN BIRGER;;OKVIST MATS;;HOVDEN ARNT OVE;;GRONVOLD MAJA SOMMERFELT;;HOIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,BIONOR IMMUNO AS (2013-10-01);;BIONOR PHARMA ASA (2013-08-14),https://lens.org/096-977-637-334-617,Patent Application,yes,0,21,24,24,69,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/21;;A61K31/454;;A61K38/15;;A61K39/42;;A61K45/06;;C12N7/00,424/85.2;;424/188.1;;424/139.1;;424/133.1;;424/173.1,8,8,082-612-863-782-637;;104-744-316-886-227;;076-403-800-982-81X;;001-786-690-520-488;;076-403-800-982-81X;;082-612-863-782-637;;104-744-316-886-227;;001-786-690-520-488,pmc2572109;;10.1038/nature07352;;18833271;;10.1126/science.1152622;;18467582;;16310557;;10.1016/s0140-6736(05)67395-3;;10.1016/j.cell.2014.01.052;;24529371;;pmc4041625;;16310557;;10.1016/s0140-6736(05)67395-3;;pmc2572109;;10.1038/nature07352;;18833271;;10.1126/science.1152622;;18467582;;10.1016/j.cell.2014.01.052;;24529371;;pmc4041625,"Barouch, D. H., 2008, Challenges in the development of an HIV-1 vaccine, Nature 455:613-619.;;Walker, B. D., and D. R. Burton, 2008, Toward an AIDS vaccine, Science 320:760-764.;;Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet 366:1894-1898.;;West, Jr., A. P., et al., 2014, Structural insights on the role of antibodies in HIV-1 vaccine and therapy, Cell 156:633-648.;;Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet 366:1894-1898.;;Barouch, D. H., 2008, Challenges in the development of an HIV-1 vaccine, Nature 455:613-619.;;Walker, B. D., and D. R. Burton, 2008, Toward an AIDS vaccine, Science 320:760-764.;;West, Jr., A. P., et al., 2014, Structural insights on the role of antibodies in HIV-1 vaccine and therapy, Cell 156:633-648.",ACTIVE
176,WO,A1,WO 2013/182660 A1,074-382-005-026-973,2013-12-12,2013,EP 2013061750 W,2013-06-06,US 201261656242 P;;US 201361768905 P,2012-06-06,HIV VACCINE,"The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.",BIONOR IMMUNO AS,SOERENSEN BIRGER;;OEKVIST MATS;;HOVDEN ARNT OVE;;GROENVOLD MAJA SOMMERFELT;;HOEIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,,https://lens.org/074-382-005-026-973,Patent Application,yes,56,13,24,24,69,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,89,60,075-889-606-900-215;;085-500-494-255-745;;133-735-389-483-67X;;088-605-909-621-20X;;050-162-387-635-663;;023-317-419-342-908;;021-312-792-828-011;;008-019-015-818-595;;006-655-500-310-036;;031-788-303-706-950;;006-482-646-188-149;;016-074-634-735-109;;065-305-126-448-376;;069-025-475-478-505;;049-267-952-264-152;;011-557-917-823-306;;117-203-049-791-548;;069-025-475-478-505;;077-532-829-551-519;;006-574-964-805-278;;042-204-626-457-327;;162-646-650-680-173;;042-235-850-564-946;;025-502-903-207-115;;056-201-471-905-934;;028-862-168-091-90X;;070-318-972-823-861;;004-080-056-048-328;;049-697-084-003-824;;006-071-768-855-708;;008-586-279-961-02X;;038-651-946-063-60X;;040-564-054-665-636;;012-233-267-251-566;;029-889-648-056-624;;100-643-690-081-324;;101-556-508-196-784;;040-248-991-014-497;;000-488-828-478-314;;077-902-281-227-830;;033-734-546-562-460;;013-156-923-422-168;;041-869-100-449-381;;154-131-435-813-225;;060-678-743-599-049;;100-232-061-503-962;;097-299-492-311-452;;088-674-448-033-446;;040-803-392-303-107;;026-100-922-350-309;;095-009-613-240-195;;016-452-999-291-294;;058-263-944-579-750;;005-538-767-286-70X;;064-865-149-673-057;;067-172-489-998-955;;157-974-914-113-933;;002-815-825-053-992;;002-815-825-053-992;;015-606-173-288-411,22339485;;10.3109/00365548.2011.653581;;22339677;;10.1111/j.1600-0463.2011.02843.x;;10.1097/01.aids.0000210620.75707.ac;;16470131;;pmc3501645;;22406268;;10.1016/j.immuni.2012.01.014;;10.1038/icb.2011.95;;22083528;;pmc3105138;;10.2119/molmed.2011.00076;;21424110;;9780250;;10.1086/314436;;10.1007/bf00918790;;1708780;;1673465;;10.1093/infdis/163.5.959;;10.1093/infdis/168.6.1523;;7504036;;9728534;;10.1086/515378;;8617980;;7730654;;10.1089/aid.2007.0194;;18544021;;10.1006/viro.1994.1293;;7514319;;1715361;;9367954;;10.1126/science.278.5342.1447;;0009367954;;10.1089/aid.2007.0194;;18544021;;10.1038/nbt1142;;16151406;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1016/0959-440x(92)90091-k;;2156132;;10.1016/0076-6879(90)83007-v;;10.1385/1-59259-192-2:185;;10547837;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1146/annurev-pharmtox-061008-103129;;18851703;;pmc2481506;;10.1016/j.jmb.2008.04.049;;18508079;;pmc3372706;;10.1016/j.vaccine.2012.04.084;;22575167;;21723901;;10.1016/j.vaccine.2011.06.070;;7919109;;10.1016/0753-3322(94)90080-9;;10.1182/blood.v89.9.3129;;9129015;;19416838;;10.1073/pnas.0903181106;;pmc2674105;;10.1016/s0140-6736(01)06957-4;;10.3410/f.1002866.32207;;11747915;;17652518;;pmc1937553;;10.1073/pnas.0703342104;;10723627;;10.1080/0738-859991229170;;10.1371/journal.pone.0003116;;18776936;;pmc2525815;;10.1080/10611860801900462;;18446607;;10.1016/j.vaccine.2008.05.074;;18599166;;17558426;;10.1016/j.vaccine.2007.12.038;;18272264;;18501482;;10.1016/j.vaccine.2008.04.023;;16054274;;10.1016/j.vaccine.2005.06.018;;19008380;;10.1099/vir.0.2008/005470-0;;10.2174/157016208785861195;;pmc2683678;;18855649;;10.1126/science.1165706;;19265012;;10.1371/journal.pone.0018270;;pmc3071729;;21483687;;pmc52816;;1682922;;10.1073/pnas.88.21.9838;;8765505;;10.1021/jm9603328;;10.1016/s0960-894x(98)00475-2;;9873600;;10.1146/annurev.immunol.15.1.617;;9143702;;10.1016/s0024-3205(96)00502-4;;9000640;;7660002;;1471428;;10.1016/0264-410x(92)90106-t;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;10.1111/j.1399-3011.1990.tb00939.x;;2191922;;10.1016/s0040-4039(00)91864-1;;22718823;;10.1128/jvi.00472-12;;pmc3416114;;22718823;;10.1128/jvi.00472-12;;pmc3416114;;10.1016/s0140-6736(05)67098-5;;16099290;;pmc1894952,"BIONOR PHARMA ASA: ""First Human Clinical Study of HIV Vaccine Vacc-C5 Approved to Begin"", 29 May 2012 (2012-05-29), pages 1 - 5, XP002714661, Retrieved from the Internet <URL:http://www.bloomberg.com/article/2012-05-29/aAPWrFGgXY00.html> [retrieved on 20131007];;BIONOR: ""Vacc-4x Therapeutic HIV Vaccine Linked to Lower Viral Load in Phase IIb Study"", 21 February 2012 (2012-02-21), pages 1 - 3, XP002714816, Retrieved from the Internet <URL:http://www.hivandhepatitis.com/hiv-prevention/hiv-vaccines/3465-vacc-4x-therapeutic-hiv-vaccine-linked-to-lower-viral-load-in-phase-iib-study> [retrieved on 20131015];;HITT EMMA: ""Vacc-4x Reduces Viral Load in HIV Patients Off ART"", 26 July 2011 (2011-07-26), pages 1 - 2, XP002714817, Retrieved from the Internet <URL:http://www.medscape.com/viewarticle/747015> [retrieved on 20131015];;LIND A ET AL: ""Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4+ and CD8+ T cell responses lasting more than seven years"", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, SCANDINAVIAN UNIVERSITY PRESS, OSLO, NO, vol. 44, no. 8, 19 February 2012 (2012-02-19), pages 566 - 572, XP008157946, ISSN: 0036-5548, DOI: 10.3109/00365548.2011.653581;;KRAN ANNE-MARTE B ET AL: ""Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection."", APMIS : ACTA PATHOLOGICA, MICROBIOLOGICA, ET IMMUNOLOGICA SCANDINAVICA MAR 2012, vol. 120, no. 3, March 2012 (2012-03-01), pages 204 - 209, XP002714818, ISSN: 1600-0463;;KRAN ANNE-MARTE B ET AL: ""Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells"", AIDS (HAGERSTOWN), vol. 20, no. 4, February 2006 (2006-02-01), pages 627 - 630, XP002714819, ISSN: 0269-9370;;LIANG SHAN ET AL: ""Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation"", IMMUNITY, CELL PRESS, US, vol. 36, no. 3, 5 January 2012 (2012-01-05), pages 491 - 501, XP028475174, ISSN: 1074-7613, [retrieved on 20120227], DOI: 10.1016/J.IMMUNI.2012.01.014;;BIONOR PHARMA: ""New Clinical Trial, HIV Vacc-4x in Combination With Revlimid (lenalidomide)"", 25 November 2011 (2011-11-25), pages 1 - 2, XP002714662, Retrieved from the Internet <URL:http://www.bionorpharma.com/en/News/2011/Scientific/New+clinical+trial,+HIV+Vacc-4x+in+combination+with+Revlimid%C2%AE+%28Lenalidomide%29.b7C_wljQ2f.ips> [retrieved on 20131002];;ROMAS GELEZIUNAS, PH.D: ""Gilead HIV Eradication Program"", 25 May 2012 (2012-05-25), pages 1 - 28, XP002714664, Retrieved from the Internet <URL:http://www.isheid.com/presentations/vendredi/12-30/geleziunas/Geleziunas.pdf> [retrieved on 20131002];;WIGHTMAN FIONA ET AL: ""HDAC inhibitors in HIV"", IMMUNOLOGY AND CELL BIOLOGY, NATURE PUBLISHING GROUP, AU, vol. 90, no. 1, 1 January 2012 (2012-01-01), pages 47 - 54, XP008160750, ISSN: 1440-1711, [retrieved on 20111115], DOI: 10.1038/ICB.2011.95;;MATALON SHAY ET AL: ""Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir"", MOLECULAR MEDICINE (BALTIMORE), vol. 17, no. 5-6, May 2011 (2011-05-01), pages 466 - 472, XP002714668, ISSN: 1076-1551;;SOMMERFELT: ""HIV/AIDS"", 2011, article ""Recent Translational Research"", pages: 493 - 510;;LOOMIS-PRICE ET AL., J. INF. DIS., vol. 178, 1998, pages 1306 - 1316;;WARREN RQ ET AL., J. CLIN. IMMUNOL, vol. 11, 1991, pages 13 - 21;;LIFSON ET AL., J. INF. DIS, vol. 163, 1991, pages 959 - 965;;WONG ET AL., J. INF. DIS, vol. 168, 1993, pages 1523 - 1527;;LIEGLER ET AL., J. INFEC. DIS., vol. 178, 1998, pages 669 - 79;;GOUGEON ET AL., J. IMMUNOL., vol. 156, 1996, pages 3509 - 20;;MURO-CACHO ET AL., J. IMMUNOL., vol. 154, 1995, pages 5555 - 66;;EASTERBROOK ET AL., J. INFECT., vol. 28, 1999, pages 71 - 73;;LOS ALAMOS HIV-DATABASE, 3 May 2008 (2008-05-03);;CADOGAN ET AL., AIDS RESEARCH AND HUMAN RETORVIRUSES, vol. 24, 2008, pages 845 - 855;;ZWART G. ET AL., VIROLOGY, vol. 201, June 1994 (1994-06-01), pages 285 - 93;;JOHNSON R.P. ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 5, 1 September 1991 (1991-09-01), pages 1512 - 1521;;ROSENBERG E.S. ET AL., SCIENCE, vol. 278, 21 November 1997 (1997-11-21), pages 1447 - 1450;;LAKE D.F. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 23, 8 November 1994 (1994-11-08), pages 10849 - 53;;KLENERMAN P. ET AL., NATURE, vol. 369, no. 6479, 2 June 1994 (1994-06-02), pages 355;;CADOGAN ET AL., AIDS RES AND HUM RETROVIRUSES, vol. 24, 2008, pages 845 - 55;;HARLOW ET AL.: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;III ET AL., PROTEIN ENG, vol. 10, 1997, pages 949 - 57;;HOLLIGER; HUDSON, NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 1136;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98;;PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;ALTSCHUL ET AL., NUCLEIC ACIDS RES. 1997, vol. 25, 1997, pages 3389 - 402;;JENNINGS; BACHMANN, ANN. REV. PHARMACOL. TOXICOL., vol. 49, 2009, pages 303 - 26;;PEABODY ET AL., J. MOL. BIOL., vol. 380, 2008, pages 252 - 63;;BARTON ET AL., CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 93, no. 1, 2013, pages 46 - 561;;HUNG CY ET AL.: ""An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection"", VACCINE, 2012;;KOLLESSERY G ET AL.: ""Tumor-specific peptide based vaccines containing the conformationally biased, response- selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model"", VACCINE, vol. 29, 2011, pages 5904 - 10, XP028248487, DOI: doi:10.1016/j.vaccine.2011.06.070;;DUNCAN E.S. STEWART-TULL: ""The Theory and Practical Application of Adjuvants"", 1995, JOHN WILEY & SONS LTD;;GREGORIADIS G ET AL.: ""Vaccines: New Generationn Immunological Adjuvants"", 1995, PLENUM PRESS;;ROESTENBERG M ET AL., PLOS ONE. 2008, vol. 3, no. 12, 18 December 2008 (2008-12-18), pages E3960;;RELYVELD E; CHERMANN JC, BIOMED PHARMACOTHER., vol. 48, no. 2, 1994, pages 79 - 83;;HSU FJ ET AL., BLOOD, vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 3129 - 35;;GALLI G ET AL., PROC NATL ACAD SCI U S A., vol. 106, no. 19, 27 April 2009 (2009-04-27), pages 7962 - 7;;BOJANG KA ET AL., LANCET, vol. 358, no. 9297, 8 December 2001 (2001-12-08), pages 1927 - 34;;ODUNSI K ET AL., PROC NATL ACAD SCI U S A., vol. 104, no. 31, 25 July 2007 (2007-07-25), pages 12837 - 42;;PATEL GB; SPROTT GD, CRIT REV BIOTECHNOL., vol. 19, no. 4, 1999, pages 317 - 57;;AGGER EM ET AL., PLOS ONE, vol. 3, no. 9, 8 September 2008 (2008-09-08), pages E3116;;KIRBY DJ ET AL., J DRUG TARGET., vol. 16, no. 4, May 2008 (2008-05-01), pages 282 - 93;;FLORINDO HF ET AL., VACCINE, vol. 26, no. 33, 17 June 2008 (2008-06-17), pages 4168 - 77;;SUN HX ET AL., VACCINE, 28 May 2009 (2009-05-28);;GUY B, NAT REV MICROBIOL., vol. 5, no. 7, 2007, pages 505 - 17;;VANDEPAPELIERE P ET AL., VACCINE, vol. 26, no. 10, 14 January 2008 (2008-01-14), pages 1375 - 86;;GHOCHIKYAN A ET AL., VACCINE, vol. 24, no. 13, 5 December 2005 (2005-12-05), pages 2275 - 82;;XIE Y ET AL., VACCINE, vol. 26, no. 27-28, 1 May 2008 (2008-05-01), pages 3452 - 60;;CHUNG YC ET AL., VACCINE, vol. 26, no. 15, 25 February 2008 (2008-02-25), pages 1855 - 62;;MAIER M ET AL., VACCINE, vol. 23, no. 44, 25 October 2005 (2005-10-25), pages 5149 - 59;;SUNDLING C ET AL., J GEN VIROL., vol. 89, December 2008 (2008-12-01), pages 2954 - 64;;ALEXAKI ET AL., CURR. HIV RES., vol. 6, 2008, pages 388 - 400;;RICHMAN ET AL., SCIENCE, vol. 323, 2009, pages 1304 - 1307;;KOVOCHICH ET AL., PLOS ONE, vol. 6, no. 4, 2011, pages E18270;;PANTALEO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 9838 - 42;;FOX ET AL., J. INFECT. DIS., vol. 164, 1991, pages 1051 - 57;;MARRIOTT, J.B. ET AL., EXPERT OPIN. BIOL. THER., vol. 4, 2001, pages 1 - 8;;G.W. MULLER ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 17, 1996, pages 3238 - 3240;;G.W. MULLER ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, 1998, pages 2669 - 2674;;L.G. CORRAL ET AL., ANN. RHEUM. DIS., vol. 58, no. I, 1999, pages 1107 - 1113;;DONNELLY JJ ET AL., ANNU. REV. IMMUNOL., vol. 15, 1997, pages 617 - 648;;DONNELLY JJ ET AL., LIFE SCIENCES, vol. 60, 1997, pages 163 - 172;;SALIOU P, REV. PRAT., vol. 45, 1995, pages 1492 - 1496;;WALKER PD, VACCINE, vol. 10, 1992, pages 977 - 990;;SCHUTZ A ET AL., TETRAHEDRON, vol. 56, no. 24, 9 June 2000 (2000-06-09), pages 3889 - 3891;;ATHERTON ET AL., J. CHEM. SOC. CHEM COMMUN, 1978, pages 539;;W.C. CHAN; P.D. WHITE: ""Solid Phase Peptide Synthesis - A Practical Approach"", 2000, OXFORD UNIVERSITY PRESS INC.;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;BARANY; MERRIFIELD: ""Peptides, Analysis, Synthesis, Biology"", vol. 2, 1980, ACAD.PRESS;;KNEIB- CORONIER; MULLEN, INT. J. PEPTIDE PROTEIN RES., vol. 30, 1987, pages 705 - 739;;FIELDS; NOBLE, INT.J.PEPTDE PROTEIN RES., vol. 35, 1990, pages 161 - 214;;AKAJI ET AL., TETRAHEDRON LETTER, vol. 33, no. 8, 1992, pages 1073 - 1076;;KEERSMAECKER ET AL., J. VIROL., vol. 86, 2012, pages 9351 - 9360;;BRENDA DE KEERSMAECKER; SABINE D. ALLARD; PATRICK LACOR; RIK SCHOTS; KRIS THIELEMANS; JOERI L. AERTS: ""Expansion of Polyfunctional HIV-Specific T Cells upon Stimulation with mRNA Electroporated Dendritic Cells in the Presence of Immunomodulatory Drugs"", J. VIROL., vol. 86, 20 June 2012 (2012-06-20), pages 9351 - 9360, XP055132916, DOI: doi:10.1128/JVI.00472-12;;LEHRMAN ET AL., THE LANCET, vol. 366, 2005, pages 549 - 555;;SHEPPARD, J.CHEM.SOC., CHEM. COMMUN., vol. 539, 1978;;See also references of EP 2858667A1",PENDING
177,MX,A,MX 2014014668 A,170-395-939-886-072,2015-03-19,2015,MX 2014014668 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 2013061752 W,2012-06-06,VACCINE.,"The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and/or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and/or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.",BIONOR IMMUNO AS,HØIE LARS;;LUNDEMOSE ANKER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SØRENSEN BIRGER,,https://lens.org/170-395-939-886-072,Patent Application,no,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,0,0,,,,PENDING
178,CN,A,CN 104717974 A,187-919-092-013-699,2015-06-17,2015,CN 201380036502 A,2013-06-06,EP 2013061752 W;;US 201261656242 P;;US 201361768905 P,2012-06-06,Vaccine,"The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and/or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and/or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.",BIONOR IMMUNO AS,HOEIE LARS;;LUNDEMOSE ANKER;;OEKVIST MATS;;HOVDEN ARNT OVE;;GROENVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SOERENSEN BIRGER,,https://lens.org/187-919-092-013-699,Patent Application,no,2,3,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,1,1,088-605-909-621-20X,pmc3501645;;22406268;;10.1016/j.immuni.2012.01.014,"LIANG SHAN ET AL.: ""Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation"", 《IMMUNITY，CELL PRESS》",DISCONTINUED
179,KR,A,KR 20150029678 A,025-484-867-160-754,2015-03-18,2015,KR 20157000149 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 2013061752 W,2012-06-06,VACCINE,,BIONOR IMMUNO AS,HØIE LARS;;LUNDEMOSE ANKER;;OEKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SØRENSEN BIRGER,,https://lens.org/025-484-867-160-754,Patent Application,no,0,1,24,24,138,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K31/19;;A61K31/4439;;A61K39/21;;A61K39/395,,0,0,,,,DISCONTINUED
180,US,A1,US 2015/0174235 A1,029-717-230-866-557,2015-06-25,2015,US 201314405093 A,2013-06-06,US 201314405093 A;;US 201361768905 P;;US 201261656242 P;;EP 2013061752 W,2012-06-06,VACCINE,"The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and/or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and/or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.",BIONOR IMMUNO AS,HOIE LARS;;LUNDEMOSE ANKER;;OKVIST MATS;;HOVDEN ARNT OVE;;GRONVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SORENSEN BIRGER,BIONOR IMMUNO AS (2013-10-01);;BIONOR PHARMA ASA (2013-08-14),https://lens.org/029-717-230-866-557,Patent Application,yes,0,5,24,24,69,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/21;;A61K31/454;;A61K45/06,,6,6,007-994-964-626-795;;030-366-026-184-050;;060-096-861-160-264;;076-403-800-982-81X;;082-612-863-782-637;;104-744-316-886-227,23613347;;10.1002/bies.201200170;;pmc4386637;;10.1371/journal.ppat.1004287;;pmc4133386;;25122219;;pmc4934743;;26984732;;10.1128/jvi.02842-15;;16310557;;10.1016/s0140-6736(05)67395-3;;pmc2572109;;10.1038/nature07352;;18833271;;10.1126/science.1152622;;18467582,"Shan, L., and R. F. Siliciano, 2013, From reactivation of latent HIV-1 to elimination of the latent reservoir: The presence of multiple barriers to viral eradication, Bioessays 35:544-552.;;Jones, R. B., et al., 2014, Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes, PLOS Pathogens, 10(8):e1004287 (1-19).;;Hashemi, F. B., et al., 2016, HIV provirus stably reproduces parental latent and induced transcription phenotypes regardless of the chromosomal integration site, J. Virol. 90(11):5302-5314.;;Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet 366:1894-1898.;;Barouch, D. H., 2008, Challenges in the development of an HIV-1 vaccine, Nature 455:613-619.;;Walker, B. D., and D. R. Burton, 2008, Toward an AIDS vaccine, Science 320:760-764.",DISCONTINUED
181,EP,A3,EP 3967323 A3,009-470-799-934-756,2022-05-04,2022,EP 21176262 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 13730828 A;;EP 2013061750 W,2012-06-06,HIV VACCINE,"The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.
",BIONOR IMMUNO AS,SØRENSEN BIRGER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT;;HØIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,,https://lens.org/009-470-799-934-756,Search Report,yes,2,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,1,0,,,"BIONOR: ""Vacc-4x Therapeutic HIV Vaccine Linked to Lower Viral Load in Phase IIb Study"", 21 February 2012 (2012-02-21), pages 1 - 3, XP002714816, Retrieved from the Internet <URL:http://www.hivandhepatitis.com/hiv-prevention/hiv-vaccines/3465-vacc-4x-therapeutic-hiv-vaccine-linked-to-lower-viral-load-in-phase-iib-study> [retrieved on 20131015]",DISCONTINUED
182,AU,A1,AU 2013/273483 A1,066-544-116-775-239,2014-12-11,2014,AU 2013/273483 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 2013061752 W,2012-06-06,Vaccine,"The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and/or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and/or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.",BIONOR IMMUNO AS,HOIE LARS;;LUNDEMOSE ANKER;;OKVIST MATS;;HOVDEN ARNT OVE;;GRONVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SORENSEN BIRGER,,https://lens.org/066-544-116-775-239,Patent Application,no,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,0,0,,,,DISCONTINUED
183,CA,A1,CA 2874936 A1,171-189-962-020-831,2013-12-12,2013,CA 2874936 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 2013061752 W,2012-06-06,VACCINE,"The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and/or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and/or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.",BIONOR IMMUNO AS,HOIE LARS;;LUNDEMOSE ANKER;;OKVIST MATS;;HOVDEN ARNT OVE;;GRONVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SORENSEN BIRGER,,https://lens.org/171-189-962-020-831,Patent Application,no,0,0,24,24,69,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,0,0,,,,DISCONTINUED
184,AU,B2,AU 2013/273481 B2,081-856-621-205-604,2018-04-05,2018,AU 2013/273481 A,2013-06-06,US 201361768905 P;;US 201261656242 P;;EP 2013061750 W,2012-06-06,HIV vaccine,"The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.",BIONOR IMMUNO AS,SORENSEN BIRGER;;OKVIST MATS;;HOVDEN ARNT OVE;;GRONVOLD MAJA SOMMERFELT;;HOIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,,https://lens.org/081-856-621-205-604,Granted Patent,no,2,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,2,0,,,http://www.marketwired.com/press-release/first-human-clinical-study-of-hiv-vaccine-vacc-c5-approved-to-begin-oslo-bionor-1662580.htm [retrieved on 2/3/17];;http://www.hivandhepatitis.com/hiv-prevention/hiv-vaccines/3465-vacc-4x-therapeutic-hiv-vaccine-linked-to-lower-viral-load-in-phase-iibstudy [retrieved on 2/3/17],INACTIVE
185,CA,A1,CA 2875624 A1,104-170-197-844-648,2013-12-12,2013,CA 2875624 A,2013-06-06,US 201261656242 P;;US 201361768905 P;;EP 2013061750 W,2012-06-06,HIV VACCINE,"The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.",BIONOR IMMUNO AS,SORENSEN BIRGER;;OKVIST MATS;;HOVDEN ARNT OVE;;GRONVOLD MAJA SOMMERFELT;;HOIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,,https://lens.org/104-170-197-844-648,Patent Application,no,0,0,24,24,69,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/00;;A61K31/00;;A61K31/19;;A61K39/21,,0,0,,,,DISCONTINUED
186,US,B2,US 7797065 B2,127-598-625-104-227,2010-09-14,2010,US 11957205 A,2005-05-02,US 11957205 A,2005-05-02,Automute detection in digital audio amplifiers,"A digital audio processor for a digital audio receiver having an improved automute sequence is disclosed. The digital audio processor includes automute detection circuitry that monitors the amplitude of digital audio signals before and after the application of digital filters by digital audio processing circuitry. The amplitude of the input signals are compared against a first threshold level, while the amplitude of the output signals are compared against a second threshold level. In response to the amplitude of the input signals for all of the audio channels falling below the first threshold for a selected time period, a gain stage in each channel ramps down the volume to a mute level, and pulse-width-modulation circuitry is disabled. If the output signal amplitude falls below a second threshold for a channel, the pulse-width-modulation circuitry for that channel is disabled. Hysteresis for the input signal amplitude is preferably added into the automute exit determination.",TEXAS INSTRUMENTS INC,ZAUCHA DAVID EDWARD;;KOWKUTLA VENKATESWAR REDDY;;BJOERN-JOSEFSEN ANKER;;RISBO LARS;;ROBERSON DOUGLAS ALLEN;;ANGILIVELIL JOSEY GEORGE,TEXAS INSTRUMENTS INCORPORATED (2005-07-28),https://lens.org/127-598-625-104-227,Granted Patent,yes,12,9,2,2,0,H03F3/72;;H03F3/72;;H03F1/12;;H03F1/12;;H03F1/26;;H03F1/26;;H03F1/305;;H03F1/305;;H03F3/181;;H03F3/181;;H03F3/217;;H03F3/217;;H03F3/68;;H03F3/68;;H03F2200/03;;H03F2200/03;;H03F2200/331;;H03F2200/331;;H03F2200/342;;H03F2200/342;;H03F2200/351;;H03F2200/351;;H03G3/341;;H03G3/341,G06F17/00;;H03F3/217;;H03G3/00,700/94;;381/107;;X330207 A,0,0,,,,ACTIVE
187,HK,A1,HK 1207967 A1,154-448-577-449-786,2016-02-19,2016,HK 15108578 A,2015-09-02,EP 2013061752 W;;US 201261656242 P;;US 201361768905 P,2012-06-06,VACCINE,,BIONOR IMMUNO AS,HIE LARS;;LUNDEMOSE ANKER;;KVIST MATS;;HOVDEN ARNT OVE;;GRNVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SRENSEN BIRGER,,https://lens.org/154-448-577-449-786,Patent Application,no,0,0,24,24,0,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K/,,0,0,,,,PENDING
188,US,A1,US 2007/0005160 A1,117-700-009-749-211,2007-01-04,2007,US 11957205 A,2005-05-02,US 11957205 A,2005-05-02,Automute detection in digital audio amplifiers,"A digital audio processor ( 20 ) for a digital audio receiver ( 21 ) having an improved automute sequence is disclosed. The digital audio processor ( 20 ) includes automute detection circuitry ( 42 ) that monitors the amplitude of digital audio signals before and after the application of digital filters by digital audio processing circuitry ( 20 d ). The amplitude of the input signals are compared against a first threshold level, while the amplitude of the output signals are compared against a second threshold level. In response to the amplitude of the input signals for all of the audio channels ( 44 ) falling below the first threshold for a selected time period, a gain stage ( 50 ) in each channel ramps down the volume to a mute level, and pulse-width-modulation circuitry ( 54 ) is disabled. If the output signal amplitude falls below a second threshold for a channel, the pulse-width-modulation circuitry ( 54 ) for that channel is disabled. Hysteresis for the input signal amplitude is preferably added into the automute exit determination.",TEXAS INSTRUMENTS INC,ZAUCHA DAVID E;;KOWKUTLA VENKATESWAR R;;BJORN-JOSEFSEN ANKER;;RISBO LARS;;ROBERSON DOUGLAS A;;ANGILIVELIL JOSEY G,TEXAS INSTRUMENTS INCORPORATED (2005-07-28),https://lens.org/117-700-009-749-211,Patent Application,yes,12,42,2,2,0,H03F3/72;;H03F3/72;;H03F1/12;;H03F1/12;;H03F1/26;;H03F1/26;;H03F1/305;;H03F1/305;;H03F3/181;;H03F3/181;;H03F3/217;;H03F3/217;;H03F3/68;;H03F3/68;;H03F2200/03;;H03F2200/03;;H03F2200/331;;H03F2200/331;;H03F2200/342;;H03F2200/342;;H03F2200/351;;H03F2200/351;;H03G3/341;;H03G3/341,G06F17/00,700/94,0,0,,,,ACTIVE
189,US,B2,US 10335482 B2,199-015-796-113-034,2019-07-02,2019,US 201314405302 A,2013-06-06,US 201314405302 A;;US 201261656242 P;;US 201361768905 P;;EP 2013061750 W,2012-06-06,Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer,"The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilization of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.",BIONOR IMMUNO AS,SORENSEN BIRGER;;OKVIST MATS;;HOVDEN ARNT OVE;;GRONVOLD MAJA SOMMERFELT;;HOIE LARS;;LUNDEMOSE ANKER;;HANSEN VIDAR WENDEL,BIONOR IMMUNO AS (2013-10-01);;BIONOR PHARMA ASA (2013-08-14),https://lens.org/199-015-796-113-034,Granted Patent,yes,9,0,24,24,69,A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K39/12;;A61K47/60;;A61K38/15;;A61K39/21;;A61P31/18;;A61P43/00;;A61P31/18;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/12;;A61K39/21;;C07K14/162;;C12N7/00;;A61K2039/55566;;A61K2300/00;;A61K39/12;;A61K45/06;;A61K31/429;;A61K31/454;;A61K31/675;;C07K14/162;;A61K2039/55566;;C12N2740/16034;;A61K47/60;;A61K39/21;;A61K38/15;;A61K39/42;;C12N7/00,A61K39/21;;A61K31/429;;A61K31/454;;A61K31/675;;A61K38/15;;A61K39/00;;A61K39/12;;A61K39/42;;A61K45/06;;A61K47/60;;C07K14/16;;C12N7/00,,21,12,076-403-800-982-81X;;082-612-863-782-637;;104-744-316-886-227;;001-786-690-520-488;;075-889-606-900-215;;085-500-494-255-745;;133-735-389-483-67X;;023-317-419-342-908;;088-605-909-621-20X;;050-162-387-635-663;;007-472-424-906-413;;126-138-973-529-869,16310557;;10.1016/s0140-6736(05)67395-3;;pmc2572109;;10.1038/nature07352;;18833271;;10.1126/science.1152622;;18467582;;10.1016/j.cell.2014.01.052;;24529371;;pmc4041625;;22339485;;10.3109/00365548.2011.653581;;22339677;;10.1111/j.1600-0463.2011.02843.x;;10.1097/01.aids.0000210620.75707.ac;;16470131;;pmc3105138;;10.2119/molmed.2011.00076;;21424110;;pmc3501645;;22406268;;10.1016/j.immuni.2012.01.014;;10.1038/icb.2011.95;;22083528;;10.1089/088922202320935438;;12487807;;20721838,"Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet 366:1894-1898.;;Barouch, D. H., 2008, Challenges in the development of an HIV-1 vaccine, Nature 455:613-619.;;Walker, B. D., and D. R. Burton, 2008, Toward an AIDS vaccine, Science 320:760-764.;;West, Jr., A. P., et al., 2014, Structural insights on the role of antibodies in HIV-1 vaccine and therapy, Cell 156:633-648.;;International Search Report for International Patent Application No. PCT/EP2013/061750, dated Nov. 6, 2013.;;Lind, A., et al., “Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years,” Scandinavian Journal of Infectious Diseases, Feb. 19, 2012, pp. 566-572, vol. 44(8).;;Kran, AM., et al., “Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection,” Acta Pathologica Microbiologica et Immunologica Scandinavica, Mar. 2012, pp. 204-209, vol. 120(3).;;Kran, AM., et al., “Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells,” AIDS, Feb. 28, 2006, pp. 627-630, vol. 20(4).;;Matalon S., et al., “Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir,” Molecular Medicine, May-Jun. 2011, pp. 466-472, vol. 17(5-6).;;Shan, L., et al., “Stimulation of HIV-1-Specific Cytolic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir After Virus Reactivation,” Immunity, Feb. 27, 2012, pp. 491-501, vol. 36(3).;;Wightman, F., et al., “HDAC inhibitors in HIV,” Immunology and Cell Biology, Jan. 2012, pp. 47-54, vol. 90(1).;;Bionor Pharma ASA, “First Human Clinical Study of HIV Vaccine Vacc-C5 Approved to Begin,” May 29, 2012, pp. 1-5, retrieved from the internet on Oct. 7, 2013: http://www.bloomberg.com/article/2012-05-29/aAPWrFGgXY00.html.;;Bionor: “Vacc-4x, Therapeutic HIV Vaccine Linked to Lower Viral Load in Phase IIb Study”, press realease; Feb. 21, 2012, pp. 1-3; retrieved from the Internet: http://www.hivandhepatitis.com/hiv-prevention/hiv-vaccines/3465-vacc-4x-therapeutic-hiv-vaccine-linked-to-lower-viral-load-in-phase-iib-study.;;Hitt, Emma, “Vacc-4x Reduces Viral Load in HIV Patients Off ART,” Medscape Medical News, Jul. 26, 2011, retrieved on Oct. 15, 2013 from the Internet: http://www.medscape.com/viewarticle/747015.;;Bionor Pharma, “New Clinical Trial, HIV Vacc-4x in Combination With Revlimid® (lenalidomide),” Nov. 25, 2011, pp. 1-2, retrieved from the Internet on Oct. 2, 2013: http://www.bionorpharma.com/en/news/2011/scientific/new+ciinical+trial,+HIV+VACC-4x+in+combination+with+revlimid%C2%AE+%28Lenalidomide%29.b7C_wljQ2f.ips.;;Geleziunas, Romas, Ph.D., “Gilead HIV Eradication Program,” May 25, 2012, pp. 1-28, retrieved from the internet on Oct. 2, 2013: http://www.isheid.com/presentations/vendredi/12-30/geleziunas/Geleziunas.pdf.;;Birgitta, A., et al., “Phase I Trial of a Therapeutic HIV Type 1 Vaccine Vacc-4x, in HIV Type 1-Infected Indificuals with or without Antiretroviral Therapy,” AIDS Research and Human Retroviruses, 2002, vol. 18(18), pp. 1357-1365.;;Hosein, Sean R., Norwegian HIV vaccine—Very modest results seen in recent clinical trial, CATIE-News, 2012, retrieved from the Internet, http://www.catie.ca/en/printpdf/catienews/2012-02-21/norwegian-hiv-vaccine-very-modest-results-seen-recent-clinical-trial, pp. 1-5.;;Jones, Taff, “Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the poptential treatment of HIV infection,” Current Opinion in Investigational Drugs, 2010, vol. 11(8), pp. 964-970.;;Levin, Jennifer, “Successfully results from clinical study with Vacc-4x and Endocine,” FiercePharma, 2012, retrieved from the Internet, http://www.fiercepharma.com/vaccines/successfully-results-from-clinical-study-vacc-4x-and-endocin, pp. 1-6.;;“Positively Aware Magazine. Current HIV news and updates,” 2012, retrieved from the Internet, http://www.positivelyaware.com/archives/2012/news_briefs/news_briefs_12-03-01.shtml, pp. 1-6.",ACTIVE
190,JP,A,JP 2002176325 A,075-969-112-047-170,2002-06-21,2002,JP 2001291741 A,2001-09-25,US 23485100 P,2000-09-22,DIGITAL AMPLIFIER,"PROBLEM TO BE SOLVED: To provide a digital amplifier, in which the noise characteristic is improved and a circuit and a load are protected from overcurrent due to shirt circuit that in the circuit. SOLUTION: This digital amplifier is provided with a noise shaping device and a dither generator for introducing noise to the noise shaping device by using a seed value derived from a state variable of the noise shaping device.",TEXAS INSTRUMENTS INC,KOWKUTLA VENKATESWAR R;;ZHAO SHIGENG;;OSSA LUIS E;;BELL KENNETH M;;JOSEFSEN ANKER;;RISBO LARS;;TSECOURAS MICHAEL J,,https://lens.org/075-969-112-047-170,Patent Application,no,0,3,5,5,0,H03F3/2171;;H03F3/2173;;H03M7/3008;;H03M7/3026;;H03M7/3042;;H03M7/3008;;H03F3/2171;;H03F3/2173;;H03M7/3042;;H03M7/3026,H04R3/00;;H03F3/181;;H03F3/217;;H03M7/36,,0,0,,,,DISCONTINUED
191,WO,A1,WO 2015/007337 A1,125-616-443-777-117,2015-01-22,2015,EP 2013065289 W,2013-07-19,EP 2013065289 W,2013-07-19,METHOD FOR THE VACCINATION AGAINST HIV,The present invention relates to methods for treating reducing and/or delaying pathological effects of human immunodeficiency virus I (HIV) in a human infected with HIV or for reducing the risk of developing acquired immunodeficiency syndrome (AIDS) in a human.,BIONOR IMMUNO AS,HØIE LARS H;;LUNDEMOSE ANKER;;ÖKVIST MATS;;HOVDEN ARNT OVE;;GRØNVOLD MAJA SOMMERFELT;;HANSEN VIDAR WENDEL;;SØRENSEN BIRGER,,https://lens.org/125-616-443-777-117,Patent Application,yes,68,10,1,1,70,A61K39/21;;A61K39/12;;A61K2039/55522;;A61K2039/70;;C07K14/161;;C12N2740/16034;;C12N2740/16134,A61K39/21,,88,75,014-623-982-973-062;;007-472-424-906-413;;060-382-418-981-620;;095-028-873-430-597;;127-706-827-894-461;;077-532-829-551-519;;006-574-964-805-278;;042-204-626-457-327;;162-646-650-680-173;;042-235-850-564-946;;025-502-903-207-115;;056-201-471-905-934;;028-862-168-091-90X;;070-318-972-823-861;;004-080-056-048-328;;006-071-768-855-708;;008-586-279-961-02X;;038-651-946-063-60X;;040-564-054-665-636;;012-233-267-251-566;;029-889-648-056-624;;100-643-690-081-324;;101-556-508-196-784;;040-248-991-014-497;;000-488-828-478-314;;077-902-281-227-830;;033-734-546-562-460;;013-156-923-422-168;;081-689-722-803-077;;041-869-100-449-381;;154-131-435-813-225;;095-009-613-240-195;;016-452-999-291-294;;058-263-944-579-750;;005-538-767-286-70X;;065-386-713-665-591;;064-638-684-564-725;;096-049-594-310-196;;088-605-909-621-20X;;048-057-623-080-06X;;014-696-433-147-048;;023-587-284-643-526;;064-865-149-673-057;;067-172-489-998-955;;157-974-914-113-933;;099-900-233-961-52X;;042-737-034-126-542;;036-034-789-927-905;;007-472-424-906-413;;060-382-418-981-620;;075-889-606-900-215;;095-028-873-430-597;;010-442-708-361-831;;085-434-807-290-371;;138-768-624-385-598;;113-340-335-931-957;;025-637-473-464-055;;007-831-789-409-366;;121-232-676-900-958;;031-146-392-849-106;;039-282-236-992-864;;033-512-972-747-093;;060-804-145-159-056;;018-125-743-674-480;;016-500-454-779-234;;020-048-273-145-271;;015-961-711-658-069;;044-994-818-694-417;;015-327-286-966-07X;;030-332-812-234-785;;055-047-782-551-812;;186-160-636-928-719;;131-816-066-300-172;;049-555-701-481-191;;108-405-185-330-649,10.1186/1742-4690-9-s2-o66;;10.1089/088922202320935438;;12487807;;10.1097/00002030-200409240-00003;;15353973;;15963359;;10.1016/j.vaccine.2005.03.010;;9415445;;10.1093/protein/10.8.949;;10.1038/nbt1142;;16151406;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1016/0959-440x(92)90091-k;;2156132;;10.1016/0076-6879(90)83007-v;;10.1385/1-59259-192-2:185;;10547837;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1146/annurev-pharmtox-061008-103129;;18851703;;pmc2481506;;10.1016/j.jmb.2008.04.049;;18508079;;21723901;;10.1016/j.vaccine.2011.06.070;;7919109;;10.1016/0753-3322(94)90080-9;;10.1182/blood.v89.9.3129;;9129015;;19416838;;10.1073/pnas.0903181106;;pmc2674105;;10.1016/s0140-6736(01)06957-4;;10.3410/f.1002866.32207;;11747915;;17652518;;pmc1937553;;10.1073/pnas.0703342104;;10723627;;10.1080/0738-859991229170;;10.1371/journal.pone.0003116;;18776936;;pmc2525815;;10.1080/10611860801900462;;18446607;;10.1016/j.vaccine.2008.05.074;;18599166;;17558426;;10.1016/j.vaccine.2007.12.038;;18272264;;18501482;;10.1016/j.vaccine.2008.04.023;;10.1016/j.vaccine.2008.01.058;;18329759;;16054274;;10.1016/j.vaccine.2005.06.018;;19008380;;10.1099/vir.0.2008/005470-0;;10.1146/annurev.immunol.15.1.617;;9143702;;10.1016/s0024-3205(96)00502-4;;9000640;;7660002;;1471428;;10.1016/0264-410x(92)90106-t;;10.1002/jcb.20532;;16088937;;10.1002/jcb.22185;;pmc2766855;;19459166;;10.1155/2011/475641;;21188171;;pmc3004414;;pmc3501645;;22406268;;10.1016/j.immuni.2012.01.014;;10.3410/f.1165504.628500;;10.1172/jci39199;;pmc2769176;;10.3410/f.1165504.723055;;19805909;;10.1182/blood-2007-06-097907;;17881634;;21992606;;pmc3215964;;10.1186/1742-4690-8-80;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;10.1111/j.1399-3011.1990.tb00939.x;;2191922;;10.1016/s0040-4039(00)91864-1;;10.1038/nm1520;;17173051;;pmc3136285;;21690407;;10.1073/pnas.1105315108;;10.1038/32588;;9521319;;10.1089/088922202320935438;;12487807;;10.1097/00002030-200409240-00003;;15353973;;22339485;;10.3109/00365548.2011.653581;;15963359;;10.1016/j.vaccine.2005.03.010;;17135583;;10.1056/nejmoa062360;;10.1086/655468;;20662716;;pmc2916952;;10.1097/01.ccm.0000186784.62662.a1;;16289707;;10.1016/j.vaccine.2005.10.012;;18502002;;10.1016/j.vaccine.2008.03.083;;pmc2849500;;20130059;;10.1128/jvi.02565-09;;19372954;;10.1097/coh.0b013e3282f54cde;;16387747;;10.1093/jac/dki472;;15718839;;pmc2869083;;10.1056/nejmoa0903175;;19828532;;15718848;;10.1128/jvi.01381-12;;pmc3497693;;22973023;;22658928;;10.1016/j.vaccine.2012.05.049;;20935558;;10.1097/qad.0b013e32833e502b;;18419344;;10.1086/587843;;10.4049/jimmunol.178.1.39;;17182538;;10.1126/scitranslmed.3004682;;23283367;;21300092;;10.1016/j.vaccine.2011.01.064;;10.1371/journal.pmed.0050203;;pmc2570418;;18942885;;22129997;;10.5772/21058;;10.1126/science.1191047;;20616270;;10.1007/978-1-59745-223-6_5;;17666743,"""""Non-patent literature cited during the examination procedure"" submitted on 14.10.2005"", 14 October 2005 (2005-10-14), pages 9PP, XP002717712, Retrieved from the Internet <URL:https://register.epo.org/application?number=EP00911492&lng=en&tab=doclist> [retrieved on 20131210];;ELLEFSEN-LAVOIE K ET AL: ""Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine"", RETROVIROLOGY, vol. 9, no. Suppl 2, 13 September 2012 (2012-09-13), BIOMED CENTRAL LTD., LONDON, GB, pages O66, XP021116303, ISSN: 1742-4690, DOI: 10.1186/1742-4690-9-S2-O66;;ASJÖ B ET AL: ""Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy"", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 18, no. 18, 10 December 2002 (2002-12-10), MARY ANN LIEBERT, US, pages 1357 - 1365, XP002687385, ISSN: 0889-2229, DOI: 10.1089/088922202320935438;;KRAN ANNE-MARTE B ET AL: ""HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)"", vol. 18, no. 14, 24 September 2004 (2004-09-24), LONDON, GB, pages 1875 - 1883, XP008157948, ISSN: 0269-9370, Retrieved from the Internet <URL:http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=yrovft&AN=00002030-000000000-00000> [retrieved on 20131211];;KRAN A M B ET AL: ""Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization"", VACCINE, vol. 23, no. 31, 1 July 2005 (2005-07-01), ELSEVIER LTD, GB, pages 4011 - 4015, XP027651909, ISSN: 0264-410X, [retrieved on 20050701];;BIONOR PHARMA: ""HIV Therapeutic Vaccine Vacc-4x 'lowered viral load in patients off ART'"", INTERNET CITATION, 15 February 2012 (2012-02-15), pages 1 - 3, XP002714663, Retrieved from the Internet <URL:http://www.natap.org/2012/newsUpdates/021512_03.htm> [retrieved on 20131007];;HARLOW ET AL.: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;ILL ET AL., PROTEIN ENG, vol. 10, 1997, pages 949 - 57;;HOLLIGER; HUDSON, NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 1136;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98;;PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402;;JENNINGS; BACHMANN, ANN REV PHARMACOL. TOXICOL., vol. 49, 2009, pages 303 - 26;;PEABODY ET AL., J. MOL. BIOL., vol. 380, 2008, pages 252 - 63;;KOLLESSERY G ET AL.: ""Tumor- specific peptide based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model"", VACCINE, vol. 29, 2011, pages 5904 - 10, XP028248487, DOI: doi:10.1016/j.vaccine.2011.06.070;;DUNCAN E.S. STEWART-TULL: ""The Theory and Practical Application of Adjuvants"", 1995, JOHN WILEY & SONS LTD;;GREGORIADIS G ET AL.: ""Vaccines: New Generationn Immunological Adjuvants"", 1995, PLENUM PRESS;;ROESTENBERG M ET AL., PLOS ONE. 2008, vol. 3, no. 12, 18 December 2008 (2008-12-18), pages E3960;;RELYVELD E; CHERMANN JC, BIOMED PHARMACOTHER., vol. 48, no. 2, 1994, pages 79 - 83;;HSU FJ ET AL., BLOOD, vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 3129 - 35;;GALLI G ET AL., PROC NATL ACAD SCI U S A. 2009 MAY 12, vol. 106, no. 19, 27 April 2009 (2009-04-27), pages 7962 - 7;;BOJANG KA ET AL., LANCET, vol. 358, no. 9297, 8 December 2001 (2001-12-08), pages 1927 - 34;;ODUNSI K ET AL., PROC NATL ACAD SCI USA. 2007 JUL 31, vol. 104, no. 31, 25 July 2007 (2007-07-25), pages 12837 - 42;;SPROTT GD, CRIT REV BIOTECHNOL., vol. 19, no. 4, 1999, pages 317 - 57;;AGGER EM ET AL., PLOS ONE., vol. 3, no. 9, 8 September 2008 (2008-09-08), pages E3116;;KIRBY DJ ET AL., J DRUG TARGET., vol. 16, no. 4, May 2008 (2008-05-01), pages 282 - 93;;FLORINDO HF ET AL., VACCINE. 2008 AUG 5, vol. 26, no. 33, 17 June 2008 (2008-06-17), pages 4168 - 77;;SUN HX ET AL., VACCINE, 28 May 2009 (2009-05-28);;GUY B, NAT REV MICROBIOL., vol. 5, no. 7, July 2007 (2007-07-01), pages 505 - 17;;VANDEPAPELIÈRE P ET AL., VACCINE. 2008 MAR 4, vol. 26, no. 10, 14 January 2008 (2008-01-14), pages 1375 - 86;;GHOCHIKYAN A ET AL., VACCINE. 2006 MAR 20, vol. 24, no. 13, 5 December 2005 (2005-12-05), pages 2275 - 82;;XIE Y ET AL., VACCINE. 2008 JUN 25, vol. 26, no. 27-28, 1 May 2008 (2008-05-01), pages 3452 - 60;;CHUNG YC ET AL., VACCINE. 2008 MAR 28, vol. 26, no. 15, 25 February 2008 (2008-02-25), pages 1855 - 62;;MAIER M ET AL., VACCINE, vol. 23, no. 44, 25 October 2005 (2005-10-25), pages 5149 - 59;;SUNDLING C ET AL., J GEN VIROL., vol. 89, December 2008 (2008-12-01), pages 2954 - 64;;DONNELLY JJ ET AL., ANNU. REV. IMMUNOL., vol. 15, 1997, pages 617 - 648;;DONNELLY JJ ET AL., LIFE SCIENCES, vol. 60, 1997, pages 163 - 172;;SALIOU P, REV. PRAT., vol. 45, 1995, pages 1492 - 1496;;WALKER PD, VACCINE, vol. 10, 1992, pages 977 - 990;;SCHUTZ A ET AL., TETRAHEDRON, vol. 56, no. 24, 9 June 2000 (2000-06-09), pages 3889 - 3891;;DOKMANOVIC; MARKS, J. CELL. BIOCHEM., vol. 96, 2005, pages 293 - 304;;MARKS; XU, J. CELL. BIOCHEM., vol. 107, 2009, pages 600 - 608;;FEDERICO; BAGELLA, J. BIOMED. BIOTECHNOL, 2011, pages 475641;;SHAN ET AL., IMMUNITY, vol. 36, no. 3, 2012, pages 491 - 501;;YANG ET AL., J CLIN INVEST., vol. 119, no. 11, 2009, pages 3473 - 3486;;SALEH ET AL., BLOOD, vol. 110, 2007, pages 4161 - 4;;SALEH ET AL., RETROVIROLOGY, vol. 8, 2011, pages 80;;W.C. CHAN; P.D. WHITE: ""Solid Phase Peptide Synthesis - A Practical Approach"", 2000, OXFORD UNIVERSITY PRESS INC.;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;BARANY; MERRIFIELD: ""the Peptides, Analysis, Synthesis, Biology"", vol. 2, 1980, ACAD.PRESS;;KNEIB-CORONIER; MULLEN, INT. J. PEPTIDE PROTEIN RES., vol. 30, 1987, pages 705 - 739;;FIELDS; NOBLE, INT.J.PEPTIDE PROTEIN RES., vol. 35, 1990, pages 161 - 214;;AKAJI ET AL., TETRAHEDRON LETTER, vol. 33, no. 8, 1992, pages 1073 - 1076;;KIEPIELA P; NGUMBELA K; THOBAKGALE C ET AL.: ""CD8+ T-cell responses to different HIV proteins have discordant associations with viral load"", NATURE MED., vol. 13, 2007, pages 46 - 53;;DAHIREL V; SHEKHAR K; PEREYRA F ET AL.: ""Coordinate linkage of HIV evolution reveals regions of immunological vulnerability"", PROC. NATL ACAD SCI USA, vol. 108, pages 11530 - 5;;BANCHEREAU J; STEINMAN RM: ""Dendritic cells and the control of immunity"", NATURE, vol. 392, 1998, pages 245 - 52, XP002134557, DOI: doi:10.1038/32588;;ÅSJÖ B; STAVANG H; SORENSEN B; BAKSAAS I; NYHUS J; LANGELAND N: ""Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy"", AIDS RES HUM RETROVIRUSES, vol. 18, 2002, pages 1357 - 65, XP002687385, DOI: doi:10.1089/088922202320935438;;KRAN, A.M.B.; SORENSEN, B.; NYHUS, J.; SOMMERFELT, M.A.; BAKSAAS, I.; KVALE, D. DOSE: ""HLA-dependent Immunogenicity of a Peptide-Based HIV-1 Immunotherapy Candidate (Vacc-4x"", AIDS, vol. 18, no. 14, 2004, pages 1875 - 83, XP008157948, DOI: doi:10.1097/00002030-200409240-00003;;LIND, A.; SOMMERFELT MA.; HOLMBERG, J.O.; BAKSAAS, I.; SORENSEN, B.; KVALE, D.: ""Short Communication: Intradermal Vaccination of HIV-infected Patients with Short HIV Gag p24-like Peptides Induces CD4+ and CD8+ T cell Responses Lasting more than 7 Years. Scand"", J. INF. DIS., vol. 44, 2012, pages 566 - 72;;KRAN, A.M.B.; SOMMERFELT, M.A.; SORENSEN, B. ET AL.: ""Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization"", VACCINE, vol. 23, 2005, pages 4011 - 4015, XP004930536, DOI: doi:10.1016/j.vaccine.2005.03.010;;""The Strategies for the Management of AntiRetroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment"", NEW ENG. J. MED., vol. 355, 2006, pages 2283 - 96;;SCHOOLEY RT; SPRITZLER J; WANG H ET AL.: ""AIDS clinical trials group 5197: A placebo-controlled trial of immunization of HIV-1 infected persons with replication deficient adenovirus type 5 vaccine expressing HIV-1 core protein"", J INF DIS, vol. 202, 2010, pages 705 - 716;;SONG M; KELLUM JA: ""Interleukin-6"", CRIT. CARE MED., vol. 33, 2005, pages 463 - 465;;NYHUS, J.N.; KRAN, A.M.B.; SOMMERFELT, M.A.; BAKSAAS, I.; SORENSEN, B.; KVALE, D.: ""Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate Vacc-4x"", VACCINE, vol. 24, 2006, pages 1543 - 50, XP028010502, DOI: doi:10.1016/j.vaccine.2005.10.012;;BART P-A; GOODALL R; BARBER T ET AL.: ""EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium"", VACCINE, vol. 26, 2008, pages 3153 - 3161, XP022710598, DOI: doi:10.1016/j.vaccine.2008.03.083;;CELLERAI C; PERREAU M; ROZOT V: ""Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R a (CD127) and perforin expression"", J. VIROL., vol. 84, 2010, pages 3868 - 3878;;KUTZLER MA; JACOBSEN JM: ""Treatment interruption as a tool to measure changes in immunologic response to HIV-1"", CURRENT OPINION IN HIV AND AIDS, vol. 3, 2008, pages 131 - 135;;BOSCHI A; TINELLI C; ORTOLANI P; ARLOTTI A: ""Safety factors predicting the duration of the first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection"", J. ANTIMICROB. CHEMOTHER., vol. 57, 2006, pages 520 - 6;;MUSSINI C; BEDINI A; BORGHI V ET AL.: ""CD4 cell-monitored treatment interruption in patients with CD4 cell count >500 x 106 cells/I"", AIDS, vol. 19, 2005, pages 287 - 94;;""INSIGHT-ESPRIT and SILCCAT study Groups. Interleukin-2 therapy in patients with HIV infection"", NEW ENGL. J. MED., vol. 361, 2009, pages 1548 - 59;;WIT FWNM; BLACKENBERG DH; BRINKMAN K. ET AL.: ""Safety of long-term interruption of successful anti-retroviral therapy: the ATHENA cohort study"", AIDS, vol. 19, 2005, pages 345 - 48;;MATTHEWS PC; KOYANAGI M; KLOVERPRIS HN; HARNDAHL M; STRYHN A; AKAHOSHI T: ""Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope"", J VIROL., vol. 86, 2012, pages 12643 - 54;;NORGATE K; SMITH P; HEGARTY E ET AL.: ""Modification of HIV type-1 peptides: impact on DC uptake and T-cell activation"", SUBMITTED, 2013;;THAKUR A; PEDERSEN LE; JUNGERSEN G: ""Immune markers and correlates of protection for vaccine induced immune responses"", VACCINE, vol. 30, 2012, pages 4907 - 20, XP028498163, DOI: doi:10.1016/j.vaccine.2012.05.049;;KRAN A-M B; JONASSEN, T0; SOMMERFELT MA; L0VG$RDEN L; SØRENSEN, B.; KVALE, D.: ""Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides"", AIDS, vol. 24, 2010, pages 2609 - 18;;DANTA M; SEMMO N; FABRIS P ET AL.: ""Impact of HIV on host-virus interactions during early hepatitis C virus infection"", J INFECT DIS, vol. 197, 2008, pages 1558 - 66;;PONOMAREV ED; SHRIVER LP; MARESZ K; PEDRAS-VASCONCELOS J; VERTHELYI D; DITTEL BN: ""GM-CSF production by autoreactive T-cells is required for the activation of microglial cells and the onset on experimental autoimmune encephalitis"", J. IMMUNOL, vol. 178, no. 1, 2007, pages 39 - 48;;GARCIA F; CLIMENT N; GUARDO AC ET AL.: ""Et al. A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication"", SCI. TRANSL. MED., vol. 5, 2013, pages 166RA2;;GUDMUNDSDOTTER L; WAHREN B; HALLER BK ET AL.: ""Et al. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial"", VACCINE, vol. 29, 2011, pages 5558 - 66, XP028240674, DOI: doi:10.1016/j.vaccine.2011.01.064;;KULLER LH; TRACY R; BELLOSO W ET AL.: ""Inflammatory and coagulation biomarkers and mortality in patients with HIV infection"", PLOS MED, vol. 5, 2008, pages E203;;COHEN SM; VAN HANDEL MM; BRANSON BM ET AL.: ""Vital Signs: HIV Prevention Through Care and Treatment - United States MMWR"", vol. 60, 2011, pages: 1618 - 1623.29;;SOMMERFELT MA: ""Recent Translational Research in HIV/AIDS"", 2011, article ""Sommerfelt MA. Towards a functional cure for HIV infection: The potential contribution of therapeutic vaccination"", pages: 493 - 510;;TRONO D; VAN LINT C; ROUZIOUX C ET AL.: ""HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals"", SCIENCE, vol. 329, 2010, pages 174 - 180;;DALVA K.; BEKSAC M.: ""HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO) and use of the Luminex technology"", METHODS MOL MED, vol. 134, 2007, pages 61 - 69",PENDING
192,DK,D0,DK 47090 D0,130-511-177-910-316,1990-02-22,1990,DK 47090 A,1990-02-22,DK 47090 A;;DK 93589 A,1989-02-27,MEDICINSK HJAELPEMIDDEL,,JENSEN LEO ANKER;;HOLM KARE;;HARALSTED HANS;;JENSEN PALLE RASMUS;;THOMSEN IB;;KRAG NIELS;;RAHBEK LARS;;FREDERIKSEN EJNER,JENSEN LEO ANKER;;HOLM KARE;;HARALSTED HANS;;JENSEN PALLE RASMUS;;THOMSEN IB;;KRAG NIELS;;RAHBEK LARS;;FREDERIKSEN EJNER,,https://lens.org/130-511-177-910-316,Patent Application,no,0,0,1,3,0,,H04B7/26,,0,0,,,,DISCONTINUED
193,EP,A2,EP 1193867 A2,178-927-034-336-151,2002-04-03,2002,EP 01000492 A,2001-09-20,US 23485100 P,2000-09-22,Digital amplifier,A digital amplifier that includes a noise shaper and a dither generator arranged to introduce noise to the shaper. The generator uses a seed value derived from a state variable of the shaper.,TEXAS INSTRUMENTS INC,KOWKUTLA VENKATESWAR R;;ZHAO SHIGENG;;OSSA LUIS E;;BELL KENNETH M;;JOSEFSEN ANKER;;RISBO LARS;;TSECOURAS MICHAEL J,,https://lens.org/178-927-034-336-151,Patent Application,yes,0,7,5,5,0,H03F3/2171;;H03F3/2173;;H03M7/3008;;H03M7/3026;;H03M7/3042;;H03M7/3008;;H03F3/2171;;H03F3/2173;;H03M7/3042;;H03M7/3026,H04R3/00;;H03F3/181;;H03F3/217;;H03M7/36,,0,0,,,,EXPIRED
194,EP,B1,EP 1193867 B1,046-018-102-742-422,2018-11-14,2018,EP 01000492 A,2001-09-20,US 23485100 P,2000-09-22,Digital amplifier,,TEXAS INSTRUMENTS INC,KOWKUTLA VENKATESWAR R;;ZHAO SHIGENG;;OSSA LUIS E;;BELL KENNETH M;;JOSEFSEN ANKER;;RISBO LARS;;TSECOURAS MICHAEL J,,https://lens.org/046-018-102-742-422,Granted Patent,yes,4,0,5,5,0,H03F3/2171;;H03F3/2173;;H03M7/3008;;H03M7/3026;;H03M7/3042;;H03M7/3008;;H03F3/2171;;H03F3/2173;;H03M7/3042;;H03M7/3026,H03F3/217;;H04R3/00;;H03F3/181;;H03M7/00;;H03M7/36,,0,0,,,,EXPIRED
195,US,A1,US 2002/0060605 A1,056-324-537-753-815,2002-05-23,2002,US 94502701 A,2001-08-31,US 94502701 A;;US 23485100 P,2000-09-22,Amplifiers,"
   A digital amplifier includes a noise shaper and a dither generator arranged to introduce noise to the shaper. The generator uses a seed value derived from a state variable of the shaper. 
",KOWKUTLA VENKATESWAR R.;;ZHAO SHIFENG;;OSSA LUIS E.;;BELL KENNETH M.;;JOSEFSEN ANKER;;RISBO LARS;;TSECOURAS MICHAEL J.,KOWKUTLA VENKATESWAR R;;ZHAO SHIFENG;;OSSA LUIS E;;BELL KENNETH M;;JOSEFSEN ANKER;;RISBO LARS;;TSECOURAS MICHAEL J,TEXAS INSTRUMENTS INCORPORATED (2006-04-21),https://lens.org/056-324-537-753-815,Patent Application,yes,3,20,5,5,0,H03F3/2171;;H03F3/2173;;H03M7/3008;;H03M7/3026;;H03M7/3042;;H03M7/3008;;H03F3/2171;;H03F3/2173;;H03M7/3042;;H03M7/3026,H03F3/181;;H03F3/217;;H04R3/00;;H03M7/36,330 1,0,0,,,,DISCONTINUED
196,DK,D0,DK 49690 D0,160-120-224-203-922,1990-02-26,1990,DK 49690 A,1990-02-26,DK 49690 A;;DK 93589 A,1989-02-27,MEDICINSK HJAELPEMIDDEL,,JENSEN LEO ANKER;;HOLM KARL;;HARALDSTED HANS;;JENSEN PALLE RASMUS;;THOMSEN IB;;KRAG NIELS;;RAHBEK LARS;;FREDERIKSEN EJNER,JENSEN LEO ANKER;;HOLM KARL;;HARALDSTED HANS;;JENSEN PALLE RASMUS;;THOMSEN IB;;KRAG NIELS;;RAHBEK LARS;;FREDERIKSEN EJNER,,https://lens.org/160-120-224-203-922,Patent Application,no,0,0,1,3,0,,G09B17/00;;H04B/,,0,0,,,,DISCONTINUED
197,EP,A3,EP 1193867 A3,121-702-666-423-362,2005-08-17,2005,EP 01000492 A,2001-09-20,US 23485100 P,2000-09-22,Digital amplifier,A digital amplifier that includes a noise shaper and a dither generator arranged to introduce noise to the shaper. The generator uses a seed value derived from a state variable of the shaper.,TEXAS INSTRUMENTS INC,KOWKUTLA VENKATESWAR R;;ZHAO SHIGENG;;OSSA LUIS E;;BELL KENNETH M;;JOSEFSEN ANKER;;RISBO LARS;;TSECOURAS MICHAEL J,,https://lens.org/121-702-666-423-362,Search Report,yes,3,0,5,5,0,H03F3/2171;;H03F3/2173;;H03M7/3008;;H03M7/3026;;H03M7/3042;;H03M7/3008;;H03F3/2171;;H03F3/2173;;H03M7/3042;;H03M7/3026,H04R3/00;;H03F3/181;;H03F3/217;;H03M7/36,,0,0,,,,EXPIRED
